var title_f30_27_31152="Saethre Chotzen radiograph";
var content_f30_27_31152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anteroposterior radiograph in a patient with Saethre-Chotzen syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 484px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterior plagiocephaly demonstrated in a patient with Saethre-Chotzen syndrome. Note the closure of the metopic suture (red arrow) although both coronal sutures (black arrows) remain present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Raoul CM Hennekam, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31152=[""].join("\n");
var outline_f30_27_31152=null;
var title_f30_27_31153="Radiopaque marker study slow transit";
var content_f30_27_31153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiopaque marker study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiopaque marker transit study showing &gt;5 radiopaque markers on x-ray taken on day 6, indicating slow transit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Satish S Rao, MD, PhD, FRCP, and Narasimha M Palagummi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31153=[""].join("\n");
var outline_f30_27_31153=null;
var title_f30_27_31154="Lipomas multiple";
var content_f30_27_31154=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple lipomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nodules are present on the arm of this patient with multiple lipomas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31154=[""].join("\n");
var outline_f30_27_31154=null;
var title_f30_27_31155="ARF Advancement flap";
var content_f30_27_31155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F79234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F79234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Advancement flap for coverage of an anal rectal fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAh0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5S/wDHuiWN3PbTvcCWF2jfERIyDg/yqhN8UvDcIJeS64/6YGvN/FsWfEWqn/p6l/8AQzXJ6jDwc9K894qadj1Fg6bjc+jbDxdpV/apPbPM0bKWGY8HArOT4j6A44kufxhNed/De636VGrcmJ8H6H/6+ax9TtPsetXtvjCrIWX6HmuqvOUI80Tjw9ONSfLM9ck+I+gojtvujtBOBCST9Knfx9oavbr5sxFxCJ4mEZKunqD7cZ+teKTIQN69R1puk+bPBJo0SBriDde6WTxnH+tgz7gnH1HpXPTxE53j16HRVw0KdpdOp7iPHGjHpJP/AN+zT18aaQejzf8AfuvHrOZLi3jmiJ2OMjIwR7H3q0rYrH65URv9RpPVXPWh4v0o9Hm/7907/hLdL/vy/wDfFeVRzYqUT0/rkw+o0/M9Q/4S3S/78v8A3xTT4w0odXm/7915l9oprTA0/rcxfUafmemN400herzf9+6jPjnRR1kn/wC/ZrzJyGqrKlS8ZMawNPzPVD490Qf8tJ/+/Rpp+IGhjrJcf9+jXkrRnNRunGe1L67U8ivqFLzPaNO8ZaTqCTtbtOVhIDFo8cms68+JXh6zvXtZpbnzU67YSR/nmuP8MQiHw5HIRhrmRpT9M4H8q82uWN5q95cf3n4/n/UV31JuFPme551KlGpV5Vse8L8TPDrdJLn/AL8mp4/iDoUn3ZLj/v0a8Hijwa1LJelcn1qZ3vA0/M9uj8aaRJ915v8Av2a2dMv4NSt/Ptixj3FfmGDmvGLNeleoeBRjRD/11b+QrejWlOVmc2Iw8KcbxOirD1fxTpWkXZtr6d0lChiBGzcH6CtyvIvicm7xLIf+mSfyrSvUdON0YYekqs+WR2DfELw6vW7l/wC/L/4VXf4neF0IDXsoJOP+Pd/8K8cuYutYOpxlQT6c/lXNHFSckmdk8FBRbV7n0zP4q0mGzlunnfyYxuYiNjgfTFUF+IPh1hxdyf8Afl/8K4nw+V1LQUifkTQGNvqBj+lcRbIUGxh8yEqfqOK3xFSVNJxOXDUoVW1I9wXx7oDdLqT/AL8t/hUg8b6EelzJ/wB+m/wrxUD0qeI5rkeMqeR2rBU33PZR400Q9Ll/+/Tf4U8eMNGbpcP/AN+2/wAK8gTOKlRsUfXKnZD+oU+7PXR4s0g9J3/79t/hS/8ACVaV/wA93/79t/hXlEc2KlE9H12fZC+oU+7PUj4q0kf8t3/79t/hTT4t0gdZ3/79t/hXl/n5prSA0/rkxfUafmennxjoo63D/wDfpv8ACmHxtoY63L/9+m/wry2QZqpJGaTxk/IpYCn3Z61/wnOg/wDP1J/36b/Cmnx5oA63Un/flv8ACvIDGRmoLkeXC7dwOPrSWMqN2SQPA0krts9ytPFek3dotzBO5hZioJjYZI69qyf+Fl+GPMdBey7kOD+4f/CuSKjSvDlvGesFvvP+8ef615XZRFlZ/wC8xNd1ao6cbrc4cNRVadnsfQqfEXw2/wB28k/78P8A4VPH470GT7t1If8Ati3+FeBwpg1sWK9K5PrczteBp92e2p4u0d/u3D/9+m/wrbtp0ubeOaI5jdQykjGRXi1ovAr17QP+QLZf9cl/lXRQqyqNpnJiaEaSTiX6xX8VaGjEPqVuCDg8mtqvnnUI8zy/7x/nTr1XTtYWGoKte72PZ28ZeHl+9q1sPxP+FJbeMvD1zOIINWtnlPRQTn+VeAXUWQeKztNk+x69aTdAHwfp/wDqzWdLEuclFo1rYSNODlFn01d+I9Is1ja6v4YxJ90sTzUH/CXaB/0FLf8AM/4V5p4tgE3hzzcZa2lV/wADwf51ycSjFVXrSpNWRnh8PGqm29T3oeKtDPTUrf8AM04eJ9FPTUYPzNeFJweKtxiuf65PsjqWAg+rPa/+El0c/wDMQg/M04eItJPS/h/OvFxxT1cij67PsP8As+Hdns/9v6Uel9D+dH9vaX/z+xfnXjy3BFP+00/rsuwvqEO7PXjr+lD/AJfYfzpp8Q6SOt/D+deRm4zUTSZo+uS7C+oR7s9fPiTRx11CD8zTT4n0UddRg/M144/NQSJSeNn2Gsvh3Z7SfFWhj/mJQfmaY/i7QUBLapbgD3NeJlDim29p9r1Kztsf62UZ+g5NVTxc5yUbE1cFTpwcrvQ94uNf0q2hMs99DHGF3FmPQVQTxt4bdQV1i1IPuf8ACvL/AIjXIi0mZF/5aMEA9h/+oVwUEO1AB0AxXRXrOnaxzYXDqte72PpFfGHh9vu6rbH8T/hUo8U6IRkalB+Zr54tl5rZtx+7rD63Lsdf1CHdmj4pjzr+p/8AXzL/AOhmuZv4QY24rrfEq513Uv8Ar5l/9CNc3eAbGFcst2dMPhQ74d3HlahcWxP3xkD9f8a3PHMYj1GyulHFxGUY/wC0tch4alFv4mtCejtsP+fxNdt4yjabQGdeXtXEo+nQ16Mf3lG3keVP91Xv5mBGu4D0NVLpJrOWO4tGCXETiWBz2cds9gRkH2JplrqEYUBmqaW5injZNw5rzYuzuj13FSVnsaLzW0t3BqFn8ljqoMgjxxDcL/rI/Ynrj1DVO/HSuf8ADVxCb288PXshij1JhJbSnpDdLyrfjgfkfWtq1laWIpdJ5N1EximjP8LqcH8O49iK3rRUrVF1/Mww0nFulLdfkWIwTTiCvWiIhR94Gns4YY4rnsjquQq+WxU2wnsajWNQ2c1YEuB2oSQhvl4pGjBHFJLLkdRVSS6EZ+9ScRpkk8e1T61n3e7yfLX78hCL9TxUk2oK2Mml0Qi+8RWijmOAGZvw6VpQp800jHEVOSm2dZrbLpuitGpx5EAjH1Ix/WvMNLXfCXPViW/M12nxCuymiEk/NJJ/T/EiuK0h8xgZ4rsxb0SOLAR95yNJI8npWlaR8ioIEzitK1j5FcKPSZp2icCvSvBAxop/66t/IV57bLwK9F8GDGjn/rq38hXXhvjOHGfAbteVfEdc+In/AOuSV6rXl/xDH/FQOf8ApmlbYr4Dmwf8Q4W4j9qxdUhGwnFdHOuQax9RUGI15x6pv/Da8J08xMfmhcH+h/lVXxFALLxFdxAYjkIlX8etZ3w/m8vWJ4P76Fh/P+hrZ8e5B0+89N0Ln9RXpVP3lK55FL91Ws+9jPVCQKsxQGqdjexuoBIzWxbujDgivMPYQ2KMAYNPaLnipDjIIp1IpEax8UuzFSA0E0WKI1XmniMUDinb8UCsNZQKidATTixJ6Ukkip1osBXuFAWq1tB9s1SxtQM+ZKC3+6OTS3V0oPWrPg9/O1a7uh923jEan/abr+grfDQ5qi8jmxc+Wk/MvfEG8EGlz7Ty7bQPYf8A6hXD2UYWBAOwArX+JVzhrSHPUbj+f/1qydNfdEoPpW+LeqRz4COkpFuKPmtWyj6VWgjzitW0j5FciO9mlapxXrGhf8gay/65L/KvLrdelepaJ/yCLP8A65L/ACrswu7POxvwou14JfJmeX/eP8697rwu9XE8n+8f50YzoTgd5GJcRVzuqJ5UyuP4WDf4/pXV3K1z+sIGyOxrjjLlkmd8480XHuelabjVNCaJuftFvg/7wH+IrhrViV2sMOvyn6jiui8AXhbRUbPzRyEfp/jmsHXQNP8AEV2nSOQiVPo1d+KjeF+x5mDlapy9yQcGrURJwKoi5jcZBGat2s6Z615x6y0LW046UlSrIjdCKX5TSsXchoqbaKNgNFguQ5pal2Cl2j2osFyHmjaT1qUlV6mo5LqJFJLCjlC5UmYLJgVqeEYxLrM9wRlbWHg/7Tf/AFhXPvcIWZieK6XwYCmiyTnhruUv/wABHArqwkPf5uxw46paHL3MD4g3HmX1pbZ6fMR+v9BWYkeABUPiy5EviicA5EZ2/wAh/Srdt84Bp4qV527DwMbU79ySCLmta3j/AHdVreOtSCP5K50dTdix4m413Uv+vmT/ANCNcpqEmA5J6V1nin/kOaj/ANfEn/oRrgPEFx5YZcnk4wOp9qcleTSM46RTZW0mZptftUjHPnDH5GvZp9PW5t3hnVhFMpRj7GvNvAWin+3rKWZd1wA0rDtGMYA+vPX2r2dlBTB6Yr0qEHCFmeTiKiqT5o7Hicvg26cT7L3y3ikaMoY84x05z3GD+NZ9z4d1bTdAvNZFzBJaWrKrBgVZixx8vXNeuT26jVLvPS5hWUf7y/Kf021j/FCFLD4U29sq4e5nVj78k0SowfQdPEVE0rni0+oHUIVmjby7iJgysvUEHIP4EV299fPfaLa+KYRtaUrbanEP4JR8qSfQgAf98mvKVZobxU3BFbqx4ArpfAvi7S7LX30m/uBc6bqim2uUI+QEj5WB6Z7fl6VhCFm6b2Z11J8yVWO6OiXXsDkUv9vt2A/OvPfGN/deEtduNJvLZpXhOUn34WZD91xx0Irm5fGV2zfu4IVX0bJ/rWPsJHQq8Wrnso8RL/ETQfESk4GfzrxtfGE2PntYSfZiKs2/i6BuLi1kT3R8/oaToSGq0T1hteHY5/GnaFJfeJ9cXTdMaFJWViHlJ28DOOO9ed2eq6feKRDdBHP8Enyn8PWu6+FEjWPi3SphnBk2k/WtKNFN+8jKvWcY+6zXt/C+p3UzJLqKptODti7/AJ11PgXQjZw3dw0jTPJIYY3xjcqnk4+v8q6jWLRdPv8AU5FGNoZ1+pHH64rQ0e0WzsYLZR/qY1Q/XHP612xpxjqkeZOrOekmeb/FWKSGwtBtIXeQfyH+FcTpUmwqK9h+I9gt7oLl494iYSEDrgHnB+ma8buIJLC9EMh3KeY5MffH+Nc+Kpt+8jqwVVRfI+p2mn/MgNbFpHk1haMxaBT3xXR2AyK4kem3oaMKACu+8Hf8gk/9dT/IVw0Q4rufB/8AyCW/66t/IV1Yf4zhxfwG5Xmvj9N2tuf+ma16VXnnjr/kMP8A9c1rbFfAc+D/AInyODuDtBrn9SlCISxroL3o1cVrUzPMsMYLyMcKo715qTbsj021FXexo+AZGn8TwhRxsfP0x/8AXr0fxDop1HSbi3wwl2+ZF/vDt+Wa5z4YaMttqs0333SMI7443Hkge3SvTph8m4/w8161KHJBRZ41aanNyR4b/wAIxqBs4rqC+j2uu7aYjx6jrRqj6t4Z0+xv9UED2F0zRpJGxDqR3Kkfd9816XLZIsF7aoB+7nYqP9l/mH/oRrlf2hFSCDQdOiUARQMxHbt/9eolQhbY1p4mpfczrDX4buHKsM0Nrio5UsOK8i0y7ntLk20ZYjqn09PwrVm1Hyf+Pm4ghPo8gB/nXBKk4ux6kKqkrnpa67F3YUHX4f7wryiTxNp8fDXqMf8AZDH+leiaB4Mu9V0uO+m1K2sElAZI5t2/B6ZAHH0qXHl3KU77GqNdiP8AGtI2uxdA61Un+Hk4i/0fXbKaY/dj2sufxP8AhXnF5qEdjqNxY3lyLe7gbY8co24P16EdwaFG+w3K256cddjHVx+FJpc2oeJY79tGWHy7JQ0jysckE4+UDrXl9xcySWp8qdZFkIQMjZ69entmvWPgI3l67dWjD93c25XHrXRQoqWsjkxNeUdIlAeH9Uuonmn1CGKNVLHbEeg/Gu18HaK1josO8MZ7j98/sO1XZ9OBsZLToZplhH0LAt/46DXTwKoUlRgdB9BXbGnGHwo82dWc/idzxT4nh49ahVgQvl8VmaTL8yrXffFHSUu5LOdspgmMSL/CSOM+oyP1rzO1Z4LwwzLslQ8j19x7VyYqm783Q7sFVVuTqd3ZgFRWvaR9Kx9OJMamt+yGVBrlR3SZeiTAr0rRf+QTaf8AXJf5V5yg4r0fRv8AkE2n/XJf5V2Ybdnn4z4UXK8T1FMSyH/aP869srxvVAN0n+8f50YvZCwO8jnbxsKa5rWJxGpLHmuh1JtsZNcbcrJqOofZ4cFj1J6IPU/4VxRi5uyO+U1Bc0tjufhlums7wAHb5gI/U/1qfx9os10LK5tmVZN/2di/QZPyk/rW78MtOSy0IMoJ812cM3UjPB/IVv67Zi8065gA+eSM7T6MOQfzr11G8eVnic7UuaJ4jdaBrtrKButmycDDkZ/Sq13qF7oesNpms2xtrxQG2lgwIIyCCPY9K9m06xTU9T0t2XKSbZGH4ZNeJ/GaQ3njnWJYzzHNtVvQqAKwnh4W0R1UsVUv7zubC6sMZBIqSPXFHVq85sdSZrYySzJCgO1jIwGD6c1HP4ksID816JD6RqT+vSuL2bvY9H2itc9P/t5B/FR/wkCdzj615JN4ys1U+Wk7t7gD+tVx4ziY/vLeUD2kBp+xl2F7WPc9k/4SCPH+sFNOvKeRJXkC+LbJj8y3S/gD/WtCDWrG5IEV+Fb0k+X+dJ0pLdDVVM9GuvECJGzMTxQtrrd3plvqMFrGtnclhFJJJ97BweBnHPrXATCSW7gXzNyYLcHOfT+te+/D2Mah8MGgYZe0nLD2BNdFGhFq8jkxGJnF2icIPD+tssbTyW4WRxGEQksSTXqFpp4srWG2jJZIFCA+uOv60RWoOqWA/hgjedh7n5V/m1dEsYEe3H1rrhCMPhR586kqjvJnzrrbsfEN2W6+aa2tJk34FSeOdIeHX9QngBLZWQxY+8pGCV98isvQZg0y7Wyp6VwYiDUrvqephKkZQUVujtLdAQK1IIvkrOtD0ragX5BWSR0yZR8Un/id6l/18Sf+hGuAjUXniNVblIlaQ59eAP513Xixsa1qntcS/wDoRrhdIQyX18U+/KUgU+mck/pWtFXqnLXlah9x6d8PbHck2oOOZjhPZB0/Pk12jLgVS0G3W202FFGAFFX26V6R5Bz2qny7mwf/AKaSRH8Rn+lYnxxYJoWh23uWI+i1t6/wlsfS7X9QRXP/AB1bJ0lPSNj+gpPYqO586+KCIIJJAASBjB/KuAcsrBl4wc8V3Pi9s20g9x/OuNhjMz7BWLdmd1OLaseq6vj4h/DNdUGG17QRtnUfekhOMn8PvfnXkZi9a7v4W6o/h/VUu0zJZvuguo3/AIk5ByPb+VWPHfhKLSNckjsyWsZ18+2Y/wBw/wAOfUdPypSnpddC6VFqSg+uqPOTEc8UCNvWumTR/WpX0cbeBzWXt0dX1KZzulSCLUYcgHa6k5HvXvvhTEF7YSDqsyH9a8OeyMF+4ZNoXYQ2OvJ/wr3Hw+jMlsw7Op/Wt4NPVHn4iLjoz3bxega8gX/n4aEf+PA/0qzb/M0h9WNReJ+b7Rc92U/krVLZ/cJ9ST+tbHGF9bLPayRsAQykEV4h4htGisLmCQZns3GG/wBkHg/9817x1yK8t8fWOzUXZBxcRtE31wdv60pK6sODs0zJ0VgYIyPQV02n9a47w1L5lnGe9dnpy9K8lbnvt6Gsg4rt/CH/ACCT/wBdT/IVxSCu28I/8go/9dD/ACFdOH+M4cV8BtV5347ONYf/AK5rXoleb/EBsaw//XNa2xXwGGD/AInyOE1FsRufauW0UJJf3t5KMrCAqn07n+ldDrD4tZD7VkeFLYXAhhxkTTtK/wDuqQMfmP0rlwqvO51Yx2p27nq3gnTms9JRpQPOlJkf6n/OK3pl/dsPaltUEduijsKdL92vSPJMADOvCPtPDG34qxH9a4T49OJvFka9orcD8ya75OPE2lf7UbL+TrXnHxobd4vuj/diUUnsXHc8S8QSG0ieaI4kBwp9M8VxMrPI5dyWZjkknOa6/wAUnzI40z95z+lZsWlGdVWNfmNc05qLPSw9CVSOhN4B0iPUtdSW8XOn2am5uT22ryF+pOBj619KaXfRxWMElx9ojeRd7qjngnnGAe3T8K8k0WOx0uxi0uzdJlcia8lAz5rDlUHsDgmum/tubaAwb8G/+tXFWk5yuj2cNhuSGu56HBq1q0uEluST/f3HH5mvEPj5p8T6xBqtsv3/ANzMemTjKnj1+b8q6s606Hcqkt/vZ/pXJeOZ21LSr4lCG2ROFzn5hJtz+TGppNxmmPE0E6bscL4PONaiQk4YHj3xX0Z8KWFv4ssMcbgy/pXzz4etJLfWrRpFKnd3+hr6A+HqsviTTH7byP0NenTkpao+cxEHB2kenakNniSGEdFeWX8lIH/oVadquYU+lUNYH/FXyf7MDn8ytaVuMRqPatjkMnxVp39oaPPCOHxlT6Ecj9a8a1qNXNleBdriTy3Hpwcj8xXv0i742B7ivE/GVv8AZJr6MDCsyzL7EMA386iorxaNKMrTTNHTjlR9K6Kw6CuX0d98UZ9QK6mwXgV5aPbkaKjivRdG/wCQTaf9cl/lXnijivQ9G/5BVp/1zX+VdeG3ZwYz4UXK8a1Q/NJ/vH+dey14rqzfvZB/tH+dGL2QsDvI5bX5fLtmNZ3h+2L2CGIf6TeyFQfqSAfwUU/xdJtszzzgmui8BWG/ULcMPltYljX/AHiASanCLVsrHS0jE9K0y0W1sooUGFRQBUlxw0Z9GqyOBiq159wH0YGu480q+C4wL5l/592lX/x44/QivnjxkBca1qkx58y4c5/Gvovwmdup6x/ssx/MKa+cPEjfvrhvWRj+tTI0hueYeKUWOWJVz8wJIrnwK6HxJ+81JV7KgrOezOzeM4rBzSdjvhSlKN0UNmaRoz2NWTGRSbKfMP2bKm16cFbvVtYHboppTbuDgqaOdB7KR2Hw4US+epzlSOp+tfTnwew2i6xbdvvY/D/61fM3w5jaK7uVPcL/AFr6W+DIKy6oh6MgP6GtINPVHHXTjJpmxpv7y8v39GjhH4DJ/U1uhc1haJz9rPrdt+gFdAvStDA4T4g2Ply2+oKPlT93L/unv+BrziC3W08QSxqMRuBIo9M9f1Br3DxHard6XNG4yCpBrxS7LLqNk7/fAeFz7qRj+dYYhXgzpwkrVUdXZHKit625jFc/p3IrorUfuhXAj1pGF4ycLq2rE/8APxL/AOhGua8IwiS7t2x/rJJZPyIQfyNbPxDm8rUdWb0uJT/48areF7f7JqGjxuesRjJ/2jgn9Sa6cNH35M8/Fy9yMT2G3XZbovoKefu0kJ3Rr9KVvu12nnnP+IR+5j9rqI/riub+NY3XGm+0Tf0ro/ERGLSPvJdx4/4Dyf5Vz/xc/eHTieTtYfypPYqO583eLRxIv+1XO6XGu/P8RNdZ4nt/MunQ92plvpdvb2ayY+fqK46srOx7GEheKYaFDJ9vmhe3CQMgkV1XGWJwwJ9eldg6DUdCfTnPmXen/v7PJ5eM/ejH0/8Aia53VbZ7Gytby4Z4WgbzuFzuXBDLj6Gn3moiJrSfR5Yr2USAF45MKnAJBOOeDjjufasoSs/J7nVVhzQsn7y1Ret7OGSNHTDKwyDU0tmix8IM/SsmSd49Zhlt7qRbO4BaO3VVIDn7wPfIJz1rQvodT0G3tJNXkN5FdOFSWOMIUGOrjOPxFYypOErXOunilVpqVrd/I4nXIZRqNyxkUxAoAitkocZOR2zkV7P4YX/QoOOuK4HU/DaHw5JrVt9pXz7hnkS5UK3XaCAP4fl4z2NeieFk/wBHtlx1K/zrtoO9zxcdFqzfW57R4k/4/wDRPxP/AJDaprPiIVD4qPl3+jseiuFP4ow/mantuEx6V1nlk/8AEa4b4jx7bXzgOUKtn6MK7muN+I/z6S6j7zssaj3JFAjzvQV8m8u7foI5SAPbOR+hFdzp44WuNjjMPiKQj7s0at+IyD+gFdhpjcDNeZUXLNo9qlLmpJm0g4rtPCYxpZ/66H+QrjYRkV2nhb/kGH/rof5CtsP8Zz4r4DXrzL4iNjWnH/TNa9Nry74jHGusP+ma1pivgMcH/EPPPEMgjsXJOOKt/Dy1IuYlcfMsaZHoWy5/VqyfE+Zlit16zOsf5kD+tdX4MATxBdKeMojr9AMf0qMJHRyNMdLVRPS+igUknSnDkU2TpXYeeYRH/FRaR/20H6rXm3xdXd4pvj/sL/KvSJW/4qXTlHVIpJD+JUD+tef/ABUXf4huT3Ma/wAqTLjueB67zcxZ6At/StDR8OF2nlTkYpJrZJtWiWQZUFjj16VreFbSOfU5F27Y9zHArzq+59Dl+kCn4wsbjRtZQ6fKf7PvIxc26ldyYbqB6EHNV7Z9fkUNDaNIv+zC+P0r0iG0g1BI9LnG66sJGuLMd5EI+eP/ANmA9quiXTQgaeaIkjOWANZc2h6cI3e55lJ/wkYjI/s4rn+L7KxI/MGnaQt3e2VxPfPJK6yeUm8bcbRkjHbBYV6hFJpE6/uJrcH2Vaw9VsUhksLC3AV5Q87N6+Y3H/jqqfxpc2hUoWauziSg+12pI5Egr2bwKuNX0zA/5aCvL9U0uax1KFHGV3qQRXq/gKPdremqOzg12YT4T57Nv4q9D0HWBnxbcn0tv/ZhWjD9xfpWZq7Y8YOP+eluwH1Vgf61pw/dH0rsPIJB0NeX/EGz8y8VMYMm5PzU/wBcV6h0rz3x7htQsVB5aQt+ABoBHKeFZPNtYyevHFdvYjgVw3h9Db3t9B2SUkfQ8j+ddxpzZUZrymuWTR7ilzRUjTVeK9A0f/kF2v8A1zX+VcFGMiu+0n/kGWv/AFzH8q6sNuzixfwot14fqrZuJB/tH+de4V4Xqbf6RL/vH+dLGdAwO8jkPEi/aLq1thz5siofpnn9M16D8OYt8JmI5Zmb8ya4LabjxHD/AHYUd/x4Uf8AoRr0X4bfLo8eeoLIfqCavCxtC/czxkr1Ldjsu4qvef6o1Y71BdcoRXScZT8OkjVNcx6j/wBFpXzn4mXEcp/2j/OvofQH/wCJhrLL0aTZ+Uaj+deBeLI/3Fxjs5/nUyNIbnmZ06XUdRuDGCdnp9K6TQdCD2KyToz7ZlVgBxtPHJ7CjwoAL67z3/wrs9Lsd+jXUbRs28Mdq9yOR9ea8ytJ8zPpcFSTppnM3vhK2LMY04PpWUnhaNZeleiSuJIElRdqyAMF9Aaa0UYCtjlqwVSSO54eD1sczaeHLdYMtGM/Sqev6NGZFFtEm1E+cjqpIOM/lXaypiJVHGailsJJ4LyR1ibGUjkXrtHBGPrmkpPdlSpRtZHD+Bodt+zEYzx+VfRvwmAW6vsdPKH9a8O8P2xt57ZSuGO4n9K91+FS4k1B+wir1cPrBHy2YK1aXy/Iu6GPkl97qU/rW8Pu1g6EeLle8d3ID+PP9a3l5Wug88jul32zg9xXiHiiHyr6Zhx5cscn/fWVP67a9ylIEbfSvG/FkBn1DVkj6pCoH+8PmH6ipmuZNF05cslI0NGO5FPqK6a3/wBWK5Hw5Lus4WHcV11scxCvLR7cjg/ihIf7S1gD/n4m/wDQjW5oNn/amUicLJGBJG3oR0/Cszx/amXXNUx3upeP+BmofAGq/Yr+3infBX9zJk9uin8sfrXVhpe9KJwYuL5YyPS9P1cA+TeD7PdL95H4B9wavSX8WMtLEg9SwqUpFKNs0aSL6MMinRWVmrbo7eFWHcIBXYcJmyRG6mS5YEQxgiEEcnPVj/SsX4pQh9H02YAZV2Un6iuwuQClYnji3+1eCnYDLQSq34HihjW58yeKY9moMe2a1dBtIr1bcOu7BBxUfjK1/wBI6YLDj3qXw9Hc6Y8YmQgL6iuHEKzPawErpo2de0y41HXdMtwmLYMDIfYc/wBKTxFoL6b4i0q40HS0nhluHmuoRJt+Y7csuflHQkjjNdVa3VvclHDLvHT2rT3KcEkEjoa4uZo9NwUjzO60Nz4rvFttHu/LDGRZ2hUR9OQh3YzyccVp+I9J1Hxh4bjgls30ny5wBHI6yO8W3B+6cKeenPSu5dgVI3AZ71XS4VTjP3u3vVc7dn2BUd09mZGsWENt4QNiq4ihhSJFznAXAHX6VL4Ti3XNimP41qt4rW5eCLKMsBcZJ71u+ArXztasUxkbga7MItGzyM0kudJdEeoeJoPtVy0O4qQFKsOxGCD+lUY70Ids5WK4H30Y4B9wfStS/YPqEh98VHNBDOoE0aOB/eGa7TyCjNqkEMZaSWNQP9rNc3qsc+qRNeyoYrS3BaJWHLn+8a6oWlnE26K3hVh0IQZrnvHOorZ6M8e4CSY7Rk9upNAHnskwbW7dVPOxs/TP/wBauu0wjivPdGn+161LOOY8BIz6qO/4kk/jXdaWxDivNrSTqNo9jDxapJM6eA12fhf/AJBp/wCuh/kK4eBuRXceF/8AkGH/AK6H+QrTD/EY4pe4a9eVfEk419/+uS16rXlXxJXd4gcf9MkrXFfAYYP+IeXatN/xN9Pyfl88Z/z9cV3GhWk00a6hYgNPAcbf76nqK4XxBaSN80XDqdyn0I5H612fw31dJZntydvmjcqk9GHVf51OEknFxKx0WpqR29hq8FxH8rgOOGjY4ZT6c1NNexAEySIq+mck/QU97a1nIM8EUh9WUE1LBZWkLb4YIlb1CjNdZxGbFC32w3cqlZJCFVT/AAIOg/rXGfFi3C63G6qAJIAf516LdAda5T4q2nmWul3ajqrRsfoaTHHc+a9RJt9VifsJCp+h/wD1V2+h2EFs/wBogBzIMnniuW8Q2jtfmOMfO0g/xrc0a7ktYlimBwPWuDELU93L5e67m9pdk9x4viZgVjUb1cdjirviPwpo2varNZTm9sblh5jSW5Bjk9yOx+nWptGvLdnV1kCyDpmt03KtMs7YLgYyK5r2PTtzHHeHPhjpOlaqkst5eXhU58vy/KQ/Xkk/hW3rmjTXXia3vYBlBw/tjpiukS/R/mZMEd6hm1AbSsS5Y9hSlLm3KhHl2OA8ZD/ibWMX8Rfn8ATXefDSPf4is+OFGa4HXLaf/hJLWS4VlDo5UH2K/wCNeofCm3zq7SkcRxk16GFVoI+ezKV6z8jp9VieW/NxCMzwuWUHuDwR+IohvYiPkdevKMcMp9CKtrgzM3qaS4s7Wc7p4Y3Pqy811HmlK91WC3iLSyqvoAck+1clrdtPLE+qXqiMkBIoz1RfU+5rtFtbSFt0NvEjeqoAa4v4karFb28Vs0gUf6yTnoO1AHJaXKH1q9APA2Z+u0V2unEECvPPCbNJJcTSDDytvI9M9vwHH4V3mlN615c2nNtHtU4tU0mdBCciu+0r/kG23/XMfyrz2Bua9C0r/kG23/XMV0YbdnJi/hRarwTVXxLMf9o/zr3uvAdWQtJLj+8f50sZ0DA7yOb0mbOtXe7H+rXH/fR/+tXoWitJo4Esif6DckPvH/LNvf615fNvstVWV+InBjY9hnBB/MD869g8HXiX2hRo+GaPKOp5/OtsM700YYqLVVm9Hdq6BlIYHupyKhuboIuSNzn/AFcY6saQaXYt92EJ7ISo/IVZtrK3tsmGNQxGNx5P51uc5V0G3+zy+XLhnky8hHdicmvDfGdt5TahFjGyRh+te+xYS8Rq8j+JlgYNd1aPb8rMXH0PNJlR3PGtKkaDVnx/EAf6f0r1rQZN9soxg4zXlK28n9ogxrkKPmx9eP616Fo2oKsMeThgMEV5eJXvH0uXT/d2ZLfWjWc0kKJi3fMyOxyWJOWX8Ov0PtWde2t7IY3hlxHngZ6fhXWFLa/8sS5ZVO5QDjB7EUjWdzm6AuIyJPuM8OWXjHYgdfaudOx6d1szMkR441kSMTSDCpF3ZiP6dfwrXtrKG0s0t4gdijAzTrKxSCUXDs8l2U2NITgY44A6AcVNcNhDtBZvQUgcrs4xlA8SSxKPljRSPxJ/wr2X4Xrt0zU5fbFeN6erya7qEkgIbzAuD1ACj/Gvb/h/F5PhW5kPWR8V7FBWgj5DGy5q0n5iRp9ju5Jjxb3GN7f3HHQ/Q1pJPjGRn0K85qSFFKFWAKkYINVn0myJz5e0eisVH6VschV1XVY7aPH35m4SJeWY/SuE1ezksCxusefPmSQ5z17fhXocdna277oIEV+m/GW/PrXlnxH1YS3dysLj5V8lOerHg4+mSfwpN21Y0ruyGeEn3adCfau0tcGIVxPhweXp8SrwAK7Gxb9yK8q+p7jWhR8TQK+uajuGf9Jk/wDQjXD6xpskUwuLY7ZV6HsR6H2r0PxAuda1D/r4k/8AQjWJcwrICGHWk5OM7olRUocrNfwR4tt9RhWyvGMV9GMbXP3h6+9dmp7qfyrxa/0ZHIZchlOQwOCp9iKbFq3iDS1229/JJGOiygN+vX9a7YYqLXvaHDUwUk/c1PbCxPWnm2F9pOoWXeSI7fqORXjMXjvxCg+b7I/1Qj+tP/4WL4mhRjbJYq5GNxjYkfrj9K0+sU+5isNVvsYOvRw3PiCytmxuhYs49x0FXvKSRvmGc1yEK3MV7Ld3DmSeVizMa6Kx1FWULIvNcFWpzyuj2MNBUoWe5qw2MYOQDn2rRhtZAo+dsfWqtndReta0dwjDgisTrU7bD4LFGA8xmP0NWktbaBwyLye7c4NVjMAPvVWuLlSpG4k9qAlNvdmn4hEd9opCKMjn6EVf+GNup1hZT92KIua419UdlMS8K/b3p+la9q+hzSPp627rImwiUE8fnXVh6qg2pHmYyi6iTievzNukZu5OabuJ6mvJZfHHiLODFZqT3Cn/ABpo8ReJbzj7THED3ii5/Umut16a6nnrDVX0PT9T1K1022ee8mWNFGTk14t4m1i48U6ixjVktOgDcZHp9P51pPotzqMol1G4nuXzn942QPw6Vt2GhQw4JHNYVMTdWgdVHB8rvMw9E01oSG24AFdJZ5V6uJaquABThbhHyK5DuNG2bOK7zwt/yC/+2h/kK4S2HSu78K/8gw/9dD/IV1Yb4jjxi9w2K8w+IKbvEDn/AKZrXp9ebePBnXn/AOua1rivgOfB/wAQ4i7tFkUgjk1y00NzpOoi7s85DAsoOM47j3rt5FrOvbZZQQwrghNwd0ejOEai5ZHaeGPEdnrtmskMgEw4eM8EH6VugkdDXiM+mNFP59tJJDMOkkbbT/8AX/Gr0XiLxHZqFW8SZR/z2jyf0IrvhioPfQ86eDnF+7qevsd2c1W8U2wvfB8+Bl7aQSfh0NeYDx1r8a/Pb2b++SKp6p8QPEFxplxY+XawQ3CFJHRCXweuCTgflVuvTXUzWGqt7HKyPDf6/cTRD93F8in1Pc1ZaBXfkVl2h+zv8i8HrWxbypIRkYrz51OeVz2qEFTgomhp+nqcEZz7Vtw6eWx8zfnVfTp4o1UbhW1FcIRkEVnudCnYkg01No8xn/A1oW9vBByiAH1PWqRu1UctVWbU1QEg0WSNfa6aieL7VJ1tLgAb4X6+x4I/kfwrsPhtCIbHULg9gEH1Nee3uoPeoYv4atad4m1nR7GW1tYbaaF235cHOfwNdmHrRiuWR42OoyqS54I9RztPFBYnqa8ofxz4gYlVtLVT65Y006/4mvQVNxHCD3iiwfzJNdDr011OFYaq+h6Hr+uWWi2bz3cqjA4XPJNeKahcXfiLU2uJgwiLbgp6n6/4VuroMt5cCe+mluJf70jZx9B0H4Vv2OiQwKCBzXPVxDkrROyhhOR809zH0axa3QkjAIrorAkEVPHajpipYrfY1cqOw0bY5Ir0bSv+Qbbf9cx/KvObcYxXouk/8gy1/wCuY/lXZht2cONXuot14deRZmlB6bj/ADr3GvF7pf30n+8f50sZ0JwO8jmdU05JomGM+xqn4U1yTw1qIiuyxsnO0v1wO2fp610sqA5rF1DT0mJJA561zUqrpu6OutRVVWe56xbTxXMKyQOHRhkEGphIwHWvE7CTVNGP/Esu3SMdIn+ZPwHUfga1ovHWuwnE9paTe6kp/jXfHEU5dTzZYWpHpc9U/iDdwa5T4uW8UJh1OXiGSDDt7iucb4j3yj5tJUn2lrn/ABr44v8AxPp0WnT2kFraRvvwrFnY9gTwMd+lOVaCW4oYepJ2sczo0CtFLcMBmVsgeg7Cr0VqGfg4qnYTCFRGQdorZs9juCDgV50p8zuz3aaUIqKNHT7WRMFHOa2reK5dgC36VHZSxAAZFacUyrypFZ2udEarQ+Ox3Y8yVvoBV+2ghhxtUfU9aoteKo5YVUm1VY+QcmmkkU6t0Z2p2EcOvzTRgATqGI/2hwT+WPyr1XQYxb+EbKPoZCX/AFryS+vJbqZZUA3LnHvWz/wn9/bWNtbHSVbyE2BlkxkeuMV6FCtHls2eBi6E3UcorRnoquVOBQWJ6mvL2+IepycQ6XEp/wBuQ/0FQy+JfEmoKUDwWyH/AJ5Rkt+ZP9K1daC6nNHD1JdDsPGfie20OyZfMBu5BtRF5OfpXj9tb3GoXn2m4HJ+6v8Ad/8Ar10MHh6S5uDPeSyTTN1eQ5P/ANauis9Ijt1G0ZrkrV3PSOx3UMKqfvS3M/TLcwW6qRit+0YiKkW0BHSpootq4rA6znvFep6jaeItU2rbzxC7lAVsowG89+az18QpudLuyuoWXliq+aoHrlef0rT8Ywudf1Q44N1Kf/HzWCFxIC3Rhsb+Vd7w8JbnkLFTjsacWqafctsiu4Wc/wABbDfkeaLhFKngGsaSCGVoWuYUlVPkdXUHiok0zyVnS1uLiB0O5dkhKlf905H6VlLB/wArN4Y7+ZFm4iUH7o/KqzKMdqgaXUE4LwXC/wC2DG35jI/QU1L1WnWCeJ4Zm+7u5V/oR/8AWNc9ShOGrR108TTqOyepFeQgglRzTNPiR2ww5q9IvFVVURS7hXOmdSRfEaxNwfzrStZBgYNYU1xuAqzZz4AJqrE8xsyk+tRFSRUSzByMmnS3AUgLRYbkElsIyWPU8j60/HmAbRwaDumQE8lea0tOtM8N0HNUSV7LTDK4Ljj3robfT441AVQKfAgTHFXkYYppARJAqDpS8U6RwOKROe1MQoHIpzoSARTkXFTqOKAGQAiu58J/8gs/9dD/ACFcaq12XhT/AJBZ/wCuh/kK6MN8ZyYz+GbNeceOh/xPX/65rXo9edeOf+Q63/XNa2xXwHJg/wCIcu61WlT2q8VqGVOK849QzZUBFUZ48DpWlKuM1TlXNBSM11XPQVBPAjqQQKszrgmoCT0pMZiXFusTHaOKns40fg8Gp7qPcDVSJvKbipuWi+oETgA8CtW0kDLgGuelm3EEVdsZ9pqhXNaUnJ5NUp5Cz7VpZLgHPNOs4TI+aVgbJrWI8Vs21p5i8im2tsEG58ADkk1rWZUwJMEbymGVJUjI9eatIkgg02JTkoD+FXFtE4AQD8KvRbHTcoB+lOKgdKqwrlZYVQcCj6VK4pgU0AOQc0/bQop1IQ6M4NejaP8A8gu1/wCua/yrzqMc16Lo/wDyC7X/AK5r/KuvC7s4sb8KLdeNXQ/fSf7x/nXsteO3I/fSf7x/nRjOhngd5FF1qtKlaDLmq0y1xHomZPEDVGaNc8gVqSjiqU68UDM9okJ+6Ko3lnG6k7Rmr8gKmoZDlaRRhGII+MVft4FMe5WxUd3FzkUW8vljBpJlF+2fa/WteKQlOGrmBL+84rWtLjEeDTsK5bkdupY/nVIuZHwKdNNkYB61YsbYtg4oSBsmtIjxWpHp4lUbhSwRRwJvlYKvqa2rbYoAYc1aRLKFvpUKcmMflVtLJM8KAPpWiUFJtp2EVxEqDgClA59qe45oVfagByLxTttKBxRSEVdevvC82t38F3qi2tytxIrrL8nzbiDjI5GaqP4Ysr+3B0vU7WY7twYODn24rT1+GObVb5Zo0kXz5OGUEfeNYEvh/SXJb+z7ZHP8USCNvzXBrt+tJOzR5v1NtXTGXfg/VEeUpEkkbLnKMOtZdxp19aRxzXFpMhX5GBU8ir7aXNbc6fq2rWhHQLds6/k+RSrq3iiy/wBVq8F2o/hu7YZ/76Uj+VWsTTZm8HUW2pzF5H5U7KcgdRkY4qjfWsd7avBLna3cdQfUV3J8YX6jGq+HLG8HdreUZP4OP60g8Q+Erl1a+0O9spB1/wBGJX/xwkVqqkJbMxdGpHdHAW+mavb2ytHazyRbchof3ikDvtbBH4Niqj3UwbbKbfd/ddjA/wCT/L+TGujvdfudT8XC7txe2WhQR+TCA7xPn+/tXnFbJuhOhYarp12p4K6lGjE+wMgR/wBTWUqdGb6XNo1a9NX1scG9x5ABuo5oFPRpEIX/AL6+7+tW4ZgyhkYMp6EHIrq59FhSHzJfD81rG4/1+lXLwhvfa/B/76rK07QrVp7yNoJfs3HkXEirFOcjncUOGwe5znNRLCL7LNY45/aRTilJI9KuQr5kgJ6UkWhanG5jh+zXS5+Vy5jYj3XB5/GrH2bUbJh9q0y4CDq8REgH4A5/SueVCa6HVHE05dTQh2xR7m7VDY3upX8Qm0rTLq8iGdxSQRADsR6//XrL8R3SSeHL57aUb1Taw3bWUd+DyDjt7133g+8FpoFpa2zgJBF5bucfKD2J7nHauOfM5KKO5WVLnWrbOZh8RBbs2hSaO8X5pLaYgkL/AHlYdRXS2dytxCskRyjDIpNe0+21mWKVpIzewcxTGMbk/EHIFU/DsTx/bEmXZOs2JUH3Q20ZK+xGDitIqSdmTJaXtY10TPWrCLiuMvZtSk1rUUh1e7toYpVRIoo4SFHlIx5aMnqxPWrtjbajNnf4g1LPtFbf/Gq15fMx5vI6vFSL0rCs9LvpnZX8Q6p90kYjtuv/AH5pV0vUduTr+qY9fLtv/jNTJqG7E6luhvCuy8J/8gs/9dD/ACFedJoOoNFv/wCEh1UHGf8AV23/AMZqzax6tZQ+VB4o1VFPzY8m0PPGesFXQrwjPU5q79tHkieq15941H/E8f8A65rWRrN34gstS8iPxVqnlmMOM29nnOef+WH0rBvl1W+u99x4i1KSTHzHyrUYHYcQ101qinHlRWFwNWL5+jNUioZVrLudNvop9g17UseWj/6u27jP/PKkstLv7u98v+3tSMSLlyI7f8B/qq42lFXbOx05RjzNaE9wvNUZVxWw3hiRuuu6qf8AgFv/APGqB4SiCs1zr+qqo6/Lbj9fKrJTi3ZM51WXY5idc1TcYrob3RdJgB/4nmryn0T7Of18nH61kXOl25JFvf6s3OMs0B/lF/WteS5vBTltFmZNyKzpxg1tP4dmYbzqmoKhJHSHg+n+r/rTJvCwBAfV77c3TIhAPt9yl7J9zf2U+xhqanjkI6Uuv6E+laYl5FqF25E8KFZPLwQ0qKQR5YPRj0NRYwKbjYxqJxfKy3Cxdxmum0yIBRxXPWCAutdVajagNIRbjg+13Mds3+pCmSbnqo6L+J/QGo7T4j2umXiafrTCOCWRvIlYYVFGPlP4nj6c1HbSSebehSdzeUgI99//ANeuX+IWgyCXTpZRHJ5OdykfeDYz+ORXn4mTqVfZttK3Tv0OyhTpyjafU9pisLbULVbi1Kxs671aPgEHpx0NZPlurPFMNsqHBA6H0I9jU/w7ubh9AtTfLGoUeXEF67BwM+/FXdfTy9UgI+66Mv5EEfzNa4OpJrkk7nnyvGo4MygnFPVcinD7xribm51WbVdREWs3dvFFOY0iiigKqAq92jJ7nqa7rXBux2hXFKFrkraLU5VJbxBqWR6RW3/xqtC006/mjl3eIdTDKuR+7tv/AIzT5fMfN5HQKMV6Do//ACC7X/rmv8q8hXTdQ25bX9VH/bO2/wDjNbUUevw2yLF4o1RUQYA8i04H/fiijiadN3Zx4m9VJI9PryKdR50n+8a0Uk1wyIh8V6rklc4gs+hP/XCuY1TSr2DVLiEa/qZVcEZjtsnP/bKtatSNZJxKwVCabXc0StV5VFZf2C9MhUa/qWAOf3dt17f8sqW50q9juZYzr2pfKQP9Xb/3Qf8Anl71hyeZ6HsJ3tYdMvWqcoqxYaHdXl1Ira5qXlIOSEt+vp/qqvt4R3ddb1U/hb//ABqspSjF2bMZy9nLlaOZnXmqjcV2S+CrYqWn13VFA68Qf/GqoXfh3RIBzrurSH0Q25/lFTSUtUxRq820WzkrgZFZ8nDV08+j6czBYL3WJCTjl4P6RGqEvhcSuGGoaiiN90Hyuf8AyHVKk+50RhOX2bfd/mY6nnNWI5iBgVoN4UCEqNTv9/XGYuf/ACF+lZepadJpWrWUP2ueeKeCVyJdnBVowMbVU/xHrVclhTpyirtF60zJIM11NjGFUcVgaVHlxXRxnYtSiCTzvKS41EjK2XEWRkGTGSSO+OPzNbGgeLtI19za3X2VdSjCrLFgKSxAOVHUjB7ViWkct5p1pbRAEybncHocuc/4VwtxYyaZ48k1A2qtIsiSw4/vKACv5ivMrSnVqSipONtjshRpyhZ7nuV/pbW9t59oWkjHWMnPHsazyAyqynKkZBrq9PcyWy+aojmZQxUHOD6VzMi+Xc3cWMBJCVHoDz/U124aq6kdTzYSbbT6EW3vTwnFKv3acDxXQaEeKdtpR1p+KBkGtD/ib3v/AF3f/wBCNUWq9rX/ACFr7/ru/wD6EaoGlLdmcPhRBKODVCdetaMlU5xxUmiMm4XrVGQVpXA5NZ8o60FFKYdazrnoa05azrnvUgZUTvZ3Aks5JLeT+/Cxjb8xg10Fv4g1NYwZbkXI7/aI1kJ/4ERu/Wufm+/VuP8A1IrWE5LZmM6cJbo6i018SYM9igb1t5WT9G35/MV0Ft4gsJFEczzp/tyRcD8VJP6VwVjya2YYEkHIrVYmaMXhKcvI0vEWj6Tr9u6JfWomYYWVZAjN7MrYJ/KqWs3Euj+CHnjyZbQO0iZxuYMc0j6UkoxnKnqCM1XutGNno9xZ2oMllIpzET/qyf7vt7VFWr7TVo6MLT9i7c2hS8D6p4gt9b+x61BCftCJMjBslUYBgCfoc/5NegWEq3N1eSx/dEgjz6lRgn8+Pwri9LiludP0C4EgS5h8zSZ5TztKfMjfUrtA+ld3YW0dpbJDCMIgwM9T7mirBRlpsOnXdWF5fEtGcxP/AMhzVv8Arun/AKJjrT059so9DWbP/wAhzV/+u6f+iY6swNtIPpS6knR2Mnl3kRPQnB/HitNYdzyxq2OThT0rAjk3gHNboVp0jnibDMvP1rOurwv2M6iuiGTUksbfbdsRETtBXls+gqiuoy+WrtHDPEWJjbBU4/A9fY1m+ILiRdSiVo/lh5Y98t/+r9amglwpKhWRxyD0NFKNldnoYbDrk53uzUv/APidNBdaeA00abJYWOGAz1HrVB7W6jbb9kkyT2U8/pUEpWEpPHIY3JwNjYYVt3etzadp9st2TJdyLkqvWt1qaPmpWjDVEWo6Ld3VwJLV41Vo0B3ZGCFA44IrQsbCPTLJUkeNT1d2ONxrm5vEN/P558uOJIxk5yW6fXFRLNLPJbiVi8hXzCewzwBjt3qJxTVjGVGrOKjJ6G/d6xZ26sYQ08g9sKK5q/uLu/uYzPJsjbcVA7AY6DoOtKZf9EuJj0ILD+lMLBYLQNzJuH4DBz/MUoxS2NqOHjTd+pSS3QMzkLmN2BdjuP3jz+WK3NH8M6jqALuht7ZyZPOn43ehC9elbXhrQbRFlv8AWNpMZLrE33Uyc5b1Pt2rH8SeN572VrbSvkhHBl9foP6n8u9aPTcwnipVJclDpu/8jYktPDfh+EHUGF3OTn94chj7J0P5GqLeK9FBKw6DGY+xMCD9DzXEsx8wyTMZJG6sxyT+JpftA7Coc+w1hb61JNv1LXxI1bSbzwtOltpP2a5NxalJEwqj/SI88A+mR0rjT90Vf8YTB9CZccm4t/8A0elUG6Ck3dGNSChKy7f5mlpvUV1EH3BXLaWMkV1Nr90VAkPic21x5pYpG6GN3H8H91voDnPsTVu90uPxIcSv5V1ZvtIxkj6+oIwQaVIg4IYAg9QartbGynjuFEuIhtWWLl1X+6y/xqPzFc+IoOok4uzRtSny+p1vg+OW3tmtJ5PNMR+RyP4T0FXdfcPeWZHTDH9B/jVHw3dw3Ui7JlfccZQ5B+vp+NS6xIJdTKodyRLsB/z+FY4SnOE3zHPPWpcgONxxXED/AJCeqn/p7b/0Fa7QmuMjGdQ1X/r6b/0Fa9IT6F+xbDlfWtrSXAuwjdHBWueibY4NakEpDK69QcinFgbiRM8DANnb2PamT6pFb24W9kEefuse9TOjh/MgPysNwHrmuV1a7zq6iSPCRjy9x9Tyf51yRpvncWTQo+1nyvY2E1Jk8p7i2QkDIeJiMr+oNSarE2oXY1DT186GRArhfvIR6is2KTEexlDR5yB3H0pBJLYustpMY5JB8oU/e9iK61ZaHqOioNOOj/AVY5Ek8sW7qSfTrWhqej30+oTta7PKkcsHJPHtjFXNS142EMEd0N1y6ZZE9axJ/El7NHK6RLHGnHzkk56djVNIy5qtS0oqx0lpYRafZrGSiKv3nc43HuapXmr2VorGM+fIPThRWI9xJJcL5zlyibmz0Geen0qrKxGmyuwwxxj8TWPs03exnHCXfNN3C7nu9QvAs7+Wm3cAOwzjgdBWfbRL5cUzcfKMs/zc4OTitKVwHtc58za2cemB/UGum8M6BaWVmdR1hkLQDPlZ+RMd27E/oK1S00N6laGGjr8kYmi+GdR1CLcY/s0S/N5lwCm4k9VGM9vatqTT/DmiQKNTnNzIOzuQpPsoPP61keI/G9xezNb6X8kQyDIR1+n+J/LvXKM5MrSzsZJW6uxyT+NJtI50q1fWb5V2X+Z2cmv+GTxHofmr2YoB/PBrgvH93pt1rujHTLSW1xb3W9XcsD80GMcnHerfnr6VzviKQSa7pmO1vcf+hQ0lK4VaChC6b6dX3NfSeorfUZFc/pI6V0cIzWaMx+lXLWQlXtETKABktGeTj6HJ+jVFeeHpru+OrWVxHiVQ6qSWUHtj61ZNt5m1kYpKh3I46g0mnTmwla3eTyVkJIhc/uyfWNu3+6ema5MRQk5c8Pmb06lk7bnoOiyiS2imKhSQN31xWPeYOp3n/AR+n/160tFZTCTvxsG8qR93/JrFDmWWaXtI5YfTt+mKWBhKKtLocdlztoeOBSUmeaXvXeWh60tIKWgoh1j/AJC99/13f/0I1QbrV7V/+Qvff9d5P/QjVJqJfEzOHwoikFVJxxVx6qzjg1JRl3A5NZs3U1qXHU1lzdTSKKktZ1z0NaE1Z1weDUjMub79W4/9SKqT/fq3HxAKtEss2P3q37XtXPWZw1b9seBQwRqQnirDrvgdfUVSiarsRyOaQzm9PDo+tWMY/ezQpqNsD/z2gYbsf8AP6V3tjOlzawzxHMcqB1PsRkVyUC/Y9e069KsUt5z5qqu4tE6lHXH0bP4V0WgRLBZNFE0j2ySsIGdcEpnI/mR+FdEnzU0+2hywThVkuj1MOf8A5Dur/wDXdP8A0THUwGORUE5/4nmrf9d0/wDRMdTowIxWRui9aPxjNdDpc260eP8AiQ5H0NcnGxRq0Ybx4CksfIB+dfVe9N6polq6sGvM1vqgaUBg8YJGPTIzWebuOFt0XzxnqAeVre1yMzQw3sX7xY1wwAySh7/hWMXtnGTaCRv+uRzSp/DZnpYaV6a7oImivdQswknBcBl9qW/na+1G6k/5bQyfIvqo4IH61HBOItUgkMSRqp6KPccHHFWtZsXg1B2hjc+YfMjkUjHPUEVp0LbtPXsVJnEjXW3pNDuX6gYP8qIZxtlbPzbFCgdT8vb8TU9hod7cyqcpCMn5fvHnrgdP1rS1CfSvBtmtwtnLfX44V2+YK306D+f1pWIqYiMNI6samhTNpMc2pSXFmrsFSJYN7EDqWGRjtxWjp9pZ6bby393cw/J91p02bB64PU/yrhLn4g65druWaOAN0Cg5H64/SsG7uL3Vpgb+5luOc7ScL+QqueKVranHKliKr9+dl2R0fi3xdPrcxtNPJSwB5YceYe5NZ0WIkCoCWP5mm2dkwUBEx7noK1bW1SI7mILeprGUmzspUo0o8sSC3tHlOZOB6VfWyjC9qjiv7OWWWG3uYZJoceYiOCyZzjI7dD19KkUGT+LilYvQ5/xvAieHpGXGRcW3/o+OsVvuCug8cwFfDMrZ6XFt/wCj46wH4jWq6HFX+P5f5l/TDjFdLZvwM1y1gcEV0Nm/SpZmjftzxVoVnWz8VfRgRTEIbS2kk8xolEv99flb8xzV+Nto4/xqoDUyGgLk5bNcjb86jqn/AF9N/wCgrXWDpXI25xqWqf8AX03/AKCtUiXuiy64Oas2z/KOelMOGXFQq2x6AOtsJzJZKFPzodv+Fc7qrrDqtwtwoKvhj7cVLaX32eVGJ/ctw/t6Gp9eUidLtk3RsoR8DOPQ/rUPSd+5rhny1fJmULpIGxktEejDmrWneXPrVqyOrRgFivuATVY/YD8y2yu57IG/kKk0aWKLXIsxpGvTAPqCP6itUejO/KyOa4a8upL37zJId47hM8H/AD60y5cGK9RcfeEg+hIP+NSXtlJZ3kkUUcpfJGQuVdT9OlOsdDvro4GyJWUphvmYD6D+pFAlOEY3voRSS5iuSuS7NtAHJPQYrUl0eX7Hay39ytkJG3JA8TMSB0LY6fSnapqGj+CUSZYpr3U2zsZ8EKe5AHA/U1zt58RdZuRmMQR56Ajdj8eKasn7xx1K1arpQ0XdnbafaWulWh1G8mtWYHIkfhUA9Aep/lXDeKfFc2uzi1sAYdOQ8BeN/ua5+7ur3WJ92oXMkwzkJ0UfhV22ttoARcY71M6i6Do4SXN7Sq+aRKhWJAiDJP5mrEFsZDmTgelOghCZPf1NTM2BwaxudvITCyj29q5XxXCsOuaXtxzb3H/oUNdPCzPwWxXN+MEKa3pJJzm3uf8A0KGric+JVoP5fmXNNfCrXQ2rZxXMae2AK37R+BSONbG5CeKkdElQpKqup6hhkVWgfgVaU5FMQlrapbuDBLPGmMGMStsP/Ac4q+jADFVFODUymgG7k27mpAahFSLQMlHSikoJpjItX/5C99/13k/9CNUmr1CTR9PkkeSS0iZ3JZiR1Jpv9h6Z/wA+UX5V0vCybvc8+OMiklY8ubpVWfpXrX9haZ/z5Q/lTT4f0o9bGE/hS+qS7lfXYdmeJXJ61mSnk1743hnRm66dAfwph8J6Eeul235Uvqku4fXodmfPMxrNnPWvpU+D/D566TbH/gNMPgrw2euj2v8A3yaPqcu4/r8OzPluTl6vAYthX0mfAvhgn/kC2n/fJp58FeHCu3+x7XHptNNYSS6ieOh2Z82Wpw9btq3Ar3VfBPhtTkaPag/7p/xqZfCWgr93S7Yf8BoeEl3BY6HZnikRq7Ca9hHhfRB0023H4U8eG9HHTT4Pyo+qS7j+vQ7M8nh2kg4Ga0I34FelDw9pI6WEP5U4aFpg6WUP5U/qsu4vr0OzPCLk/wDE71Y/9N0/9Ex0B8Vf8XQx23jTX4oECRrPFhR0H+jwmsrmuaa5ZNHXTfNFS7ltX3DFO854hkVWjPNXIQGGCKSYx1vrEtpEyL88R6pnBX/dNLBqWlyOA92IkI+5OpVs/wC8Dtx+FVLyxcgtHXO6hYXRz+73VaYKKbunZneW95o0QL3NzZNj7oWbIX8M0l545sIokhsIEu51GPMYFQPrnr+VeTzQzqxUoQataRbTGf5hjjil1uaRp3+JtnZz+ONYf92kdoidgEP9DXO63qd/qUbpd3L7T0jiGP8A9f41disJJTkKc1fi0UsmW+U45I61V2zWMIxOZ0e1XaCLeVyO8hrca4t7FY/tBiheQ7Y1Y/M59FHUn2FY2o3jxX01vYrdwwxkJJfPCZUDbgCFUcnAJ+b7oI74NdHYaGscpmiWSSRmZhLM5kZd3UKT90cDgYHAqHG25qqnNpEr2suralGr2dvFZ27xkiS7DeYrZIGYhjjAzywPI4qd/DEd15n9p3s92kqKrQs22IYxyFGOpGeSepHTitaG1kjbBarC2+fvMaL9h8qfxala10qzt87Aqbjk7QBk+pq6lrbHhXYfjQlumec0828R45HuKBvyOb+INq0fhqRlfdH9otsj/t4jrmJuET3r0fU7GG7hsba5US28uoWSOhP3gbqLIr0hvAXhhgN2kxHH+2/+NbQoupG6PMxeIjSqWfb/ADPnayOCK3rZsYr2xPAfhlPu6TEP+Bv/AI1Mvg3w+vTTYx/wJv8AGq+qT7nMsdDszyG3kwBV6KavVB4T0MdNPj/76b/GnDwtoo/5cE/76b/Gj6rPuP69DszzFZc1PFICa9IHhjRh0sU/76b/ABpw8N6QOlkn/fTf40fVZdxfXYdmefociuQiONS1T/r6b/0Fa9zGg6YOlon/AH0f8a8W1qOO28U67DCuyNbs4A7fIlTOi6auzSliI1ZWSHq3FRS8jjrTBJS7waxudFiIzMgwRkHqKsxay0Nv5E4Z4DxuUAso9MEYIqBgGGKp3NtJglOaAsnozYtrmyndlF9D5WPkRpPLcn3zx+VX4/7Ogj825miRxnYTMCE/LArznULS45Pkk/SsSRJASAjA1Td0Woy/ndj1/U/GmmR7Vs7ZLydRy2Ts/M/0BrDuPHepONkNrbRD8T/LFcZo0MzM+4HI9a2orCSQ5CGndlqlG2pS17Vb7U4il5cFEznZEMf4mq2mRQrGGZJpMcZet+exis7VprhliH97GWJ9AO59qfodhIgF4WunLZJSePZtyOAAVB/GplfdnRCy0Q7TIkubcvaxNkHafMQptPoQee4PSrkFndT2BZhDbXPI2tlxkH1GODjrjoac8k5Y4XAqzbGc8HH5VnfyN+VpbkQ02ZZoytxEUDZcMnUc8dfx/Co0sPsup3Mslwbi2dV8qFlx5bc7unUHIq8YpT1Ymmm3Y0xcqbvcqRoN3BIrmfGKldb0rJyPs9zj/vqGuz+yAD7xBqbRPDVj4g8Y2dtqayNFHYXMi7H2nPmW4/rVUoOUrI58ZUUaTk+lvzRw9g3ArbtnxivV4vhp4dj+7Fc/jMasr4A0Jekc/wD39NbPCzPJWNp+Z5lBLgVdjlr0UeBtGHSOf/v6acPBWkDok/8A38NP6rMPrtPzPP1kFWInzXdDwdpI/hm/7+VIvhPS16LN/wB/KPq0xfXKfmcSvNSrXajwzpw6LL/33Tv+Eb0/+5J/33T+rTH9dp+ZxWaaW5rt/wDhG9P/ALsn/fdH/CN6f/ck/wC+6Pq0w+u0/M2aKKK7zygooooAKKKKACiiigAooooAKKKKACiiigAooooA8K8bD/iuvEH/AF3i/wDSaGsfFbfjMZ8deIf+u8X/AKTQ1khcmvKqr32e3Q/hx9BqL6VYi3L1pYoqvwQZA3VKRbZWa7VUOQeKzrm/3nEaEmti5tQ7BFHHenLp8Uabioq7AmjkZrSWZy5XGfarmlWLC/hz93nNdHa2Ml7Lst0G1fvO3AWtfSNM0vUQxgvDcLC2JPLO0KcfTP601BtXWw3WjFpNmcIoImAByx6AdTSX2k6lf2UkVnF5bSDYGkcxbQTgnOCQQMkcHnFbEmr6bYRSfYo87QQQiZJPQZP5/lVWTxLexpGkdtEPlJJdyTx64qtEa8tWa91HKRXkeiasdGjtY1itAsQVTkYAGMH6YrrdD0HS7TTklS5js7W4Zp0hMnALHJCg5xyeg4BNcL4vtJH1S01KE7HvN0bqOQHG3afyOPwNXP7JS5KC/vbu5SS3W3CpK0KAIQQVCEEE49T3Hc5hPubzouSjyaPqd4qeH0OGunJ6ZEcmKc9roUisYdVjUf7x/rmvPp9A0qLzPtmnW1zbzBFd5kEh+UALuznOMcGp5/DulSCaWKxtw80gmk2jb5rDOGyO/wAx/OndE/Vp7qT+/wD4B2/9hPNGZNPuoLpP9lgcfl/hWdc2k1sSJ4mXH8Xb/wCt+NcrDpsEMy3mn3ep2kqymV/Ju5Mg9xtJI2+qgCuw0PxJc2ttBBrMrapAeBcyKol5PfaFU8ew+tDSZLjXp/3l+Jmzki60sdjqdj/6VRV7ZXl+sW2lXEdjeaZcAmPU7DdEOCM3cQ5U8jrXqFdeGVov1PFx9RVKifl/mFFFFdBxBRRRQAUUUUAFeA+J2x4x1/8A6/P/AGmle/V8/eKs/wDCZa//ANff/tNK5sV8B2YL+J8imXpVc0xVJqZY6889UVHOanEoC1GkfNXILbzOCOKpCMy5us5CoSfpWPJaPI+4qBmu1OnRqm4imW9g11IwiRRGgy8jcKo9zVWDmSMDQ7Jvt2GA2lea6UQQwKSSB7mtTT9F0+7hE6XolijzveBgF46g9T+tJPd6PYxs1rAjS42qTHucsTxyf8e9XytbjhV5/g1OUM0er63FaC9t7S1t2DvJM6jzG9Fz1A5/H0xz0SX3hgTy241RL+4h4kWGcNsPuFIFSHXvJmdIdNjxJ+8YyS98YJwBgdO1cpdeVqWhNFPpMI1CL5IpEtid7nrIZMYGSu7OfwzxRoaONS65lZep1h1LwrGpMiQ5HXfGhP6mnR6j4VmOxYF39cxooOPwOawUsLN1WSGFFPYqMY/DpUTwwq4ivbeFg33ZNgw3sfQ1Nzf6rF/af3nVCDQ5gDBfSQZ/vlh+rAilbQpnXfY3MFzH9f6rn+Vcm+l2sILwwYT+NI2ZD+G0jP0pYke2C3NtqE6QdjwxjPoTjOPfPt9TRidCUfhl95u3FncQZ863kAH8SjcP06fjirngIqfHluUIYf2bdcg5/wCWtvVPTfE2p2+2PVUt7uNhlXClHx6VueGL2zvvHtnLZoyP/Zl15gZQD/rbbHI6961ope0TOLGuoqMozXbX5notFFFd54IUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4b4y/5HrxD/13i/8ASaGqES5NX/GP/I9+IP8ArvF/6TQ1UtxkivLqfGz2qP8ADj6Fu3i9qvImBUUC8VaUcU0ixI4wWyar3CtcXUdtCcMxxn0Hc1azjJp2ix757uYjkARqfryf6UpNRVydjMubxDMLezmmSGNSuFH3vc+ueuT60/TdR/sqYOpZom+V1YdR+NNnVWuJ4X5KyHpx9P0qlKYlcCJPNk6DcSRT5r7Ho0qEFDVXvuaOqWsMLRzWI/0K5KsjDopzyvt9Kpyf8vLHqFwPyq3pV5FHbXFjqGTDI275Fzsb1z2PSrH9iSXO77FeQTiX5SSCuMfTIoavsUp+z92f3mNrqA6faMf+Wd9AfzDj/ClsQ81oYUhkmkTOAg6fj0H40eMra807T7C3uFTzJr6LGxs7lUNn9WWux1m9sdF8q2S3HTcQpCr16+5pPRGcq1n7ivf9DnY9GvjE8l3dxQwkZZVAkKj3OQv61Cmmab92PUpCvoZlH6YrqYhaeKdLltIZ2tbnggHkN3GfauMvrW80u9kgvYsGPqOox/eHqKUVJq4qNSdRuMnaS6GxH4esiAUlnBPO8SY/kKp3WhTQM7WVwZVI+7KMfkfX8qq2d+8RBhkcL/d/+t+NdHp9+twAMgS47dDWM+eOtzOr7ei+ZO6OZMdymqaN9ptponGp2QZiCVb/AEiPv6177XlWqOdtgOx1Ow/9K4q9Vr0MHLmhfzPGxtZ1qik10Ciiius4wooooAKKKKACvAvEy58Y6/8A9fn/ALIle+14P4iXPjDX/wDr8P8A6Alc2K+A68F/E+RRjjqcLilRcCngVwWPUCNcmtS0TpxVKNeRWhbnatUhMmkUzSLCpC55Y+g7ms25v1lZobe4MNtt2iPYMHnPIPJP1rZ0yPzYriQ4Jc+WM+g6/wBaw4wJF5yrZJYodvP4VSmk2lua0KaqS97ZFvRtRg04NbSbWtJxtcAdPfFRX9mtldrBDk27MHic9HXGev6VRmaPzMKrTydPnYsK1dPuYJ9NXT71xHJG+YXAzsJOcemPanfm3OtwVN80Vp1/zM2U/ublu5O38OKmuJPItoFUdZSPyhlP8wKuS6FeyK6Wz28/mHdlHxt+uaqXdvOmo6LZXkDRNPeqCCeGUI4bBH+8KSQTqwcXZkDjcwaz8x5W/wCWcQ3E+5FWv7Iv3t2N/NbwwHk/xlR79v1rbudQ0rTZ3toYZAkZ2kKowSPxyfxq3d2SeJdHA0q4Ec8bBjBJwHx/KpV27JGE8TNWdrRfU5WLSoG2pHqxkHsy5P4AmraeG4FH7u7nVjnJB4rEcS2k0kV1AUKHYwIwUPvV6z1OWIgLKWT0bnilNS6M2qU6rV4SEudJvrXd9mlFyucr1Vh9BWx8Od3/AAn8fmRSwv8A2ZcZV1x/y1t+RVuzu1uFypww6r1q/wCG2J8eWWf+gbd/+jbanhakvaqMjysViajpSpzX9XPQ6KKK9Y8cKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8M8Zf8j54h/67xf+k0NQWvUVJ40OPHviH/rvF/6TQ1FZnkV5dT+Iz2qP8OPoasI4qcVDF0qcetNFMSThCat6AAdPL/35XP5HH9KzrqZY0LSMFUdzV/Q0X+zIAxznc2M8csT/AFrHEO0GS1oZ+s2Ef2xrqMM7ykKBnC5xzk+mBVJkWEBYRulb+Mjgf4D2rpNRgW4hCDG9TuUVz80saORnkcADq309aVGTcdT0MLPmjbsV5YgFWBCfn5du+KkARYbhMYiBU4HHIB5/WowzqWZh++kOFX0FZfiLVoNJsAHPmSv9yMH5pWz/ACz1P4da1Opli8nk1jxN4W0vzWkaA+dO2cnLHfg+4VF/Out8ZW+3VY5pRiPyup6cE/4isL4UeHZrRZ9d1fP2u4J2bxgjPVvb0H413XivTm1PTf3KZuIT5sY9fVf898U9GeY68YYiK6LT7zg0TY6SwloJD02nH5iuy03UbPxNZCx1NQ1yq7o3HysQOCR7juK4zziFIwd3Q56j1qSCU21zBd252yRydfrx+WcfrTi+U7sRQVWN1utmO1LRm0m/eOUMUPzRSL/EPb8+RUEJ8uZXRzwcggYr0Mi11/TQsq7SRkf3om74/Hj/ACK4rU9Olsrho5Rz2cfdf6UmZYfEqqvZ1NJIuXcomh0xx31Ox/D/AEqKvXa8MinZbjToTna2p2P4EXUVe511YSPLBrzPCx9L2VXlCiiiuo4gooooAKKKKACvC9eGfF2v/wDX4f8A0BK90rw7XR/xVmvf9fh/9ASufE/AdeD/AInyKwFPQUlSRDmuE9MmjWrIUrHTIhyKnupEig3SMFHvTQmaOigf2ZAezAt+ZJrC1DT0hvJHhLM07EgZwoHU59ua3NKj26dapITuWJQV7ZxSarB5yIVOGTtntXLGf71+ZVGfJUOdZFhIjg5kb7znsP8APamSRA7bdM7fvOe5/wD11PJNGpJHXoFHU1ArOqngefIc49BXUeqiTzngs5PJleMRyMybGIwcAfzFJHdz6z8Q9CtDJ5i6fCZZn6/Oygt/NB9QaxfE2rxaXYpHHiSd/wDUxHkyH1x/dB6nuePXHS/CTQZtKsJdT1Isb29YFS/3sZyTz6k/oKd7HJinGEHLrr+JJ4htEh1q7aZBsOH5Hc9cfjmqdnJLp86z2krwOPmwDkYFdb4109rq2ju7dS8tufmAGcoe+O+P8a47zgcADPv7UNWNMLUVakr+jO1AsPF1gTKBFfxL8zx8cHoT6qcfhXETac2nXcsFyWSSM49Rg9/pVvS7s6bqVvcW4JUgoyj+IZzt/n+OK7bUbK212ySSJ1WYDMUvp7H2qm+b1OfneDqcr+B/gcDZSG3uA6t07Doa63wq4k8dWLKcg6ZdH/yLbVy95aSW0rRyxski9VP9PWtf4eys/jm3RuQum3RH4y21OlG9WMiMzpqdH2seh6xRRRXonzoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4N43OPH3iH/rvF/6TQ1Xs35FS+Oj/AMV94h/67xf+k0NZ9tJhhXlVH+8Z7dH+HH0OlgbIqznisu0myBzWgjZFUmNox5reW/u3mcE2sRKqM4yR/n+VX4hNHAXgzGUGdvQN9a1vDlsLiyuoMDMchJ+hP/6qu/2VuDgbzEg5yeAK8nEc7qMv2iWhxdl8RNJQGLUormxuBw+6IyKfcMuc1V1bxj4bKebY6nmXncpgk5/8d60zVPBNxc6k62nlx2gOVdmzkHnpitbS/hvp0W2S6zcSdTngfl/9et4zUdUzdzw9J86bv2OQg1691iZ4vD2nXFzI3HnTrtUf8BUnP4nHqK6zwp4DCaguo+J7gXV85GIhzt7DJ7Aeg6V1+n2KWMJitYliROAqDAqaEskqlxgg5q3Xb0OarjXPSGn5mlfMqEoo6gYA7AVFbXDBwWJPY5qW5UM249QMVVkXGSKU5tTucBk+LdJUub21X5iN0ij+If3vw7/n61yhP7t17EV6TCwniCSHvwfQ/wCHauB1W1ayv5YWGNp49wehrqi1JXPZy+u5x9nLdGv4VuiGePeSXIkQn1xgj8eK3p4YrmMxzjcjdfUe4rg7CWSCcFG2+Xgofx/+tXfowkXeowG5ArCt7rUkYY6nyTU11OO1XTpdP1XSklGQdTstrjow+0x17RXm+vYNtYBuq6nYFf8AwLir0ivTwkuaF/M8rGVXVmnLe3+YUUUV1HIFFFFABRRRQAV4frv/ACNevf8AX4f/AEBK9wrw7XT/AMVZr3/X4f8A0BK58T8B14P+J8iHvUkfWou9SL1rhPTLkbDIqlcRvdytNIGMKcIvrUy5zWzoVoLvSlUgfI21j6f5xWGIclD3RqSjqzKa5uLW1aeEM6RgkxDGW+hJ4qvY+PvDs8e2a7+xTHh0uY2DL+mD+ddNLpImhkWQsYSNrHpge9ebXPgm+ub1kjQJAp2iSRgdw9RjmuOjpuzSCpVE+d2NTVvEnh+AiWy1a0cEYIGWI+gAz/SsCLxDdarI0Ph/T7i5mc482Vdqf98jOfzA9RXUaX8MtPiCvd5nfrj7q12Om2Mdha+XZwrEi/KFQY//AF11qtYcsZTguWDucr4M8BeVqaaj4kuFutQc7hHndjjuen4DivQb1wrFVHIORjtwP8Kp2LEXMZPBzirlwgZ9/c0SqOUGzzq1WVR3kLa3JMnzkkGuT8UaOtlMZ7VMQMfmUdEJ7/Q/z/CuicFDkdqnljW+tWifqVIB9u4/r9RV0al9GVhqzozUlt1POGbER7YwwPpius8MXbeQ0Ib5kJIPqpOf0Oa5e7haC4lhkXDISpGc1PotzJb3iPnhGVTnuuef0NayV0e3iKarU7I7G8so76Ly5CFc/cc/wn/CszwXay2fxFjinQq4025z6H97b8itocr603SGLePdOBJLDTLsZ9vNtanBT99RZ4FSrJUZU+j/AMzuaKKK9g84KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8C8ef8j94h/67xf+k0NY6Ng1614g+GtjrWuXuqSaxq9rLdsrPFAYNgKoqcb4mPRB3PNUf+FR6f8A9DDr/wCdr/8AGK4amGnKTaPSp4yEYKLvocFaz4PWta3nyBzXUL8JrFeniHX/AM7X/wCMVKvwttV6eI9e/wDJX/4xQsNNDeMp+Zz1pfSadc/a7cjBGJVPQj1/z2rpZLua5iRZtigDlI+FJ9fegfDODBH/AAkmvYPta/8AxirUXgLy40RfE2u7UAUZW06D/thWdXBzmtCJYqm9bGew9BzVxG3xZXhh2qwngd1OR4n1z/vi0/8AjFO/4QqQNkeJ9cB/3LT/AOMVh/Z9TujKdeMnoZ5eXdvC4HTFLKxkKlQQwrQHguUDH/CUa5j/AHLT/wCMUh8EyE5/4SfXP++LT/4xT+oVPIn20RVPm2+e/eoCMirCeDZ0BC+KNcwf9i0/+MUf8IZN/wBDRrn/AHxaf/GKqeBqSs9Cfaopodknsay/F1uJrZLjA8yPgn1GcfzI/M1vN4JkPXxPrn/fFp/8YqO48CtcRlJfE2uspGCNtp/8Yq6eEqQ3sb0MUqU1M84HByK7TQJvO0uE5yVypPuD/gRUv/Cr7b/oY9e/8lf/AIxVuy8A/Y4mjt/E2uqhO4graHn/AL8Vc8JKSsduKzGjWhZJ3/rzM3X/APU2Htqdh/6VxV6RXHnwQHmtmufEOs3EcFxFceU62wV2jkWRQdsIOMqM4IrsK3wtGVGDjLueRVmpu6CiiiukzCiiigAooooAK8L18/8AFXa+P+nw/wDoCV7pXDat8OLPUdXvNQ/trWLZ7qTzHihNvsU4A43RMe3cmsq0HONkb4eoqcuZnnwqVDzXaD4X2w/5mPXv/JX/AOMUf8Kwtv8AoY9e/wDJX/4xXN9Wmdn1yn5nJocmr2l6hLpk7eUokhnIDIegbt+ddAPhnAOniTXv/JX/AOMUP8M4HRkbxJr2GGD/AMev/wAYoeGk1ZieLpvRpiz3UtyAr4RAB+6Q/KD/AF/Gofu9BWj/AMIK3X/hJ9c/75tP/jFOXwQ6nI8T65+KWn/xiuWWAqN3TRn9ZhayRBvzHuTt1FQCWRWLbPkPatBfBUi5x4n1zn/YtP8A4xS/8IXLjH/CT65j/ctP/jFH9n1PIx9rEz3fMqvH1HJrQf54Qwpv/CEyZz/wk+uf98Wn/wAYqRfB06rtHijXMf7lp/8AGKqOBqJNaA6sSswyKZAxSTGcdxVr/hDJv+ho1z/vi0/+MUn/AAhMhOf+En1zP+5af/GKUcDVi73QKqjmPGNuDLHdIuC3yuR09v5EfQCubU4ORXo114DN1GY5/E2ush7bbT/4xVL/AIVfbf8AQx69/wCSv/xiur6vPqerh8zp06ahNPT+u4/TphPZQy9Sygk+/Q/qDUmj/wDI+6f/ANgy7/8ARtrU9r4Ea1gEMPifXQgJIBW0PX/thWhovhZdM1ddRl1bUb+dIHt0W5EIVVdkZiPLjU5zGvUmopYSUKqn0PMr1oTvynR0UUV6ByhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHDfFz4gR/DnQrDU5tNl1CO5vVtGSOTYyAo7Fxwc4CHjj61h2Pxs8Pz+JvE1lcKYNF0OBZn1YM0qS5dYztRVJIDsVyCeldj418JWviz+xBezNHHpepRaiECBhKUVhsYH+EhjmuN1n4MeHJotVt7S4fS7HUNMj0qO3hA2xbZvODAscsS3UHrzQB1erfELwvpE2rRahqixTaW8Ed1H5MhZXnUtEqgL87MAThcnjnFUL74reELC3tpbvULmMzxPP5X2C4MscSOUeSRNm6NQwIywA44zWA/wbW5fUL3UfE2oXWt3N3Y38eoG3iQw3FqjJGwQDaRhyMEdhyTzVnW/hbe6tcG+m8W3iatc6dLpN/dLZxYubZ3LbQmMIRuwGHOKAOmXx/4ck8QLotvfSXN8fKDfZ7aWWKPzRmPfKqlF3DkZIrJ1T4qaHFpGuTaYbifUNN0+XUVtLq1mtTPGn8SmRBlc4GRnrWX/wAKcsV8Wadq9vqs9rDYeSIY7a3jinKxRiNUadcM64UZDZPbOKoaT8C7Kxiv1l1y4uJLvTbnTGmNrEkjJMwYu7gbpHGMZYnj0oA6Txt8RY/C3wys/FUtg0813Hb+TaqW2+ZKAcM4U4UDPJHOAOpAqr4b+J6Xb66uuafJa/2W9pH/AKFFPdNK08Ik4jEYcY5HKg+uOlbXiTwPba74CtfC0t5NFbwLbKJ1UFj5LIRx052D86wtf+Flrrlzrd3DrM8R1a/tr+RREksJ8mMoI3Q8SIQckHuB6UAak/xW8HQ6Zp1+2qSPBqHn/ZhHZzu7mHHmgoqFlK7hkMBWtceNfD9v4NXxXJqI/sBkWQXaRO42swUEqFLDkgHjjvjBrzNvhDqek3/hK18M6xJbWmntqbz3/kxb4jcrHtVYsbSPlYcAY9q7y08E6Lpvw2HggzH+zWspLXfKw8xtwJZ/TOWLexoAsr4/8MNqE9imqK13BqEelSRLDISty+4rHwv+y3zfdG05IxXLeHfi/p+oXfhi0urZvO1yOeRJbKOeaFCkxiUZMSsckHJIAXGTwQSnhj4QaPoviTQ9Xt9Uuri60uNjOr7SLyZvOInl9XHnyYP0qxoPwrXQE8J/2VrtzFJoH2lN7QI/2mKeXzHRgfu+gI5oAk+GXxY0bxpHZWkh+xa9crNJ9hKSFdscjL8shUKxwoYgHjPsa1/FHxJ8K+F9Uk0/XNTe3u4o0mkUWs0gjjdtqszKhUDPGSay/C3wtsvD914Unh1G4mPh9L1Ig6KPN+0uzNux0xu4xWL4z+GepeLPiFrNxPqEun+HtQ0u3s52gEbST7JS7R/MCU7fMKAOvn+JHhSDxImhSaqv29pkt/likaISuMpGZQuwOw6Atmue8TfG7wnpFjNLYzz6pPBdLaywQ28y+WS5RiWKY4IPHfjHUZSf4PWL6808OrXcOiyajDqsulLGhVriJcKRIfmCnAyv6ir9/wDDC0uvANx4YXUrmJXv31CO6VFLRyGczD5TwQCcUAPi+J2jxX3iH+0LiKCw0wWPlssc5uJDdR70VoTGCGORhV3HruCkYqaT4r+DY9Ptbx9Vk2XM0ttHGLOdpfNiAMkbRhNysARwwHUYzWXqHwojvr3VtSm126GsX1xp16t2sCDybmzj2LIE6ENkkqeOeKfoHwotNL1vS9Zm1a6u9TttRutTuJnjVRczTxiNvlHCKABgCgDt/DWu6b4m0O01fRLkXWnXSlopQpXdglTwQCCCCMEdq06534feFofBfhGx0C1uJLmG1MpWWRQGbfI0hyB6F8fhXRUAFFFFABRRRQAUUUUAFeC6T8T/ABXqA8TTskUdtpq6l5WzRZzETAknl5uTJszlVyNvPI4zXvVczoOjeG7jwzqOnaPEsmj30tyt0iyyEO8hYTDcTuGSW6EY7YoA4e5+McOjHw/b6rYLcSXtrZyXE1vdxb42nVefIzuC5YdccdM1eh+LkL+Jhpsug30dgddk8Pf2j5sZT7Uoyo2Z3YPrjA9+QNG4+H3gWbXTayQquoyW1vI9kmpTIZYrcqsMjxLIN4QqqhmB9M81H4Z+Ful6X4g1LWdTkfUbyfWbjV7QM8ixWrSBQMRbyjOMH95tzyPQUAO+KPxLg8AvAJrBb0PC07Kt7FFIFU87Y2O5u/IGOOtc142+Lt1HFfxeE9LllWwewF1qE5QRw/aXQqmwncxKNjI6E133ifwH4e8Taj9u1i0mkujaPYO8N3NB5tuxyYn8tl3Lk5we9Ur34X+Er29e5n02UPIkCSJHeTxpL5OPKLqrgOV2gAsCaAMy1+KtnceIk0IaXcpqv9o3NjLC0igRJBGJGnLHjYVZcdM5rEsPjrp89rr8k2kSrLpViNQ2wXkVwk0fmCMgSIduQxHqPeuz03QPB2s+I9b16wtbS71ZxJpGozq7N90KHiZc7QcBQSBnGBmqtr8J/B1taXFsumTyQ3Fl/Z0gmv7iT/Rg+8RLlztUMARtxQBjf8LfjiOsWl74c1G21uxvbOxj05pomaeS6BMIDqxRchSTyQPU1H4q+MP/AAjD29pq3hy5h1draS8msmu4spErlQUYZEjNgkKOeOcV12p+APDWpXGrXF3p2651R7eS5mWeRXLwDELoQ37tlB4KYPrmoJvh14fl+yuRqiXdurxrex6pcpcujtuZXmEm91J5wxIHbFAHCeMPjDeG3c+E9KmNtBcafHcahclAifaQjiMRk7idjgE9j+dd/wCN/GB8OXujaZZaZNqus6vJKlpaRypEGESb5GLtwAF/PNZOoeAvA1x4jW2u7eU6lcRwz/ZhfXCrKIMLHIyh9rMu0Dccn8zXT+J/C+leJVtP7Uim860dpLa4t55IJoSw2ttkQhgCDgjOCOtAHAf8Lw0UaGmqy6feRW02mSX8HmFQZZI5vJe3H+2HK+xDA065+NFjbeKo9Fm0i6DLcwWdzIJkLQTSKpI8vqyoWAZuOc4BrqZvhr4QnstBs5dEgNtoUhl0+MO4ELFgxJw3z5ZQTuzk9c1YuPA2hz69Nq4jvYLueRJbhba+nhiuHTG1pI0cI5GB1HPfNAFD4cePH8cRzXEGhX1jp8ZdEu53QpK6OUKqAc9s5IFdtWX4b0DTPDWlrpuiW32ayV3kEfmM/wAzsWY5Yk8kk9a1KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzr4y63rGi2ehf2ZdXGnadc34h1LUre2FxJaw7SQQpVgMnjcQcfjXmWjweI/Gvi74XXvitrl4kN9L+9sUVJBEwMczoyfI0i7R2xtBTaTmvpKigDyT4uar4ut9durbwxqlzp9ra+HrrU/3NlHP5s8TrtjyynBIJGB+VcfeeMPiHYeHPFNw19dXN1Dp2l6jbOunRgwGZlM8artIYBS2c5IxnjrX0XRQB87678RPFNxYeIbzS9TmttOTWYorKSaxaB2tPJLMsbNA20swGGkUjtnJGZ4/G3iS4fQ/7a1nXPDljPpYuIJn0dJ5r25MrKUkCxlRhQpCqE3Bg3GcD6BooA8M03x74lm8Zadocs979pTxLd216h07CCxG4wDzPL24Ixgg7j3JrgbbxT4q8L/DDwlpugvq2n30elTXYX7KrRSuLhx5eDDIzPt525QAEEtX1jRQB5Z4M1LxbrvxL1gXuqSWmg6db2Ey2JsU23DTWzFwJSNw2yYJ5PYcDrw/xI0K9u/iT4/1cpJc/YPDqtYxzWMc6bmjdSib0PcsxA67iDkcV9F0UAfLt1qXiHQfH3ii58Pz3ttqt2NDS1sI9O8yLUMQKsiM2wiNUVmJwV/TjpdM8Y+NpviXdWd/fx2cUeoz240qW2c+ZahT5ckZW3Iz/FvabB6YHGffaKAPm648VfEGy+G3h/WtR8TP9q1OQvPA2nJbyxom4GNHELoGbg5dR0wO9e6+B7271Hwfo95qK3a3k9qjyi7iWKXcRzvVeAfYAfQdK3KKACiiigAooooAKKKKACiiigAooooAKKKKACvAofh54n1O58NWuuwX39mwy6w18I9S2HErlrbJSQMwPGAM46HHSvfaKAPnrSPh/wCKoNd8Oape6fdPqieGW05rz7arfY78MfLkk/efMgXH3Q+T2J5rJ074f+O4vCPiC1jt9YTWLnS0t3R7mFYri5WeNvNWX7QxZtvmfMVTg49BX03RQB4R4u+F2qXes3UOnpqs+lReGLhLZ31ZwzamZWdNxMgZuWzlsp0z0FZviLwl4+v/ABNp95DpdxHc2aaayXsF4pMpUILgSs04CkfONqxkNzk+v0TRQB578N/D2s6NY+OUuols7nUtfvr6xdnVw0cgXy5DtJxyOh545FeQjwv4v8P+GNdv7yDUtO+z+Hb2PVrm41ETC/uyWZJYgHYjAwdxCkdPr9QUhAYEMAQeoNAHzbD4K8Z3eia3P4dttS07Tb6HT2Fld6iJZrxkIad1PmkKGHYuu4cHHQX9D+HXiG6u/D1pqEOtjw6mo3k13DPdpbNDDJAoVVEVw7bPMBwoYnrkAHn6EHHSigD550XwR4+g8PWdtdQ3huYvDOq6ed1/Gx+0ySyfZxnf12FMN0XoSMVQ8TeDvEXhjQfEk0U91ZaRc6Xp32iS41fAkuRMgnTzGclCwJXdwvOM4r6VpGUMpVgCDwQe9AHjf7OVyl9/wmF1YxXEOjtqKJZRyXJuFRVjAZVk3MGAPcEj3r2WkRVRQqKFUdABgCloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a schematic diagram of creating an advancement mucosal flap. A probe is inserted from the external opening of the fistula to the internal opening. The fistulous tract is curetted and debrided. The flap includes mucosa, submucosa, and a portion of the sphincter muscle fibers and is advanced to cover the internal primary opening. The lateral view shows the fistulous tract and the components of the advancement flap.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31155=[""].join("\n");
var outline_f30_27_31155=null;
var title_f30_27_31156="Pilocytic astrocytoma MRI";
var content_f30_27_31156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Pilocytic astrocytoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cervical spine MRI postenhancement in a 20-year-old male. Left panel: The sagittal image demonstrates a contrast-enhancing, circumscribed lesion at the C6-7 level (arrow). Right panel: Axial images confirm this finding (arrows). The lesion was completely excised without causing neurological deficit and no radiation was administered.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Welch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31156=[""].join("\n");
var outline_f30_27_31156=null;
var title_f30_27_31157="Nifedipine: Patient drug information";
var content_f30_27_31157=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nifedipine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     see \"Nifedipine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/2/9256?source=see_link\">",
"     see \"Nifedipine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adalat&reg; CC;",
"     </li>",
"     <li>",
"      Afeditab&reg; CR;",
"     </li>",
"     <li>",
"      Nifediac CC&reg;;",
"     </li>",
"     <li>",
"      Nifedical XL&reg;;",
"     </li>",
"     <li>",
"      Procardia XL&reg;;",
"     </li>",
"     <li>",
"      Procardia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F201400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adalat&reg; XL&reg;;",
"     </li>",
"     <li>",
"      Apo-Nifed PA&reg;;",
"     </li>",
"     <li>",
"      Mylan-Nifedipine Extended Release;",
"     </li>",
"     <li>",
"      Nu-Nifed;",
"     </li>",
"     <li>",
"      Nu-Nifedipine-PA;",
"     </li>",
"     <li>",
"      PMS-Nifedipine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15804618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691459",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop high pressure in the lungs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Raynaud's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691647",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop early labor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3546342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat water in the lungs caused by high altitude.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nifedipine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703919",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: If you have a narrowing of the GI (gastrointestinal) tract or a bowel block.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3380191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Adalat&reg; CC:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-galactose or lactose-free diet.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698205",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may see the tablet shell in your stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694381",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Adalat&reg; CC, Afeditab&trade; CR, Nifediac&trade; CC: Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10908 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31157=[""].join("\n");
var outline_f30_27_31157=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201399\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201400\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804618\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013494\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013493\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013498\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013499\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013501\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013496\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013497\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013502\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013503\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=related_link\">",
"      Nifedipine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/2/9256?source=related_link\">",
"      Nifedipine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_27_31158="Tubular amyloidosis";
var content_f30_27_31158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F63533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F63533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Renal tubular amyloidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Amyloidosis with marked deposition in the tubular basement membranes on light microscopy (left panel, arrows). The amyloid deposits show green birefringence when viewed under polarized light with Congo red stain (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31158=[""].join("\n");
var outline_f30_27_31158=null;
var title_f30_27_31159="Metoprolol and hydrochlorothiazide: Drug information";
var content_f30_27_31159=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metoprolol and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/37/36437?source=see_link\">",
"    see \"Metoprolol and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1698647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dutoprol&trade;;",
"     </li>",
"     <li>",
"      Lopressor HCT&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F1698651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker, Beta-1 Selective;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F1709261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Dosage should be determined by titration of the individual agents and the combination product substituted based upon the daily requirements.",
"     <b>",
"      Note:",
"     </b>",
"     Hydrochlorothiazide &gt;50 mg/day is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol",
"     <b>",
"      tartrate",
"     </b>",
"     (immediate release) and hydrochlorothiazide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dosage range: Metoprolol tartrate 100-200 mg and hydrochlorothiazide 25-50 mg once daily",
"     <b>",
"      or",
"     </b>",
"     metoprolol tartrate 50-100 mg and hydrochlorothiazide 12.5-25 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol",
"     <b>",
"      succinate",
"     </b>",
"     (extended release) and hydrochlorothiazide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dosage range: Metoprolol succinate 25-200 mg and hydrochlorothiazide 12.5-25 once daily; titration may occur once every 2 weeks to the maximum daily dose of metoprolol succinate 200 mg/hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Metoprolol",
"     <b>",
"      succinate",
"     </b>",
"     50 mg and hydrochlorothiazide 6.25 mg dose may be achieved by splitting the metoprolol succinate 100 mg/hydrochlorothiazide 12.5 mg tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Concomitant therapy:",
"     </i>",
"     It is recommended that if an additional antihypertensive agent is required, gradual titration should occur using",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the usual starting dose of the other agent to avoid hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F1698674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14209359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Loop diuretics preferred; the use of hydrochlorothiazide may not be effective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Anuria: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14209360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild impairment: No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate impairment: Initial: Consider lower hydrochlorothiazide doses.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1698721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral: 50/25: Metoprolol tartrate 50 mg and hydrochlorothiazide 25 mg; 100/25: Metoprolol tartrate 100 mg and hydrochlorothiazide 25 mg; 100/50: Metoprolol tartrate 100 mg and hydrochlorothiazide 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lopressor HCT&reg; 50/25: Metoprolol tartrate 50 mg and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lopressor HCT&reg; 100/25: Metoprolol tartrate 100 mg and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dutoprol&trade;: 25/12.5: Metoprolol succinate 25 mg [extended release, expressed as mg equivalent to tartrate] and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dutoprol&trade;: 50/12.5: Metoprolol succinate 50 mg [extended release, expressed as mg equivalent to tartrate] and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dutoprol&trade;: 100/12.5: Metoprolol succinate 100 mg [extended release, expressed as mg equivalent to tartrate] and hydrochlorothiazide 12.5 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F1698649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1698675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To avoid nocturia, doses should be taken early in the day and last dose of multiple doses should be taken no later than 6 pm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol tartrate (immediate release) and hydrochlorothiazide: Administer with or immediately following meals (or as directed).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol succinate (extended release) and hydrochlorothiazide: May administer with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1698652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension (not recommended for initial treatment)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F1698661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions noted here have been reported with the combination product; see individual drug monographs for additional adverse reactions that may be expected from each agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Bradycardia (6%), edema (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Drowsiness (10%), headache (10%), vertigo (10%), dizziness (3% to 10%), fatigue (3% to 10%), abnormal dreams (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Purpura (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (&lt;10%), gout (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Anorexia (1%), constipation (1%), diarrhea (1%), nausea (1%), vomiting (1%), xerostomia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Impotence (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (&le;2%), myalgia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Earache (1%), tinnitus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (&le;3%), dyspnea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome (10%), diaphoresis (1%), exercise tolerance decreased (1%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1698657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metoprolol, hydrochlorothiazide, sulfonamide-derived drugs or any component of the formulation; sinus bradycardia, heart block (greater than first degree), cardiogenic shock, overt cardiac failure; anuria",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Metoprolol",
"     <b>",
"      tartrate",
"     </b>",
"     (immediate release) and hydrochlorothiazide: Additional contraindications: Sick sinus syndrome, severe peripheral arterial disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1704801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, and hyponatremia can occur with hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; however, metoprolol, with B",
"     <sub>",
"      1",
"     </sub>",
"     selectivity, has been used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating metoprolol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use metoprolol with caution in patients with compensated heart failure and monitor for a worsening of the condition (only the extended release product is indicated for heart failure).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use metoprolol with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD): Use metoprolol with caution in patients with PVD (including Raynaud's).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use metoprolol with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Avoid hydrochlorothiazide in severe renal disease (ineffective).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Hydrochlorothiazide can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Beta-blockade may mask signs of hyperthyroidism (eg, tachycardia). Abrupt discontinuation of beta-blockade may exacerbate symptoms of hyperthyroidism and may also induce thyroid storm. Alterations in thyroid function tests may be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers (nondihydropyridines): Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 inhibitors: Use with caution in patients receiving CYP2D6 inhibitors (eg, bupropion, chlorpromazine, cimetidine, diphenhydramine, hydroxychloroquine, fluoxetine, paroxetine, propafenone, propoxyphene, quinidine, ritonavir, terbinafine, thioridazine); concurrent use may increase metoprolol plasma concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal:",
"     <b>",
"      [U.S. Boxed Warning]: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered over 1-2 weeks to avoid acute tachycardia, hypertension, and/or ischemia.",
"     </b>",
"     Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Used as a replacement for separate dosing of components or combination when response to single agent is suboptimal; the fixed combination is not indicated for initial treatment of hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F1698667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F1698666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors: May increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: May diminish the antihypertensive effect of Metoprolol. Mirabegron may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives.  Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1698668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F1698653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C/D (expert analysis) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1698654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F1698655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F1698656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F14209361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol tartrate (immediate release) and hydrochlorothiazide: Take with or immediately following meals (or as directed).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol succinate (extended release) and hydrochlorothiazide: May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Dutoprol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-12.5 mg (30): $19.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-12.5 mg (30): $19.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-12.5 mg (30): $19.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lopressor HCT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-25 mg (100): $248.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-25 mg (100): $388.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Metoprolol-Hydrochlorothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-25 mg (100): $113.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-25 mg (100): $177.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-50 mg (100): $187.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1698677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Weight, I &amp; O; blood pressure, heart rate; serum electrolytes, BUN, creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Beloc Comp (AT);",
"     </li>",
"     <li>",
"      Beloc-Zok Comp (DE);",
"     </li>",
"     <li>",
"      Betoprolol (CO);",
"     </li>",
"     <li>",
"      Seloken Retard Comp. (AT);",
"     </li>",
"     <li>",
"      Selokomb 200 (NL);",
"     </li>",
"     <li>",
"      Selokomb Zoc 100 (NL);",
"     </li>",
"     <li>",
"      Selopres Zok (MX);",
"     </li>",
"     <li>",
"      Selozide (BE, IT);",
"     </li>",
"     <li>",
"      Zok-Zid (DK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1698697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1698671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9465 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31159=[""].join("\n");
var outline_f30_27_31159=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709083\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698647\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698651\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1709261\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698674\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14209359\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14209360\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698721\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698649\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698675\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698652\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698661\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698657\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1704801\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698667\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698666\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698668\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698653\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698654\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698655\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698656\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14209361\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422162\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698677\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539962\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698697\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698671\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9465\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9465|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/37/36437?source=related_link\">",
"      Metoprolol and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_27_31160="Herpetic gingivostomatitis in young children";
var content_f30_27_31160=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Herpetic gingivostomatitis in young children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/27/31160/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/27/31160/contributors\">",
"     Martha Ann Keels, DDS, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/27/31160/contributors\">",
"     Dennis A Clements, MD, PhD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/27/31160/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/27/31160/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/27/31160/contributors\">",
"     Ann Griffen, DDS, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/27/31160/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/27/31160/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/27/31160/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gingivostomatitis is the most common manifestation of primary herpes simplex virus (HSV) infection during childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/1\">",
"     1",
"    </a>",
"    ]. Primary herpetic gingivostomatitis is characterized by ulcerative lesions of the gingiva and mucous membranes of the mouth, often with perioral vesicular lesions (",
"    <a class=\"graphic graphic_picture graphicRef58542 \" href=\"mobipreview.htm?27/3/27702\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of mucocutaneous herpes simplex virus type 1 (HSV-1) disease are due to tissue destruction, a direct consequence of viral replication and cell lysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/1\">",
"     1",
"    </a>",
"    ]. Inoculation of HSV-1 at mucosal surfaces or skin sites permits entry of the virus into sensory and autonomic nerve endings through which it is transported to the cell nuclei (eg, the trigeminal ganglion), where it remains latent. Reactivation results in recurrent herpes simplex virus disease (eg, herpes gingivostomatitis, herpes labialis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29544?source=see_link\">",
"     \"Pathogenesis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpetic gingivostomatitis is almost always caused by herpes simplex virus type 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary herpetic gingivostomatitis typically occurs in children between six months and five years of age, but it can occur in older children and adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Herpetic gingivostomatitis occurs throughout the year, with no particular seasonal distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/2\">",
"     2",
"    </a>",
"    ]. In a retrospective review at a single institution, herpes simplex virus (HSV) gingivostomatitis was diagnosed in 1.6 per 10,000 emergency department visits and 5.6 per 10,000 hospital admissions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus type 1 (HSV-1) infections usually result from direct contact with infected oral secretions or lesions. HSV infections can be transmitted from symptomatic or asymptomatic individuals with primary or recurrent HSV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with primary gingivostomatitis typically shed HSV for at least one week, and occasionally for several weeks (median three weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Intermittent asymptomatic reactivation and shedding occurs throughout life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Incubation period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period for HSV infection beyond the neonatal period ranges from two days to two weeks, with a mean of four days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/2,5,7\">",
"     2,5,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38021?source=see_link\">",
"     \"Epidemiology of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gingivostomatitis is the most common manifestation of primary herpes simplex virus (HSV) infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/1\">",
"     1",
"    </a>",
"    ]. It occurs in 13 to 30 percent of affected children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Herpetic gingivostomatitis occurs approximately one week after contact with an infected child or adult (the contact case often is asymptomatic). It generally begins with a prodrome that lasts about four days and may include fever (&gt;38&ordm;C (100.4&ordm;F)), anorexia, irritability, malaise, sleeplessness, and headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/1,12,13\">",
"     1,12,13",
"    </a>",
"    ]. Parents may attribute these symptoms to teething in children whose primary teeth are erupting, but children who are teething do not have oropharyngeal lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The enanthem begins with red, edematous marginal gingivae that bleed easily and clusters of small vesicles (",
"    <a class=\"graphic graphic_picture graphicRef58944 \" href=\"mobipreview.htm?33/23/34175\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/1,12,13\">",
"     1,12,13",
"    </a>",
"    ]. The vesicles become yellow after rupture and are surrounded by a red halo. They coalesce to form large, painful ulcers of the oral and perioral tissues (",
"    <a class=\"graphic graphic_picture graphicRef58542 \" href=\"mobipreview.htm?27/3/27702\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73566 \" href=\"mobipreview.htm?39/28/40385\">",
"     picture 3",
"    </a>",
"    ). They bleed easily and may become covered with a black crust [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/15\">",
"     15",
"    </a>",
"    ]. The lesions involve the buccal mucosa, tongue, gingiva, hard palate, and pharynx; the lips and perioral skin are affected in approximately two-thirds of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. Mild lesions typically heal without scarring in about a week, but healing may require 14 to 21 days in severe cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Natural history'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Associated symptoms and signs may include bad breath, refusal to drink, anorexia, fever, arthralgia, headache, and submandibular or cervical lymphadenitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. Refusal to drink may result in dehydration, which is the most frequent complication. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    After the primary infection, HSV migrates to the trigeminal ganglion, where it remains in a latent state unless it is reactivated. Reactivation can be induced by exposure to sunlight, cold, trauma, stress, or immunosuppression and may occur in the oral cavity (recurrent stomatitis) or on the lips (herpes labialis) (",
"    <a class=\"graphic graphic_picture graphicRef80183 \" href=\"mobipreview.htm?0/55/881\">",
"     picture 4",
"    </a>",
"    ). Herpes labialis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\", section on 'Recurrent infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of herpetic gingivostomatitis may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/1,8,16\">",
"     1,8,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dehydration (the most common complication), which may require hospitalization for parenteral fluid therapy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=see_link\">",
"       \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6470?source=see_link\">",
"       \"Maintenance fluid therapy in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link\">",
"       \"Treatment of hypovolemia (dehydration) in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Herpetic whitlow (",
"      <a class=\"graphic graphic_picture graphicRef75510 graphicRef52029 \" href=\"mobipreview.htm?9/42/9892\">",
"       picture 5A-B",
"      </a>",
"      ) or herpetic keratitis (",
"      <a class=\"graphic graphic_picture graphicRef69359 \" href=\"mobipreview.htm?8/6/8289\">",
"       picture 6",
"      </a>",
"      ) from autoinoculation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/61/37846?source=see_link\">",
"       \"Paronychia and ingrown toenails\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33992?source=see_link\">",
"       \"Herpes simplex keratitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Secondary bacteremia with upper-respiratory bacteria (eg,",
"      <em>",
"       Streptococcus pyogenes",
"      </em>",
"      ,",
"      <em>",
"       Kingella kingae",
"      </em>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Esophagitis, epiglottitis, or pneumonitis (particularly in immunocompromised children) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Herpes simplex virus (HSV) encephalitis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1001?source=see_link\">",
"       \"Herpes simplex virus type 1 encephalitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Eczema herpeticum in children with atopic dermatitis and other dermatitides (",
"      <a class=\"graphic graphic_picture graphicRef74838 \" href=\"mobipreview.htm?7/29/7634\">",
"       picture 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef64142 \" href=\"mobipreview.htm?19/0/19459\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lip adhesions, which may be prevented through the application of lip barrier cream [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications in immunocompromised patients include severe local lesions, disseminated HSV infection with visceral involvement, HSV pneumonitis, and HSV encephalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of gingivostomatitis generally is made clinically, based upon the typical appearance and location of oral and extraoral lesions (",
"    <a class=\"graphic graphic_picture graphicRef58542 \" href=\"mobipreview.htm?27/3/27702\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58944 \" href=\"mobipreview.htm?33/23/34175\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cases where it is necessary to confirm an etiologic diagnosis, herpes simplex virus type 1 (HSV-1) can be diagnosed with viral culture, serology, immunofluorescence, or polymerase chain reaction (PCR). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Tzanck smear, which demonstrates the cytopathic effect of herpes viruses, can be performed in patients with active lesions. However, it has limited utility because it is only helpful if it is positive and does not distinguish between HSV-1, HSV-2, and varicella zoster virus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=see_link&amp;anchor=H12#H12\">",
"     \"Dermatologic procedures\", section on 'Tzanck smear'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus (HSV) gingivostomatitis must be differentiated from a number of other conditions with oral lesions because the treatment, clinical course,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    public health implications may differ (eg, herpangina; hand, foot, and mouth disease; oral candidiasis; aphthous ulcers; Stevens-Johnson syndrome; and Behcet's disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/8\">",
"     8",
"    </a>",
"    ]. HSV gingivostomatitis can usually be differentiated from these conditions by the presence, appearance, and location of oral and extraoral lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Herpangina &ndash; Herpangina, which is usually caused by group A coxsackieviruses, typically causes painful posterior pharyngeal lesions that do not bleed, has a more acute onset and shorter duration than HSV gingivostomatitis, and occurs primarily in the summer and early fall [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/15,20\">",
"       15,20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=see_link\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hand, foot, and mouth disease &ndash; Hand, foot, and mouth disease (",
"      <a class=\"graphic graphic_picture graphicRef52800 graphicRef58566 graphicRef53423 graphicRef71314 \" href=\"mobipreview.htm?23/26/23978\">",
"       picture 9A-D",
"      </a>",
"      ) is caused by a number of coxsackie A and B viruses. It occurs in the spring and early summer. The extremity lesions usually are bilateral (in contrast to herpetic whitlow, which typically is unilateral) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/26/41383?source=see_link\">",
"       \"Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oral candidiasis &ndash; Oral candidiasis is characterized by white plaques on the buccal mucosa, palate, tongue, or oropharynx (",
"      <a class=\"graphic graphic_picture graphicRef69465 \" href=\"mobipreview.htm?9/63/10228\">",
"       picture 10",
"      </a>",
"      ). It occurs in infants after exposure to the microorganisms of the vaginal tract, in children who are treated with antibiotics or inhaled glucocorticoids, and in immunocompromised children. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=see_link\">",
"       \"Treatment of oropharyngeal and esophageal candidiasis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31481?source=see_link&amp;anchor=H3#H3\">",
"       \"Overview of Candida infections in children\", section on 'Oropharyngeal candidiasis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aphthous ulcers &ndash; Aphthae, also called canker sores, are painful oral lesions that appear as localized, shallow, round to oval ulcers with a grayish base (",
"      <a class=\"graphic graphic_picture graphicRef56488 graphicRef63475 \" href=\"mobipreview.htm?12/44/12997\">",
"       picture 11A-B",
"      </a>",
"      ). They are not preceded by vesicles and occur exclusively on nonkeratinized mucosal surfaces; lesions on the lips and perioral lesions exclude a diagnosis of aphthous ulcer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25786?source=see_link&amp;anchor=H16#H16\">",
"       \"Oral lesions\", section on 'Aphthous ulcerations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stevens-Johnson syndrome &ndash; Stevens-Johnson syndrome is characterized by a prodrome of malaise and fever, followed by the rapid onset of erythematous or purpuric macules and plaques. The skin lesions progress to epidermal necrosis and sloughing. Mucosal membranes are affected in at least 90 percent of patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Behcet's disease &ndash; Behcet's disease is characterized by recurrent oral aphthae and any of several systemic manifestations, including genital aphthae, ocular disease, skin lesions, gastrointestinal involvement, neurologic disease, vascular disease, or arthritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/18/298?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of herpes simplex virus type 1 (HSV-1) gingivostomatitis was evaluated in a prospective study of 36 children who presented with clinical manifestations lasting &lt;72 hours and were followed with examination and viral culture every two to three days until symptoms resolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/12\">",
"     12",
"    </a>",
"    ]. The mean duration of signs and symptoms was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever &ndash; 4.4 days (range 0 to 8 days)",
"     </li>",
"     <li>",
"      Oral lesions &ndash; 12 days (range 7 to 18)",
"     </li>",
"     <li>",
"      Extraoral lesions &ndash; 12 days (range 0 to 19)",
"     </li>",
"     <li>",
"      Eating difficulty &ndash; 9.1 days (range 4 to 17)",
"     </li>",
"     <li>",
"      Drinking difficulty &ndash; 7.1 days (no range provided)",
"     </li>",
"     <li>",
"      Drooling &ndash; 6.6 days (range 0 to 13)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Viral shedding persisted for a mean of 7.1 days (range 2 to 12 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Indications for hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for hospitalization in children with herpetic gingivostomatitis may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inability to maintain adequate hydration (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=see_link\">",
"       \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Immunocompromised host (such children should be treated with systemic",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Immunocompromised children'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Eczema herpeticum",
"     </li>",
"     <li>",
"      Encephalitis, epiglottitis, or pneumonitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Fluid intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of hydration is a major component of the management of herpetic gingivostomatitis. Fluid intake should be encouraged to avoid dehydration. Analgesics, antipyretics, and oral rinses may make the child more comfortable and help to increase fluid intake. Children who are unable to drink sufficiently to maintain hydration should be hospitalized for parenteral fluid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The assessment of hydration status and treatment of dehydration are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6470?source=see_link\">",
"     \"Maintenance fluid therapy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate pain control may facilitate fluid intake. Oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    may be administered if the child can take them. In severe cases, oral opiates may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Topical therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A barrier cream (eg, petroleum jelly) should be applied to the lips to prevent adhesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/19\">",
"     19",
"    </a>",
"    ]. A number of topical therapies have been suggested to coat the lesions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    soothe pain in children with herpes simplex virus (HSV) gingivostomatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/3\">",
"     3",
"    </a>",
"    ]. Although these therapies are routinely suggested, there is little evidence to support a benefit, and we do not suggest their use in young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical therapies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Magic mouthwash\", various combinations of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , magnesia-alumina (Maalox&reg;), Kaolin pectin (Kaopectate&reg;),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      viscous xylocaine. There is no standardized \"recipe\", volume, frequency of administration, or mode of application (eg, swish and spit, swish and swallow, apply with swab) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/3\">",
"       3",
"      </a>",
"      ]. The use of viscous xylocaine is controversial; it may be associated with systemic toxicity or predispose to self-injury if the child chews on anesthetized oral mucosa or chokes on secretions secondary to pharyngeal anesthesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/15,21\">",
"       15,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Zilactin, a nonprescription topical medication containing",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29714?source=see_link\">",
"       hydroxypropyl cellulose",
"      </a>",
"      , which adheres to mucosa, may be used to protect lesions from trauma and irritants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/22\">",
"       22",
"      </a>",
"      ]. ORA5, another nonprescription topical therapy (0.11%",
"      <span class=\"nowrap\">",
"       iodine/potassium-iodide/copper",
"      </span>",
"      sulfate solution) works by the same mechanism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Topical therapies are potentially problematic for a number of reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic absorption of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , xylocaine, or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/19/11574?source=see_link\">",
"       benzocaine",
"      </a>",
"      may result in toxicity or adverse effects, such as sedation or seizures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/3,21\">",
"       3,21",
"      </a>",
"      ]. The risk of overdose can be minimized by making sure that the prescribed dose and dosing interval are within the normal dosing range. Topical benzocaine may cause methemoglobinemia and should not be used in children younger than two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8729?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical features, diagnosis, and treatment of methemoglobinemia\", section on 'Acquired causes'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link&amp;anchor=H44#H44\">",
"       \"Topical anesthetics in children\", section on 'Benzocaine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most children in the gingivostomatitis age group are unable to swish and spit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/3,24\">",
"       3,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Young children with painful oral lesions are unlikely to allow manipulation of inflamed mucosa for application with a swab [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Oral acyclovir",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30286066\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    for immune-competent children with herpetic gingivostomatitis who present within 72 to 96 hours of disease onset if they are unable to drink or have significant pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/25-30\">",
"     25-30",
"    </a>",
"    ]. Oral acyclovir also may be beneficial for children with less significant disease, particularly if they attend child care. Topical acyclovir has no effect. Treatment of immunocompromised children is discussed below. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Immunocompromised children'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Systematic reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/25,28\">",
"     25,28",
"    </a>",
"    ], and observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] indicate that initiation of oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    during the first three to four days of clinical manifestations is beneficial in decreasing the duration of symptoms. It also may shorten the period of viral shedding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/25\">",
"     25",
"    </a>",
"    ]. In the largest randomized placebo-controlled trial, treatment with oral acyclovir 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    five times per day (maximum single dose 200 mg) for five to seven days within 72 hours of the onset of lesions was associated with [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Shorter duration of lesions (median 4 versus 10 days)",
"     </li>",
"     <li>",
"      Earlier disappearance of fever (1 versus 3 days)",
"     </li>",
"     <li>",
"      Earlier resolution of extraoral lesions (0 versus 5.5 days)",
"     </li>",
"     <li>",
"      Decreased duration of eating difficulties (4 versus 7 days)",
"     </li>",
"     <li>",
"      Reduced viral shedding (1 versus 5 days)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At the eight-day follow-up, treatment with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    was associated with a reduction in [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The number of children with oral lesions (risk ratio [RR] 0.1, 95% CI 0.02-0.38)",
"     </li>",
"     <li>",
"      New extraoral lesions (RR 0.04, 95% CI 0-0.65)",
"     </li>",
"     <li>",
"      Difficulty eating (RR 0.14, 95% CI 0.03-0.58)",
"     </li>",
"     <li>",
"      Difficulty drinking (RR 0.11, 95% CI 0.01-0.83)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30286073\">",
"    <span class=\"h3\">",
"     Dose and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding the optimal dose or duration of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/27\">",
"     27",
"    </a>",
"    ]. We use",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    by mouth (maximum single dose 200 mg) five times per day for five to seven days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    include nausea, vomiting, diarrhea, headaches, and renal failure caused by crystallization in the renal tubules, which is more likely if the patient is dehydrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/27\">",
"     27",
"    </a>",
"    ]. Theoretic concerns about the possible selection of acyclovir-resistant strains of HSV-1 and earlier and more severe recurrences in treated patients have not been demonstrated in patients treated with short courses of acyclovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/27,31\">",
"     27,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Topical antivirals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical antiviral agents (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/19/7475?source=see_link\">",
"     penciclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/57/6034?source=see_link\">",
"     docosanol",
"    </a>",
"    ) are not helpful in the treatment of primary herpes gingivostomatitis in immunocompetent patients and are not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/4,32\">",
"     4,32",
"    </a>",
"    ]. However, topical acyclovir (5% ointment every six hours for seven days) may speed the resolution of lesions in immunocompromised children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Immunocompromised children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials in immunocompromised patients with mucocutaneous HSV infection have demonstrated that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    (intravenous or oral) is associated with shorter duration of development of new lesions, earlier crusting of lesions, and shorter duration of pain and viral shedding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/33-36\">",
"     33-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dosing for systemic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    is as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous (IV) &ndash; 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in three divided doses (for children of all ages)",
"     </li>",
"     <li>",
"      Oral &ndash; 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      divided in three to five doses (for children &ge;2 years)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The total duration of treatment is 7 to 14 days.",
"   </p>",
"   <p>",
"    As of November 2012, there is a shortage of IV",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/38\">",
"     38",
"    </a>",
"    ]. Pending resolution of the shortage, existing supplies of IV acyclovir are reserved for neonates with proven HSV disease, individuals with HSV encephalitis, and pregnant women. Alternatives to IV acyclovir during the shortage are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link&amp;anchor=H72507949#H72507949\">",
"     \"Acyclovir: An overview\", section on 'Acyclovir shortage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     Acyclovir",
"    </a>",
"    -resistant HSV should be suspected in children with a prolonged course of HSV stomatitis despite parenteral acyclovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/4/24646?source=see_link\">",
"     Foscarnet",
"    </a>",
"    80 to 120",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two to three divided doses has been recommended as the drug of choice for acyclovir-resistant HSV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are not routinely administered unless a secondary bacterial infection is diagnosed. If a secondary bacterial infection develops, then antibiotics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    in patients with penicillin allergy) may be administered for 7 to 10 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral herpes simplex virus (HSV) infections are common in young children. Most of these infections are asymptomatic, with shedding of virus in the absence of clinical disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Child care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with gingivostomatitis who do not have control of oral secretions should be excluded from child",
"    <span class=\"nowrap\">",
"     care/school",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contact precautions are recommended for hospitalized children with severe mucocutaneous HSV disease (in addition to standard precautions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31160/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H11#H11\">",
"     \"General principles of infection control\", section on 'Contact precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Herpetic gingivostomatitis is caused by herpes simplex virus type 1 (HSV-1). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HSV-1 gingivostomatitis typically occurs in children between six months and five years of age. It occurs throughout the year. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical features of HSV-1 stomatitis include a prodrome of fever and constitutional symptoms, followed by oral and extraoral lesions. The lesions begin as vesicles, which coalesce to form painful ulcers with generalized edematous and bleeding gingiva (",
"      <a class=\"graphic graphic_picture graphicRef58944 \" href=\"mobipreview.htm?33/23/34175\">",
"       picture 2",
"      </a>",
"      ). Associated findings include fever, bad breath, refusal to drink, anorexia, and submandibular or cervical lymphadenitis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dehydration is the most common complication. Less common complications include spread of herpes simplex virus (HSV) to other sites (eg, herpetic whitlow (",
"      <a class=\"graphic graphic_picture graphicRef75510 \" href=\"mobipreview.htm?30/31/31231\">",
"       picture 5A",
"      </a>",
"      ), herpetic keratitis (",
"      <a class=\"graphic graphic_picture graphicRef69359 \" href=\"mobipreview.htm?8/6/8289\">",
"       picture 6",
"      </a>",
"      ), encephalitis, esophagitis, pneumonitis, eczema herpeticum (",
"      <a class=\"graphic graphic_picture graphicRef74838 \" href=\"mobipreview.htm?7/29/7634\">",
"       picture 7",
"      </a>",
"      )), secondary bacteremia, and lip adhesions. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of gingivostomatitis usually is made clinically based upon the typical appearance and location of oral and extraoral lesions (",
"      <a class=\"graphic graphic_picture graphicRef58542 \" href=\"mobipreview.htm?27/3/27702\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef58944 \" href=\"mobipreview.htm?33/23/34175\">",
"       picture 2",
"      </a>",
"      ). If necessary, HSV-1 can be confirmed with viral culture, serology, immunofluorescence, or polymerase chain reaction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of HSV-1 gingivostomatitis includes herpangina; hand, foot, and mouth disease (",
"      <a class=\"graphic graphic_picture graphicRef52800 graphicRef58566 graphicRef53423 graphicRef71314 \" href=\"mobipreview.htm?23/26/23978\">",
"       picture 9A-D",
"      </a>",
"      ); oral candidiasis (",
"      <a class=\"graphic graphic_picture graphicRef69465 \" href=\"mobipreview.htm?9/63/10228\">",
"       picture 10",
"      </a>",
"      ); aphthous ulcers (",
"      <a class=\"graphic graphic_picture graphicRef56488 graphicRef63475 \" href=\"mobipreview.htm?12/44/12997\">",
"       picture 11A-B",
"      </a>",
"      ); and Stevens-Johnson syndrome. The presence, appearance, and location of oral and extraoral lesions help to distinguish HSV-1 gingivostomatitis from these conditions. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive care, with an emphasis on maintenance of hydration, is the mainstay of therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Fluid intake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest the use of topical therapies to coat the lesions or soothe pain in children with HSV gingivostomatitis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Topical therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest oral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      for immune-competent children with herpetic gingivostomatitis who present within 72 to 96 hours of disease onset if they are unable to drink or have significant pain (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). We use 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum single dose 200 mg) five times per day for five to seven days. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Oral acyclovir'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/1\">",
"      Kolokotronis A, Doumas S. Herpes simplex virus infection, with particular reference to the progression and complications of primary herpetic gingivostomatitis. Clin Microbiol Infect 2006; 12:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/2\">",
"      Kimberlin DW. Herpes simplex virus infections in neonates and early childhood. Semin Pediatr Infect Dis 2005; 16:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/3\">",
"      Faden H. Management of primary herpetic gingivostomatitis in young children. Pediatr Emerg Care 2006; 22:268.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Herpes simplex. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.398.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/5\">",
"      Richardson M, Elliman D, Maguire H, et al. Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatr Infect Dis J 2001; 20:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/6\">",
"      Daniels CA, LeGoff SG. Shedding of infectious virus/antibody complexes from vesicular lesions of patients with recurrent herpes labialis. Lancet 1975; 2:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/7\">",
"      Manzella JP, McConville JH, Valenti W, et al. An outbreak of herpes simplex virus type I gingivostomatitis in a dental hygiene practice. JAMA 1984; 252:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/8\">",
"      Amir J. Clinical aspects and antiviral therapy in primary herpetic gingivostomatitis. Paediatr Drugs 2001; 3:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/9\">",
"      Cesario TC, Poland JD, Wulff H, et al. Six years experience with herpes simplex virus in a children's home. Am J Epidemiol 1969; 90:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/10\">",
"      Schmitt DL, Johnson DW, Henderson FW. Herpes simplex type 1 infections in group day care. Pediatr Infect Dis J 1991; 10:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/11\">",
"      Becker TM, Magder L, Harrison HR, et al. The epidemiology of infection with the human herpesviruses in Navajo children. Am J Epidemiol 1988; 127:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/12\">",
"      Amir J, Harel L, Smetana Z, Varsano I. The natural history of primary herpes simplex type 1 gingivostomatitis in children. Pediatr Dermatol 1999; 16:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/13\">",
"      Kuzushima K, Kimura H, Kino Y, et al. Clinical manifestations of primary herpes simplex virus type 1 infection in a closed community. Pediatrics 1991; 87:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/14\">",
"      King DL, Steinhauer W, Garc&iacute;a-Godoy F, Elkins CJ. Herpetic gingivostomatitis and teething difficulty in infants. Pediatr Dent 1992; 14:82.",
"     </a>",
"    </li>",
"    <li>",
"     Guiterrez KM, Arvin AM. Herpes simplex viruses 1 and 2. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/16\">",
"      Amir J, Yagupsky P. Invasive Kingella kingae infection associated with stomatitis in children. Pediatr Infect Dis J 1998; 17:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/17\">",
"      Amir J, Nussinovitch M, Straussberg R, Harel L. Bacteremia with group A Streptococcus associated with herpetic gingivostomatitis. Pediatr Infect Dis J 2001; 20:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/18\">",
"      Bogger-Goren S. Acute epiglottitis caused by herpes simplex virus. Pediatr Infect Dis J 1987; 6:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/19\">",
"      Thomas E. A complication of primary herpetic gingivostomatitis. Br Dent J 2007; 203:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/20\">",
"      PARROTT RH, WOLF SI, NUDELMAN J, et al. Clinical and laboratory differentiation between herpangina and infectious (herpetic) gingivostomatitis. Pediatrics 1954; 14:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/21\">",
"      Hess GP, Walson PD. Seizures secondary to oral viscous lidocaine. Ann Emerg Med 1988; 17:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/22\">",
"      Rodu B, Mattingly G. Oral mucosal ulcers: diagnosis and management. J Am Dent Assoc 1992; 123:83.",
"     </a>",
"    </li>",
"    <li>",
"     Questions &amp; Answers: Reports of a rare, but serious and potentially fatal adverse effect with the use of over-the-counter (OTC) benzocaine gels and liquids applied to the gums or mouth www.fda.gov/Drugs/DrugSafety/ucm250029.htm (Accessed on August 03, 2012).",
"    </li>",
"    <li>",
"     McDonald RE, Avery DR, Stookey GK. Dental caries in the child and adolescent. In: Dentistry for the Child and Adolescent, 7th ed, McDonald RE, Avery DR (Eds), Mosby, Philadelphia 2000. p.209.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/25\">",
"      Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. BMJ 1997; 314:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/26\">",
"      Nasser M, Fedorowicz Z, Khoshnevisan MH, Shahiri Tabarestani M. Acyclovir for treating primary herpetic gingivostomatitis. Cochrane Database Syst Rev 2008; :CD006700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/27\">",
"      Hudson B, Powell C. Towards evidence based medicine for paediatricians. Does oral aciclovir improve clinical outcome in immunocompetent children with primary herpes simplex gingivostomatitis? Arch Dis Child 2009; 94:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/28\">",
"      Ducoulombier H, Cousin J, Dewilde A, et al. [Herpetic stomatitis-gingivitis in children: controlled trial of acyclovir versus placebo]. Ann Pediatr (Paris) 1988; 35:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/29\">",
"      Cataldo F, Violante M, Maltese I, et al. [Herpetic gingivostomatitis in children: the clinico-epidemiological aspects and findings with acyclovir treatment. A report of the cases of 162 patients]. Pediatr Med Chir 1993; 15:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/30\">",
"      Mueller R, Weigand KH. The treatment of herpetic gingivostomatitis with aciclovir suspension. Der Kinderarzt 1988; 19:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/31\">",
"      Murph JR, Grose C. Routine acyclovir therapy: isn't it time? Contemp Pediatr 1999; 16:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/32\">",
"      Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992; 327:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/33\">",
"      Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982; 73:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/34\">",
"      Mitchell CD, Bean B, Gentry SR, et al. Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Lancet 1981; 1:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/35\">",
"      Wade JC, Newton B, McLaren C, et al. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med 1982; 96:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31160/abstract/36\">",
"      Shepp DH, Newton BA, Dandliker PS, et al. Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients. Ann Intern Med 1985; 102:783.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Antiviral drugs. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.841.",
"    </li>",
"    <li>",
"     Current Drug Shortages. US Food and Drug Administration. www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm (Accessed on November 28, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6046 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31160=[""].join("\n");
var outline_f30_27_31160=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Incubation period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Indications for hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Fluid intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pain control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Topical therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Oral acyclovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30286066\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30286073\">",
"      - Dose and duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Topical antivirals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Immunocompromised children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Child care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Isolation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6046\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6046|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/3/27702\" title=\"picture 1\">",
"      Herpetic stomatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/23/34175\" title=\"picture 2\">",
"      HSV gingivostomatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/28/40385\" title=\"picture 3\">",
"      HSV lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/55/881\" title=\"picture 4\">",
"      Cold sore PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/31/31231\" title=\"picture 5A\">",
"      Herpetic whitlow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/30/9696\" title=\"picture 5B\">",
"      Herpetic whitlow finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/6/8289\" title=\"picture 6\">",
"      Herpes simplex keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/29/7634\" title=\"picture 7\">",
"      Eczema herpeticum hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/0/19459\" title=\"picture 8\">",
"      Eczema herpeticum face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/12/4293\" title=\"picture 9A\">",
"      Hand-foot-and-mouth disease - lip and hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/2/13344\" title=\"picture 9B\">",
"      Hand-foot-and-mouth disease - buccal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/22/14689\" title=\"picture 9C\">",
"      Hand-foot-and-mouth disease - foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/27/20912\" title=\"picture 9D\">",
"      Hand-foot-and-mouth disease - tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/63/10228\" title=\"picture 10\">",
"      Thrush infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/61/30687\" title=\"picture 11A\">",
"      Aphthous ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/25/13713\" title=\"picture 11B\">",
"      Aphthous ulcers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38021?source=related_link\">",
"      Epidemiology of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/26/41383?source=related_link\">",
"      Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33992?source=related_link\">",
"      Herpes simplex keratitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1001?source=related_link\">",
"      Herpes simplex virus type 1 encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25786?source=related_link\">",
"      Oral lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31481?source=related_link\">",
"      Overview of Candida infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/61/37846?source=related_link\">",
"      Paronychia and ingrown toenails",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29544?source=related_link\">",
"      Pathogenesis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=related_link\">",
"      Treatment of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_27_31161="Pyogenic granuloma lip";
var content_f30_27_31161=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60189%7EPC%2F66965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60189%7EPC%2F66965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma of the lip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma of the gingival mucosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 546px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mucosal pyogenic granuloma in a 26 year-old woman in her fourth month of pregnancy. Excessive tissue growth impeding proper teeth contact and chewing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31161=[""].join("\n");
var outline_f30_27_31161=null;
var title_f30_27_31162="Endovascular repair of abdominal aortic aneurysm";
var content_f30_27_31162=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endovascular repair of abdominal aortic aneurysm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/27/31162/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/27/31162/contributors\">",
"     Rabih A Chaer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/27/31162/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/27/31162/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/27/31162/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/27/31162/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/27/31162/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/27/31162/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/27/31162/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2369875877\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular aneurysm repair (EVAR) is an important advance in the treatment of abdominal aortic aneurysm (AAA). EVAR is performed by inserting graft components folded and compressed within a delivery sheath through the lumen of an access vessel, usually the common femoral artery. Upon deployment, the endograft expands, contacting the aortic wall proximally and iliac vessels distally to exclude the aortic aneurysm sac from aortic blood flow and pressure (",
"    <a class=\"graphic graphic_figure graphicRef56289 \" href=\"mobipreview.htm?32/11/32949\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Compared with open AAA repair, EVAR is associated with a significant reduction in perioperative mortality, primarily because EVAR does not require operative exposure of the aorta or aortic clamping. Since the approval of endograft devices for use in the United States, there has been a 600 percent increase in the annual number of EVAR procedures performed, with EVAR accounting for nearly half of AAA repairs. Concurrent with the increased use of EVAR, a decrease in the incidence of ruptured AAA and associated morbidity and mortality has been reported in the United States, likely due to the ability to offer EVAR to patients who would not otherwise be candidates for open surgical repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endovascular repair of abdominal aortic aneurysm is reviewed here. General issues regarding the management of abdominal aortic aneurysm, and the clinical features and diagnosis of this condition, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38746?source=see_link\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440564\">",
"    <span class=\"h1\">",
"     ANATOMIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abdominal aorta is the most common site of arterial aneurysm. The abdominal aorta is defined as aneurysmal when a localized dilation is identified, and the diameter of the dilated region is increased more than 50 percent relative to normal aortic diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/3\">",
"     3",
"    </a>",
"    ]. The normal diameter of the aorta at the level of the renal arteries is approximately 2.0 cm (range 1.4 to 3.0 cm). An aortic diameter greater than 3.0 cm is considered aneurysmal for most individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440571\">",
"    <span class=\"h2\">",
"     Aortoiliac anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abdominal aorta is a retroperitoneal structure that begins at the hiatus of the diaphragm and extends to its bifurcation into the common iliac arteries at the level of the fourth lumbar vertebra (",
"    <a class=\"graphic graphic_figure graphicRef51087 \" href=\"mobipreview.htm?42/14/43234\">",
"     figure 2",
"    </a>",
"    ). It lies slightly left of the midline to accommodate the inferior vena cava which is in close apposition. The branches of the aorta (superior to inferior) include the left and right inferior phrenic arteries, left and right middle suprarenal arteries, the celiac axis, superior mesenteric artery, left and right renal arteries, possible accessory renal arteries, left and right gonadal arteries, inferior mesenteric artery, left and right common iliac artery, middle sacral artery and the paired lumbar arteries (L1-L4).",
"   </p>",
"   <p>",
"    The common iliac artery bifurcates into the external iliac and internal iliac arteries at the pelvic inlet (",
"    <a class=\"graphic graphic_figure graphicRef60420 \" href=\"mobipreview.htm?39/52/40777\">",
"     figure 3",
"    </a>",
"    ). The internal iliac artery, also termed the hypogastric artery, gives off anterior and posterior branches to the pelvic viscera and also supplies the musculature of the pelvis. The external iliac artery passes beneath the inguinal ligament to become the common femoral artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441378\">",
"    <span class=\"h2\">",
"     Aneurysm extent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal aortic aneurysms (AAAs) are described as infrarenal, juxtarenal (pararenal), or suprarenal depending upon the involvement of the renal or visceral vessels.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infrarenal &ndash; aneurysm originates below the renal arteries",
"     </li>",
"     <li>",
"      Juxtarenal &ndash; aneurysm originates at the level of the renal arteries",
"     </li>",
"     <li>",
"      Suprarenal &ndash; aneurysm originates above the renal arteries",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abdominal aortic aneurysms (AAAs) most often occur in the segment of aorta between the renal and inferior mesenteric arteries; approximately 5 percent involve the renal or visceral arteries (",
"    <a class=\"graphic graphic_figure graphicRef60682 \" href=\"mobipreview.htm?9/29/9683\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Up to 40 percent of AAAs are associated with iliac artery aneurysm(s). The normal size and diameter corresponding to aneurysm for the iliac artery is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29304?source=see_link&amp;anchor=H20024768#H20024768\">",
"     \"Iliac artery aneurysm\", section on 'Definition of iliac aneurysm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the majority of endovascular aneurysm repairs are performed on aneurysms affecting the infrarenal aorta and iliac arteries, endovascular repair of juxtarenal and suprarenal aneurysms has been performed using advanced endovascular techniques with specialized investigational endografts. (See",
"    <a class=\"local\" href=\"#H444449\">",
"     'Advanced devices and techniques'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441448\">",
"    <span class=\"h2\">",
"     Measurement definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several aortic measurements are important for determining the feasibility of endovascular aneurysm repair and for endograft sizing. The definitions of important terms are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aortic neck diameter &ndash; The aortic diameter at the lowest renal artery.",
"     </li>",
"     <li>",
"      Aortic neck length &ndash; The distance from the lowest renal artery to the origin of the aneurysm.",
"     </li>",
"     <li>",
"      Aortic neck angulation &ndash; The angle formed between points connecting the lowest renal artery, the origin of the aneurysm, and the aortic bifurcation.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Conical/reverse",
"      </span>",
"      tapered aortic neck &ndash; A conical neck is present when the diameter of the aorta 15 mm below the lowest renal artery is &ge;10 percent larger than the diameter of the aorta at the lowest renal artery.",
"     </li>",
"     <li>",
"      Infrarenal aortic length &ndash; The distance from the lowest renal artery to the aortic bifurcation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other measurements that are important for sizing endografts include the maximal common iliac artery diameter, minimum external iliac artery diameter, distance from the aortic neck to the iliac bifurcation, and maximal AAA sac diameter. The criteria defining anatomic suitability for endovascular aneurysm repair are discussed below. (See",
"    <a class=\"local\" href=\"#H440175\">",
"     'Anatomic suitability'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441631\">",
"    <span class=\"h2\">",
"     Renal artery anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accessory renal arteries are present in up to 30 percent of the population, and commonly originate from the lumbar aorta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/6\">",
"     6",
"    </a>",
"    ]. Exclusion of an accessory renal vessel by an endograft can lead to partial renal infarction.",
"   </p>",
"   <p>",
"    Horseshoe kidney, a renal fusion abnormality, is associated with anomalous arterial supply with multiple renal arteries that may be derived from the aorta, or the iliac (common, external, or internal) or middle sacral arteries. Renal arteries often arise from the aneurysmal aortic segment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28487?source=see_link\">",
"     \"Renal ectopic and fusion anomalies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440427\">",
"    <span class=\"h1\">",
"     AORTOILIAC IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to consideration for endovascular aneurysm repair, aortoiliac imaging is needed to define the anatomy, determine the feasibility of endovascular repair, and choose the size and configuration of endograft components. Computed tomography (CT) is typically used for elective abdominal aortic aneurysm (AAA) repair, but under urgent or emergent circumstances, endograft feasibility and sizing can be determined intraoperatively using arteriography. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30904?source=see_link&amp;anchor=H108749259#H108749259\">",
"     \"Surgical and endovascular repair of ruptured abdominal aortic aneurysm\", section on 'Endovascular repair'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We obtain CT angiography of the abdomen and pelvis with &le;2.5 mm cuts with three-dimensional (3-D) reconstruction. Although two-dimensional (2-D) CT images can be used, measurement errors (aortic diameter, aortic length) can occur due to volume averaging. In addition, aortic diameter measurements will be overestimated if the aorta is angulated and the longitudinal axis is not perpendicular to the imaging plane. CT angiography with 3-D reconstruction allows measurements to be made that are perpendicular to the true axis of the aorta (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72328 \" href=\"mobipreview.htm?8/49/8976\">",
"     image 1",
"    </a>",
"    ). Centerline length measurements can also be obtained with 3-D reconstruction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81447 \" href=\"mobipreview.htm?9/0/9221\">",
"     image 2",
"    </a>",
"    ). 3-D length measurements are more accurate than 2-D measurements and can improve graft sizing, particularly in patients with tortuous vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance (MR) angiography can be used for preoperative endograft planning preoperatively; however, gadolinium administration in the setting of renal dysfunction is a relative contraindication.",
"   </p>",
"   <p>",
"    The use of digital subtraction arteriography (DSA) to obtain aortic measurements is limited by measurement errors due to parallax and magnification. Since the inner lumen is imaged, but not the wall of the aorta, DSA cannot evaluate the true lumen diameter, extent of thrombus, plaque, or degree of calcification. Errors in length measurement can occur when intraluminal catheters that follow the shortest distance around the curves of the aorta are used. Arteriography can be used in emergent situations to estimate the proximal aortic diameter and the diameter of the iliac graft landings zones when treating a ruptured AAA with EVAR, but it is otherwise not recommended as a routine pre-EVAR imaging modality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30904?source=see_link&amp;anchor=H108749259#H108749259\">",
"     \"Surgical and endovascular repair of ruptured abdominal aortic aneurysm\", section on 'Endovascular repair'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surface duplex ultrasound is not an adequate imaging modality for determining feasibility or planning EVAR. On the other hand, intravascular ultrasound (IVUS), which provides accurate intraoperative diameter and length measurements (based on branch vessel location), can be used as the sole imaging modality during EVAR and is a particularly attractive imaging alternative for patients with renal insufficiency. IVUS is best used during EVAR and not as a preoperative imaging modality given its invasive nature, but has limited availability and requires significant skill and experience to perform and interpret.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25899791\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair of AAA is indicated for patients with abdominal aortic aneurysm (AAA) who are symptomatic (tenderness or abdominal or back pain, evidence for embolization, rupture), have an AAA &ge;5.5 cm, or an AAA that has expanded by more than 0.5 cm within a six-month interval. The clinical evaluation and management of AAA are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32010?source=see_link\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38746?source=see_link\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440175\">",
"    <span class=\"h2\">",
"     Anatomic suitability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomic suitability is the most important determinant for successful endovascular aneurysm repair (EVAR) in the long term. With early endograft designs, about 50 percent of patients were not candidates for EVAR because of the site, extent, or morphology of the aneurysm, or unsuitability of access vessels. The availability of devices that allow for shorter proximal seal zones and lower profile devices has expanded the use of EVAR to almost two-thirds of patients with an infrarenal AAA. &nbsp;",
"   </p>",
"   <p>",
"    To exclude blood flow from the aneurysm sac, the endograft must provide an adequate seal where the endograft contacts the arterial wall proximally at the aortic neck and distally in each of the iliac arteries, otherwise known as the landing zones. The security of the repair relies solely upon the radial force generated by the graft at the landing zones since endografts do not have any suture-mediated stability. Thus, certain anatomic criteria must be fulfilled to perform EVAR (",
"    <a class=\"graphic graphic_figure graphicRef69792 \" href=\"mobipreview.htm?18/50/19234\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/8\">",
"     8",
"    </a>",
"    ]. These criteria are measurements of the aortic neck, iliac, and femoral arteries (",
"    <a class=\"graphic graphic_figure graphicRef69792 \" href=\"mobipreview.htm?18/50/19234\">",
"     figure 5",
"    </a>",
"    ). Definitions for the measurement terms are described above and the criteria for each are described in detail below. (See",
"    <a class=\"local\" href=\"#H441448\">",
"     'Measurement definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Characteristics of currently available endografts and potential advantages for different anatomic situations are given in the table (",
"    <a class=\"graphic graphic_table graphicRef67461 \" href=\"mobipreview.htm?4/16/4365\">",
"     table 1",
"    </a>",
"    ). The specific criteria recommended for a specific device are given in the instructions for use (IFU) that are published and packaged with each device used. Failure to follow device specifications increases the risk for complications. (See",
"    <a class=\"local\" href=\"#H433042\">",
"     'Perioperative morbidity and mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441797\">",
"    <span class=\"h3\">",
"     Aortic neck diameter",
"    </span>",
"    &nbsp;&mdash;&nbsp;The required endograft diameter is determined by measuring the aortic neck diameter (eg, 20 mm) and adding an additional 15 to 20 percent of the aortic neck diameter (20 mm + 3 to 4 mm = 23 to 24 mm). Under-sizing the diameter of the endograft will lead to an inadequate seal and failure to exclude the aneurysm. Over-sizing the endograft 15 to 20 percent over the measured aortic neck diameter should provide sufficient radial force to prevent device migration. Commercially-available devices have endograft diameters as large as 36 mm, which allow endovascular repair of aneurysms to a maximal aortic neck diameter of 32 mm. However, the durability of EVAR fixation in an aneurysmal aortic neck (ie, &ge;30 mm) remains to be determined. Over-sizing the endograft may lead to kinking of the device, which can form a nidus for thrombus formation or endoleak. Over-sizing may result in incomplete expansion of the endograft with infolding and inadequate seal, and can also be associated with intermediate and long-term neck expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441855\">",
"    <span class=\"h3\">",
"     Aortic neck length",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aortic neck length should be at least 10 to 15 mm to provide an adequate proximal landing zone for endograft fixation.",
"   </p>",
"   <p>",
"    Qualitative assessment of the proximal neck is also important. Ideally, the proximal aorta should be normal in appearance, without significant thrombus or calcification. Although not an absolute contraindication for EVAR, large amounts of thrombus or calcification will interfere with fixation of the graft and increase the risk for graft migration or type I endoleak. (See",
"    <a class=\"local\" href=\"#H436569\">",
"     'Handling endoleak'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441862\">",
"    <span class=\"h3\">",
"     Aortic neck angulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, the aortic neck angle should be less than 60&ordm;. Angles that are greater lead to difficulties in implantation, kinking, endoleak, and the potential for distal device migration. Severe angulation (&gt;60&deg;) is generally considered to be a contraindication to EVAR. However, the ability to place a device in aneurysms with significant angulation at the neck is ultimately determined by the conformability of the specific device type and its delivery characteristics (",
"    <a class=\"graphic graphic_table graphicRef67461 \" href=\"mobipreview.htm?4/16/4365\">",
"     table 1",
"    </a>",
"    ). The specific characteristics of individual devices are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/29/9689?source=see_link\">",
"     \"Endovascular devices for abdominal aortic repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441871\">",
"    <span class=\"h3\">",
"     Iliac artery and access vessel morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suitable iliac artery morphology is also required for endograft placement. The iliac arteries should have a minimal amount of calcification and tortuosity, and no significant stenosis or mural thrombus should be present in the distal graft landing zones. The common iliac artery is the preferred distal attachment site, but the external iliac artery can also be used. When the external iliac artery is used for distal fixation (eg, common iliac artery aneurysm), the origin of the hypogastric artery (ie, internal iliac artery) is covered by the endograft. Thus, prior to endograft placement, the hypogastric artery will need to be embolized to prevent backbleeding into the aneurysm sac, unless there is severe stenosis at its origin. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8809?source=see_link&amp;anchor=H519609202#H519609202\">",
"     \"Surgical and endovascular repair of iliac artery aneurysm\", section on 'Associated abdominal aortic aneurysm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A minimal external iliac artery diameter of 7 mm is needed to allow safe passage of the endograft delivery sheath. The common iliac artery diameter should measure between 8 and 22 mm, and the length of normal diameter common iliac artery into which the limbs of the endograft will be fixed should measure at least 15 to 20 mm to achieve an adequate seal.",
"   </p>",
"   <p>",
"    Focal narrowing and mild angulation can be overcome with standard guidewire and catheter techniques, while diffuse narrowing or significant calcification is more problematic. If the device fails to pass, an iliac conduit can be created [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H841452215\">",
"     'Iliac conduits'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Aneurysmal iliac arteries (&gt;22 mm) are treated by excluding them. The management of iliac artery aneurysm in conjunction with abdominal aortic aneurysm is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8809?source=see_link&amp;anchor=H519609202#H519609202\">",
"     \"Surgical and endovascular repair of iliac artery aneurysm\", section on 'Associated abdominal aortic aneurysm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441905\">",
"    <span class=\"h3\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inferior mesenteric artery is often occluded by thrombus in patients with an abdominal aortic aneurysm, and in these cases, excluding the inferior mesenteric artery with an endograft will be of no consequence. However, if the inferior mesenteric artery is patent but associated with significant stenosis of the superior mesenteric artery, the inferior mesenteric artery may provide important collateral blood flow to the intestine. Under this circumstance, covering the origin of a patent inferior mesenteric artery with an endograft may lead to intestinal ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A visceral hybrid procedure combines endovascular exclusion of the aneurysm with open visceral revascularization, and is more commonly used for the endovascular repair of thoracoabdominal aortic aneurysm (TAA), but in some circumstances may be needed in patients with AAA who have visceral artery disease. Prior to endovascular repair, retrograde revascularization of the visceral and renal arteries is performed (surgical debranching) using an open approach, allowing subsequent coverage of the origins of these vessels during endovascular stent-graft placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25900007\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular repair of AAA is contraindicated in patients who do not meet the anatomic criteria required to place any of the available endografts (",
"    <a class=\"graphic graphic_table graphicRef67461 \" href=\"mobipreview.htm?4/16/4365\">",
"     table 1",
"    </a>",
"    ). Adverse anatomic features include suprarenal or juxtarenal AAA, small caliber vessels, circumferential aortic calcification, and extensive tortuosity. Depending upon the location of the main and accessory renal arteries, endovascular repair may also be contraindicated for the management of AAA associated with horseshoe kidney. A variety of next-generation devices are being developed to treat suprarenal and juxtarenal abdominal aortic aneurysms. (See",
"    <a class=\"local\" href=\"#H440175\">",
"     'Anatomic suitability'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H441000\">",
"     'Endografts'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/29/9689?source=see_link\">",
"     \"Endovascular devices for abdominal aortic repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A relative contraindication to endovascular aneurysm repair (EVAR) is the inability to comply with the required post-EVAR surveillance. (See",
"    <a class=\"local\" href=\"#H2369876318\">",
"     'Endograft surveillance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Whether younger patients (&lt;60 years of age) who are not at high risk for open surgery should undergo open surgical repair versus EVAR remains controversial. Surveillance over an extended period of time exposes the patient to greater levels of cumulative radiation, and EVAR does not completely eliminate the risk of future aortic rupture. Guidelines from major medical and surgical societies emphasize an individualized approach when choosing endovascular repair, taking into account the patient's age and risk factors for perioperative morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The decision for open surgical repair versus endovascular repair is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38746?source=see_link&amp;anchor=H783678#H783678\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Open versus endovascular aneurysm repair'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2369876062\">",
"     'Preoperative risk assessment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441000\">",
"    <span class=\"h1\">",
"     ENDOGRAFTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular repair of abdominal aortic aneurysm is accomplished using a fabric-covered stent, termed an endograft or stent-graft. The first endovascular aneurysm repair (EVAR) was performed in 1987 by Nicholas Volodos in Kiev [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/17\">",
"     17",
"    </a>",
"    ]. Juan Parodi popularized stent-grafting following his initial clinical experience in 1991, and was the driving force for commercializing stent-graft systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/18\">",
"     18",
"    </a>",
"    ]. Stent-grafts were approved for clinical use in the United States in 1999.",
"   </p>",
"   <p>",
"    Adoption of stent-graft technology by vascular surgeons has been rapid. EVAR has become a preferred approach across all ages for the repair of infrarenal abdominal aortic aneurysm (AAA) due to decreased perioperative morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/1,2,19\">",
"     1,2,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441022\">",
"    <span class=\"h2\">",
"     Stent-graft design",
"    </span>",
"    &nbsp;&mdash;&nbsp;Six stent-graft systems are currently available in the United States. These are listed below and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/29/9689?source=see_link\">",
"     \"Endovascular devices for abdominal aortic repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      AneuRx",
"      <sup>",
"      </sup>",
"      (Medtronic, Inc., Minneapolis, MN)",
"     </li>",
"     <li>",
"      Talent (Medtronic, Inc., Minneapolis, MN)",
"     </li>",
"     <li>",
"      Endurant (Medtronic, Inc., Minneapolis, MN),",
"     </li>",
"     <li>",
"      Excluder (W.L. Gore and Associates, Flagstaff, AZ)",
"     </li>",
"     <li>",
"      Zenith (Cook, Inc., Bloomington, IN)",
"     </li>",
"     <li>",
"      Powerlink (Endologix, Irvine, CA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    New endograft designs are continually being tested to enhance performance. Targeted improvements have focused upon lower device and delivery profiles, more accurate deployment, improved fixation systems, and flexibility in managing challenging anatomy. These improvements, along with increased operator experience, have led to improvements in the short-term and long-term results of endovascular aneurysm repair, and have expanded the application of endovascular repair to many whose aortic anatomy was previously deemed unsuitable. Careful preoperative sizing and planning, along with strict adherence to device-specific instructions for use, lead to the best outcomes. Other devices that have received approval for use in other countries or are at the clinical trial or preapproval stage in the United States are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/29/9689?source=see_link&amp;anchor=H861292399#H861292399\">",
"     \"Endovascular devices for abdominal aortic repair\", section on 'Withdrawn and investigational devices'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endovascular grafts for infrarenal aneurysm repair share a bifurcated, modular design. Although there are variations from device to device, three components (delivery system, main body, and iliac extensions) are common to all endograft device systems and are briefly described below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delivery system &ndash; The endograft is typically delivered through the femoral artery, either percutaneously or by direct surgical cutdown. If the femoral artery is too small to accommodate the delivery system, access can be obtained by suturing a synthetic graft to the iliac artery (ie, iliac conduit) through a retroperitoneal low abdominal incision. The size of the delivery system varies depending upon the device diameter.",
"     </li>",
"     <li>",
"      Main body device &ndash; The main body device is usually a bifurcated graft, but unibody grafts are available for use in special circumstances (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68234 \" href=\"mobipreview.htm?42/18/43301\">",
"       image 3",
"      </a>",
"      ). Bifurcated-to-unilateral graft conversion kits are also available and effectively turn a bifurcated main body graft into a unibody graft by occluding one of the two proximal iliac limbs. The length of the limb(s) of the main body device varies. Two-component bifurcated grafts have one short and one long iliac limb. Three-component bifurcated devices have two short limbs. Endovascular grafts rely primarily upon tension to maintain the positioning of the main body device. Main body fixation is classified as infrarenal or suprarenal. Devices with infrarenal fixation may have barbs or hooks on the outer aspect of the devices, whereas suprarenal fixation is accomplished with a portion of uncovered graft extending superior to the renal arteries. Devices with suprarenal fixation may also have barbs and hooks.",
"     </li>",
"     <li>",
"      Iliac extensions &ndash; One or more iliac extension devices are required to complete the endograft construction. Following the deployment of the main body of a two-component system, the attached iliac limb is pulled down and deployed into the ipsilateral iliac artery. A separate iliac device is introduced into the contralateral iliac artery to complete the endograft. For a three-component device, both of the iliac limbs are introduced separately. Additional iliac extensions may be needed to obtain a proper seal in the iliac artery distally. (See",
"      <a class=\"local\" href=\"#H2369876151\">",
"       'Endograft placement'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The degree of structural support (nitinol or stainless steel stents) throughout the graft varies from device to device. The support structure may be internal or external to the graft fabric, which is typically made of polyester (eg, Dacron) or polytetrafluoroethylene (PTFE). Proponents of designs that have less metallic support structure claim the device is better able to adapt to changes in aneurysm configuration over time. On the other hand, some physicians feel that fully supported endografts are less prone to kinking and subsequent thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444449\">",
"    <span class=\"h2\">",
"     Advanced devices and techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;When aneurysmal disease is more extensive, involving the visceral vessels proximally or associated with common or hypogastric artery aneurysms, the complexity of the required endovascular or open repair increases. Fenestrated and branched graft technology is under investigation to manage more challenging anatomy without the need for surgical debranching. The early results using these endografts have been promising, with high rates of successful exclusion of juxtarenal and thoracoabdominal aneurysms, but with an increased risk of visceral artery or stent-branch occlusion. The devices and techniques for more advanced endovascular repair are briefly reviewed below and are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/29/9689?source=see_link&amp;anchor=H1191837723#H1191837723\">",
"     \"Endovascular devices for abdominal aortic repair\", section on 'Advanced devices'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=see_link&amp;anchor=H958071030#H958071030\">",
"     \"Complications of endovascular abdominal aortic repair\", section on 'Ischemic complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fenestrated &ndash; Fenestrated endografts have openings in the fabric of the endograft, which allow flow into the visceral arteries. Stent-grafts with fenestrations at the renal arteries can be used when the proximal aortic neck is short (ie, &lt;10 mm) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Branched &ndash; Branched grafts have a separate small graft sutured to the basic endovascular graft for deployment into a vessel to preserve flow into it. Branched grafts have been designed to accommodate the hypogastric (ie, internal iliac) and renal arteries.",
"     </li>",
"     <li>",
"      Chimney grafts &ndash; The chimney (ie, snorkel) endografting technique is used to preserve perfusion to branch vessels when an endograft needs to be placed in a suprarenal position to gain additional neck length [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/22\">",
"       22",
"      </a>",
"      ]. Peripheral stents are placed into the branch vessel(s) before the aortic endograft is completely deployed. The branch vessel stent is deployed alongside the endograft (parallel position between the inside of the aortic wall and outside the endograft) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Although this technique maintains flow into the visceral vessels, complications related to device insertion and type I endoleak continue to be a problem. In the absence of available fenestrated or branched grafts in the United States, chimney grafts remain a feasible endovascular option for high-risk patients who have more extensive abdominal aortic aneurysms, particularly in emergency situations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441029\">",
"    <span class=\"h2\">",
"     Choice of graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clear advantages of one stent-graft design over another. The overall performance among the available devices is similar and the available data confirm uniformly low complication rates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/29/9689?source=see_link\">",
"     \"Endovascular devices for abdominal aortic repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of a particular device design is based upon multiple factors, including patient anatomy, operator preference, and cost. An endograft system that can handle all types of AAA, including those with angulated or tortuous anatomy, has yet to be achieved.",
"   </p>",
"   <p>",
"    Bifurcated grafts are most often chosen, but are not appropriate for patients with unilateral severe iliac stenosis or occlusion. Under this circumstance, unibody (nonbifurcated) grafts, also known as aorto-uni-iliac (AUA) devices, are used. AUI devices are used when contralateral iliac access or gate cannulation is difficult or impossible, and for the treatment of some ruptured aneurysms for expeditious control of hemorrhage. After deployment of an AUI device, a plug will need to be inserted into the contralateral iliac artery if it remains patent to prevent retrograde flow of blood into the aneurysm sac. To provide adequate perfusion to the contralateral lower extremity, a femoro-femoral crossover bypass may be needed.",
"   </p>",
"   <p>",
"    Whether to use a graft with suprarenal or infrarenal fixation remains debated. Suprarenal fixation may provide more durable proximal fixation of the stent-graft when anatomic features are not optimal, such as with a short aortic neck, aortic angulation, conical aortic neck, or circumferential mural thrombus or calcification. However, the placement of stents in the region of the visceral vessels has raised concerns for embolization both at the time of the endograft placement and over time. Suprarenal fixation may lead to a higher incidence of small renal infarcts, but most are not clinically evident. However, in the face of preexisting renal insufficiency, suprarenal fixation should be used with caution.",
"   </p>",
"   <p>",
"    Aortic endografts are prefabricated in various diameters and lengths. Once the graft design has been chosen, the particular device components that are used are determined by the measurements and configuration of the aneurysm being treated. The various manufacturers provide templates to assist the surgeon in choosing graft components based upon aneurysm measurements. (See",
"    <a class=\"local\" href=\"#H441448\">",
"     'Measurement definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89888610\">",
"    <span class=\"h3\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some variability in the cost of EVAR, partially based upon the choice of the endograft and number of device components needed to complete the repair. The list price for main body devices ranges from about $8300 for the AneuRx graft to $11,200 for the Powerlink graft. Various other components, such as ipsilateral and contralateral limbs, limb extensions, and other devices needed to correct any endoleaks add cost per component used. Negotiated institutional prices for the grafts may vary from the list price, and costs related to the surgical suite, operating personnel, anesthesia services, and hospital costs based on the type of hospital bed and length of hospital stay are also variable. Other costs are incurred following discharge from the hospital for ongoing surveillance and re-intervention due to endoleak, when needed.",
"   </p>",
"   <p>",
"    Compared with open repair of AAA, EVAR is more costly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/25-31\">",
"     25-31",
"    </a>",
"    ]. In an analysis of the EVAR 1 trial, the mean costs for the initial EVAR and open repair were &pound;13,019 ($20,271 US) and &pound;11,842 ($18,438 US), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/26,30\">",
"     26,30",
"    </a>",
"    ]. The difference in lifetime cost was &pound;3519 ($5479 US) higher with EVAR, but there was only a very small difference in quality-adjusted life-years (QALYs) of -0.032 (95% CI, -0.117 to 0.096) in favor of open repair. In EVAR 2, the mean cost difference was &pound;10,596 ($16,499 US) higher for EVAR compared with open repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2369876062\">",
"    <span class=\"h1\">",
"     PREOPERATIVE RISK ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although endovascular aneurysm repair (EVAR) is associated with lower perioperative morbidity and mortality compared with open surgical repair, there is a small risk that the endovascular repair may need to be converted to an open repair, and thus, patients should be evaluated and prepared as if undergoing an open surgical repair. Coronary artery disease (CAD) is the leading cause of early and late mortality following AAA repair, and other comorbidities such as chronic obstructive pulmonary disease (COPD) and renal insufficiency also increase perioperative morbidity and mortality. We agree with the Society for Vascular Surgery and other societies that recommend a comprehensive assessment of medical comorbidities prior to endovascular aneurysm repair (EVAR) including cardiac, pulmonary, and renal evaluation, also taking into account hypertension and patient age as relevant risk factors for morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The evaluation of cardiopulmonary risk and risk management strategies are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link\">",
"     \"Management of cardiac risk for noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=see_link\">",
"     \"Strategies to reduce postoperative pulmonary complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H439885\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444809\">",
"    <span class=\"h2\">",
"     Antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing AAA repair (endovascular or open surgery) are considered to be at moderate to high risk for deep venous thrombosis and thromboprophylaxis is indicated. Thromboprophylaxis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H37#H37\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Moderate risk general and abdominal-pelvic surgery patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H38#H38\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'High risk general and abdominal-pelvic surgery patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 193 patients undergoing AAA repair, the incidence of thromboembolism was lower for endovascular aneurysm repair compared with open surgery; however, the incidence of deep vein thrombosis following EVAR was 5.3 percent in spite of pharmacologic thromboprophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/34\">",
"     34",
"    </a>",
"    ]. Delayed initiation of pharmacologic prophylaxis was associated with a trend toward an increased incidence of deep venous thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444816\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to endograft placement, antibiotic prophylaxis is recommended within 30 minutes of the skin incision (",
"    <a class=\"graphic graphic_table graphicRef63103 \" href=\"mobipreview.htm?33/9/33950\">",
"     table 2",
"    </a>",
"    ). A first generation cephalosporin or, in the case of a history of penicillin allergy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , is recommended. Antibiotics are discontinued within 24 hours given the lack of added benefit beyond that time frame. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2357599518\">",
"    <span class=\"h2\">",
"     Prevention of contrast-induced nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;EVAR increases the risk of renal complications, primarily due to the administration of intravenous contrast agents but potentially also related to the dislodgement of embolic debris by manipulation of catheters and wires near the renal arteries, or impingement of the real ostia by the graft or suprarenal fixation portion of the stent-graft. When EVAR will be performed in a patient with preexisting renal insufficiency, strategies to reduce the risk for contrast-induced nephropathy should be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/32\">",
"     32",
"    </a>",
"    ]. These strategies are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444823\">",
"    <span class=\"h2\">",
"     Prophylactic renal artery stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need to deploy a stent-graft near the origin of stenotic renal arteries is not uncommon. Although grafts with suprarenal fixation do not seem to affect renal function in patients with normal renal arteries, it is not clear if this holds true in the setting of severe renal artery stenosis and preexisting renal insufficiency. Whether prophylactic renal artery stenting should be performed in this setting is unclear. If a device with suprarenal fixation is needed, the possibility that the renal artery flow will be compromised due to the suprarenal struts needs to be weighed against the risks and potential benefits of prophylactic renal artery stenting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33433?source=see_link\">",
"     \"Chronic kidney disease associated with atherosclerotic renovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444831\">",
"    <span class=\"h2\">",
"     Hypogastric embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypogastric (ie, internal iliac artery) embolization may be needed to prevent type II endoleak during endovascular repair of aortic aneurysms involving the distal common iliac artery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypogastric artery (ie, internal iliac artery). When unilateral hypogastric embolization is needed, it is often performed preoperatively; however, it can also be performed just prior to endovascular stent-graft placement. Patients with bilateral iliac artery aneurysms generally undergo a staged approach. Hypogastric embolization increases the proportion of patients who will have anatomy that is suitable for endovascular aneurysm repair. The endovascular management of patients with iliac artery aneurysm in conjunction with abdominal aortic aneurysm repair is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8809?source=see_link\">",
"     \"Surgical and endovascular repair of iliac artery aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2369876151\">",
"    <span class=\"h1\">",
"     ENDOGRAFT PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular aneurysm repair (EVAR) is performed by inserting folded graft components into the aorta to construct an endograft, which expands upon deployment, contacting the aortic wall proximally and the iliac vessels distally to exclude the aortic aneurysm sac from aortic blood flow and pressure.",
"   </p>",
"   <p>",
"    The chosen device and its components should be present in the operating room before the start of the procedure and additional device components, guidewires, and sheaths should be immediately available to manage any technical issues that might arise.",
"   </p>",
"   <p>",
"    Centers treating AAA using EVAR should ideally be equipped with a dedicated endovascular operating suite in which conversion to open repair can be performed efficiently, if needed. Endovascular aneurysm repair (EVAR) can be performed using portable digital subtraction fluoroscopic imaging or fixed imaging systems. Although fixed imaging systems provide better image quality and may include concomitant computed tomography (CT) and three-dimensional imaging, newer generation portable fluoroscopic systems provide adequate detail for routine EVAR.",
"   </p>",
"   <p>",
"    Once the patient is anesthetized, endovascular aneurysm repair is accomplished through an orderly sequence that includes gaining vascular access, placement of arterial guidewires and sheaths, imaging to confirm aortoiliac anatomy, main body deployment, gate cannulation (bifurcated graft), iliac limb deployment, graft ballooning, and completion imaging. The general technique for routine endovascular repair is described below, and typical variations needed for troubleshooting common problems. The complications associated with EVAR are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=see_link\">",
"     \"Complications of endovascular abdominal aortic repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H841452149\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular aneurysm repair (EVAR) can be performed under general anesthesia, regional anesthesia, total intravenous anesthesia (TIVA) or local anesthesia with conscious sedation. The type of anesthesia used is often one of surgeon preference, but multiple studies have shown a benefit to limiting the use of general anesthesia, when possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Local anesthesia is associated with shorter operating times, shorter hospital stays and fewer complications. If the cooperation level of the patient is anticipated to be poor, general anesthesia may be preferred to limit patient movement to allow accurate graft positioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H841452056\">",
"    <span class=\"h2\">",
"     Vascular access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral femoral access is needed to place endografts. Endovascular repair of AAA can be performed via surgical femoral cutdown or percutaneously. The cutdown approach is similar to that used for femoral embolectomy or femoral graft placement; however, in patients with a limited amount of atherosclerotic disease and no evidence for femoral aneurysm, exposure can be limited to the area of the common femoral artery that will be punctured. The incision can be longitudinal or transverse, but if patch repair of the common femoral artery is anticipated a longitudinal incision is preferred.",
"   </p>",
"   <p>",
"    Open access can be more challenging in obese patients or in patients with prior groin surgery. Arteriotomy repair with a percutaneous suture device is feasible, even after the use of large-bore introducers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/8,38-40\">",
"     8,38-40",
"    </a>",
"    ]. In determining whether an artery is suitable for use with a percutaneous arterial closure device, several factors are important, including the size of the femoral artery, prior groin surgery or use of a closure device, significant arterial occlusive disease, and common femoral aneurysm.",
"    <br/>",
"    <br/>",
"    Once the common femoral artery is accessed, deployment of the sheath into the anterior common femoral artery is critical. More proximal punctures through the inguinal ligament may cause problems with proper knot tying, and the proper application of pressure to achieve hemostasis may be more difficult. More distal access (eg, superficial femoral artery) can lead to vessel thrombosis.",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H841452208\">",
"    <span class=\"h2\">",
"     Percutaneous access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous access uses standard guidewire access and then uses progressive dilators to place the endograft sheath rather than direct exposure of the access vessel. Once the endograft is in place, closure of the defect in the vessel is accomplished using specialized vascular closure devices (eg, Perclose). The success rates of percutaneous endovascular aneurysm repair (EVAR) in various clinical studies approach 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/8,38\">",
"     8,38",
"    </a>",
"    ]. Variability in success appears to be related to the degree of femoral artery calcification and operator experience with the technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/40\">",
"     40",
"    </a>",
"    ]. Sheath size and obesity do not appear to have a significant impact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H841452215\">",
"    <span class=\"h3\">",
"     Iliac conduits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small diameter access vessels increase the technical difficulty of EVAR, particularly in the setting of vessel calcification and tortuosity. Severe vascular stenoses or occlusions of the iliac arteries (TASC C and D lesions) increase the risk of a major iliac vessel complication and are an independent predictor of procedural failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/41\">",
"     41",
"    </a>",
"    ]. Iliac rupture is a potentially fatal complication that appears to be more common in women, likely related to the generally smaller caliber of iliac artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/42\">",
"     42",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Small caliber iliac vessels can be handled in a step-wise fashion. The initial approach is stretching the artery using graduated dilators or focal balloon angioplasty, as needed. If these maneuvers are not successful, the stent-graft can be delivered through an iliac conduit, which is a graft (eg, Dacron, expanded polytetrafluoroethylene [ePTFE]) that is sutured to the common iliac artery or distal aorta. The need for an iliac conduit should be anticipated based upon preoperative imaging. After providing adequate exposure of the pelvic vasculature through a low retroperitoneal incision, the iliac conduit is sutured into place, and the sheath inserted into the conduit (",
"    <a class=\"graphic graphic_picture graphicRef56546 \" href=\"mobipreview.htm?25/27/26040\">",
"     picture 1",
"    </a>",
"    ). To provide a less acute angle to pass the endograft, the iliac conduit can be passed through a subcutaneous tunnel under the inguinal ligament into the groin region before placing the sheath.",
"   </p>",
"   <p>",
"    <br/>",
"    An alternative technique is termed an internal endoconduit. A covered stent is deployed within the iliac artery, and the endovascular sheath is subsequently passed from a common femoral artery access site; an adequately-sized femoral artery is a prerequisite for this technique. Any disruption of the iliac artery during passage of the sheath is contained by the covered stent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/43\">",
"     43",
"    </a>",
"    ]. Unexplained hemodynamic instability may indicate avulsion of the iliac artery. This technique can be useful in patients with a hostile retroperitoneum or colostomy, which can complicate the placement of an open iliac conduit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H841452071\">",
"    <span class=\"h2\">",
"     Graft deployment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once vascular access is established and landmarks for positioning the device are obtained with aortography, the main device is positioned with particular attention paid to the location of the opening for the contralateral iliac limb (&ldquo;contralateral gate&rdquo;). The aortic neck is imaged; a slight degree of craniocaudal and left anterior oblique angulation may improve imaging of the renal ostia. With the proximal radiopaque markers of the graft positioned appropriately below the lowest renal artery, the body of the graft is deployed to the level of the contralateral gate.",
"   </p>",
"   <p>",
"    A guidewire is advanced through the contralateral access site into the contralateral gate. Gate cannulation is confirmed by placing a pigtail catheter over the guidewire into the main body of the graft, removing the guidewire and confirming that the pigtail catheter rotates freely within the main body of the graft; if it does not, the catheter is assumed to be in the aneurysm sac. Once the contralateral guidewire is positioned within the main body of the endograft, the deployment of the endograft at the neck of the aneurysm is completed followed by deployment of the contralateral, then ipsilateral iliac artery limbs (depending on the type of graft). Once the endograft components are in place, the attachment sites and endograft junctions are gently angioplastied with a compliant or semi-compliant balloon.",
"   </p>",
"   <p>",
"    Completion aortography is performed to evaluate the patency of the renal arteries and evaluate for endoleak. Guidewire access is maintained throughout the procedure but is particularly important when removing the main graft body device sheath since disruption of the access vessels by an oversized sheath may not become apparent until after sheath has been removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64453742\">",
"    <span class=\"h2\">",
"     Troubleshooting",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64453750\">",
"    <span class=\"h3\">",
"     Gate cannulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deployment of the main body of the device with the gate low in the aneurysm sac or below the aortic bifurcation can lead to a situation in which the contralateral gate does not open up when the device is deployed. This is referred to as &ldquo;jailing the contralateral gate.&rdquo; In some cases, pushing the device upward will allow the gate to flare open. Many currently available endovascular graft devices allow recapture of the graft to reorient the gate opening. If the gate of the graft cannot be moved more superiorly, conversion to an aortouniiliac (AUI) configuration or open conversion may be needed.",
"   </p>",
"   <p>",
"    Even with correctly positioned grafts, it is not uncommon to encounter difficulties with gate cannulation, particularly with large aneurysm sacs that have minimal mural thrombus. Catheters with reverse angulation (eg, Vansche catheter, Cook Inc) can help engage the gate. If various types of catheters do help the wire pass through the gate, a wire can be passed up and over the graft flow divider from the ipsilateral to contralateral femoral access, or alternatively from an access site in the arm antegrade down through the gate. The antegrade wire can then be snared and pulled through the contralateral femoral access sheath.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436569\">",
"    <span class=\"h3\">",
"     Handling endoleak",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoleak is a term that describes the presence of persistent flow of blood into the aneurysm sac after device placement, indicating failure to completely exclude the aneurysm from the aortic circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/44\">",
"     44",
"    </a>",
"    ]. Type I and type III endoleak identified at the time of endograft placement are repaired and generally respond to additional ballooning or the placement of additional endograft components. Open conversion is almost never required. Type II and type IV do not require any specific intervention when identified at the time of endograft placement.",
"   </p>",
"   <p>",
"    Five types of endoleaks are described (",
"    <a class=\"graphic graphic_figure graphicRef64707 \" href=\"mobipreview.htm?36/13/37074\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I endoleak is due to an incompetent seal at the proximal (Ia) or distal (Ib) attachment sites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. Etiologies include under-sizing of the diameter of the endograft or ineffective attachment of the endograft to a vessel wall that is heavily calcified or surrounded by thick thrombus. Type I endoleak is associated with significant pressure elevation in the aneurysm sac and has been linked to an ongoing risk of rupture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. All type I endoleaks should be corrected promptly, as spontaneous resolution, though possible, is not typical, and treatment can usually be accomplished by endovascular means. The initial treatment of procedural type I endoleak typically involves re-ballooning of the distal attachment sites, but placement of additional aortic cuffs, iliac limb extensions, or balloon expandable stent (eg, Palmaz) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef86466 \" href=\"mobipreview.htm?19/32/19973\">",
"       image 4",
"      </a>",
"      ) is sometimes required. Open conversion is almost never required at the time of EVAR, but is sometimes needed for delayed type I endoleak.",
"     </li>",
"     <li>",
"      Type II endoleaks (",
"      <a class=\"graphic graphic_picture graphicRef66670 \" href=\"mobipreview.htm?23/47/24307\">",
"       picture 2",
"      </a>",
"      ) are caused by flow into and out of the aneurysm sac from patent branch vessels (eg, lumbar arteries, inferior mesenteric artery) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/45\">",
"       45",
"      </a>",
"      ]. The incidence of type II leak has been correlated with the number of patent aortic branches prior to endograft placement. Type II endoleaks are the most frequent type, occurring in 10 to 25 percent of endovascular aortic aneurysm repairs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type III endoleaks (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74867 \" href=\"mobipreview.htm?14/45/15057\">",
"       image 5",
"      </a>",
"      ) represent flow into the aneurysm sac due to separation of the components of the modular graft system (IIIA), or tears in the endograft fabric (IIIB). Type III endoleaks are as serious as type I endoleaks because they pressurize the aneurysm sac. As with type I endoleaks, the treatment usually involves deployment of additional stent graft components to seal the fabric defect or bridge disjoined modular components.",
"     </li>",
"     <li>",
"      Type IV endoleak is due to egress of blood through the pores of the fabric and typically resolves in 24 hours. It has not been associated with any long-term adverse events and does not require any treatment. It can, however, be quite disconcerting to see at completion aortography, because it often obscures the more serious type I or III leaks.",
"     </li>",
"     <li>",
"      Type V endoleak occurs in the postoperative period as continued aneurysm sac expansion without a demonstrable leak on any imaging modality. These are not apparent at the time of initial graft placement",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436613\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following endovascular repair of abdominal aortic aneurysm, patients can be transferred to a regular floor once they have recovered from anesthesia. The patient can drink clear fluids and advance to a regular diet, as tolerated. Treatment of acute postoperative pain consists mainly of nonsteroidal antiinflammatory drugs (NSAIDs)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    opioids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ambulation is resumed on the first postoperative day. The majority of patients can be discharged home within 24 hours following EVAR, provided no complications have occurred. Fluid therapy is continued to minimize the risk of contrast nephropathy, particularly in patients with preoperative renal insufficiency. (See",
"    <a class=\"local\" href=\"#H2357599518\">",
"     'Prevention of contrast-induced nephropathy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The peripheral pulse exam should be assessed at regular intervals and compared with the baseline preoperative examination. Any abnormalities should prompt duplex evaluation for potential endograft limb complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=see_link&amp;anchor=H1191827380#H1191827380\">",
"     \"Complications of endovascular abdominal aortic repair\", section on 'Extremity ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2369876318\">",
"    <span class=\"h2\">",
"     Endograft surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure of aortic endografts is well documented and can lead to continued aneurysm expansion and potential rupture. Thus, it is mandatory for all patients to undergo routine surveillance to assure the integrity of the repair. The principle concerns are endoleak, aneurysm sac enlargement, migration of the stents at the aortic and iliac landing zones, and separation of the device components. The most commonly used imaging modalities for ongoing endograft surveillance are contrast-enhanced computed tomographic (CT) arteriography and duplex ultrasonography (DU). Other surveillance modalities include magnetic resonance (MR) imaging and aneurysm sac pressure measurements.",
"   </p>",
"   <p>",
"    Abdominal plain films are an economical and quick way to evaluate the integrity of the metallic structure of the graft and endograft alignment, and can be obtained prior to discharge from the hospital.",
"   </p>",
"   <p>",
"    CT angiography with delayed images is the most widely used modality for follow-up after endovascular aneurysm repair (EVAR). It is accurate for maximal diameter measurement, and for the detection of endoleak (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79584 \" href=\"mobipreview.htm?34/24/35204\">",
"     image 6",
"    </a>",
"    ) and other device-related complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. However, CT angiography is costly and repeated radiation exposure is associated with an increased lifetime cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/47\">",
"     47",
"    </a>",
"    ]. Repeated administration of intravenous contrast may also contribute to a progressive decline in renal function that has been observed following EVAR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    The guidelines for the management of abdominal aortic aneurysm (AAA) from the Society for Vascular Surgery advocate CT angiography at 1 and 12 months during the first year after EVAR. Imaging at six months is no longer routinely recommended unless an endoleak or other device-related abnormality is identified at the one-month imaging study after EVAR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/32\">",
"     32",
"    </a>",
"    ]. If an endoleak or aneurysm enlargement is not documented during the first year after EVAR, DU is an alternative to CT angiography for ongoing postoperative surveillance.",
"   </p>",
"   <p>",
"    DU and unenhanced CT scan are acceptable alternatives to avoid intravenous contrast load and repeated exposure to radiation associated with repeated CT angiography. An advantage of DU is that it is noninvasive and less expensive compared with CT angiography, but DU needs to be performed by a skilled technician in an appropriately credentialed laboratory. Several studies have established the efficacy of DU, and its ability to detect endoleaks and evaluate sac expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/55-67\">",
"     55-67",
"    </a>",
"    ]. However, some speculate a lower sensitivity of unenhanced ultrasound for diagnosis of endoleak, which has led to increasing interest in contrast-enhanced ultrasound imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/50\">",
"     50",
"    </a>",
"    ]. Systematic reviews have found a pooled sensitivity and specificity of contrast-enhanced ultrasound for detecting any type of endoleak to be 96 to 98 percent, and 85 to 88 percent, respectively, using contrast-enhanced CT angiography as the diagnostic standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In comparing contrast-enhanced ultrasound to unenhanced ultrasound for all types of endoleak, contrast-enhanced ultrasound had a greater sensitivity but lower specificity than unenhanced ultrasound; however, for only type I and type III leaks, no differences were found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/65\">",
"     65",
"    </a>",
"    ]. This appears to suggest that the greater sensitivity of contrast-enhanced ultrasound compared with unenhanced ultrasound is related to identifying type 2 endoleak, for which the need for intervention is less certain.",
"   </p>",
"   <p>",
"    MR imaging is not a standard modality for EVAR surveillance, but can be used in specific situations where CT angiography is contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The advantage of MR imaging is the lack of exposure to ionizing radiation. Disadvantages are its lack of wide availability and difficulty evaluating device integrity due to artifact. The placement of stent-grafts made of nitinol does not preclude MR imaging, though MR imaging is contraindicated for stainless-steel-based grafts (eg, Cook, Zenith) (",
"    <a class=\"graphic graphic_table graphicRef67461 \" href=\"mobipreview.htm?4/16/4365\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Direct measurement of the pressure within the aneurysm sac after EVAR can be performed and is a reliable indicator of intra-sac pressure, but is invasive. Noninvasive aneurysm sac pressure measurements using implantable wireless pressure sensing systems have been developed, but accuracy may be limited by the presence of mural thrombus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/68\">",
"     68",
"    </a>",
"    ]. For type II endoleaks of unclear clinical significance, the sensor may assist in therapeutic management. However, remote pressure sensing does not provide any information about device integrity and these devices are unlikely to be used as stand-alone surveillance after EVAR, but may complement other low-risk modalities such as DU imaging.",
"   </p>",
"   <p>",
"    Digital subtraction arteriography is reserved for the evaluation of specific problems such as decreased limb flow, graft limb thrombosis, documented endoleak, or to measure aneurysm sac pressure when an enlarging aneurysm is identified in the absence of an endoleak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433042\">",
"    <span class=\"h1\">",
"     PERIOPERATIVE MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall complication rate for endovascular aneurysm repair, including access-related issues, is approximately 10 percent. The complications associated with endovascular aneurysm repair are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=see_link\">",
"     \"Complications of endovascular abdominal aortic repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Device-related complications may include vascular injury as a result of device deployment and endoleak. Following successful endograft repair, the aneurysm sac will eventually thrombose, and the sac of most aneurysms progressively shrinks. The endograft repair may respond to the changing configuration of the aneurysm which can lead to late endograft complications such as angulation, kinking, thrombosis, or migration. Thus, lifetime endograft surveillance is required. (See",
"    <a class=\"local\" href=\"#H2369876318\">",
"     'Endograft surveillance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The short-term technical success rate for endovascular aneurysm repair has improved with increasing experience with the technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/16\">",
"     16",
"    </a>",
"    ]. Technical failures may be due to a vascular complication or inability to resolve a type I leak. Open conversion at the time of repair is uncommon and is required in fewer than 2 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Thirty-day technical success rates range from 77 to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review identified four trials that included 1532 patients who were considered suitable candidates for endovascular or open repair of nonruptured abdominal aortic aneurysms larger than 5.0 cm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/74\">",
"     74",
"    </a>",
"    ]. The 30-day all-cause mortality was significantly lower with endovascular repair (1.6 versus 4.8 percent). The short-term survival advantage of endovascular repair appears to be much greater when endovascular repair is limited to patients at highest risk for open surgery. This was illustrated in a report of 454 consecutive patients who underwent elective repair (206 endovascular and 248 open surgeries) of an abdominal aortic aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/75\">",
"     75",
"    </a>",
"    ]. The overall 30-day mortality rates did not significantly differ for endografting and surgery (2.4 and 4.8 percent, respectively). However, among patients at highest surgical risk (American Society of Anesthesiologists [ASA] class IV), the 30-day mortality rates were lower for endovascular compared with open repair (4.7 versus 19.2 percent).",
"   </p>",
"   <p>",
"    Using the United States Medicare database, long-term survival was evaluated in 22,830 matched pairs of patients who underwent elective repair with an open or endovascular technique between 2001 and 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/72\">",
"     72",
"    </a>",
"    ]. There was a significantly lower rate of perioperative mortality with endovascular repair (1.2 versus 4.8 percent); a more pronounced benefit was seen with increasing age. However, as seen with other studies, overall mortality at three to four years following repair was nearly identical in the two groups.",
"   </p>",
"   <p>",
"    Over the long-term, however, it has not been definitively established that endovascular repair is superior to open surgical repair, even among patients at highest risk for surgery. Although a 3 percent reduction in aneurysm-related mortality persisted throughout the follow-up period, in both the DREAM and EVAR1 trials, the initial reduction in all-cause mortality was eliminated within one to two years with equivalent overall survival in both treatment groups. A later analysis from the Medicare database of 4529 patients treated between 2003 and 2007 and followed over a median of 2.4 years found similar results in the perioperative period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/27/31162/abstract/76\">",
"     76",
"    </a>",
"    ]. Aneurysm-related mortality and perioperative (30-day) mortality were reduced in the endovascular group. Among patients who survived longer &gt;30 days, no difference in all-cause mortality was seen (HR 1.01, 95% CI 0.84-1.22). However, in this study, the survival advantage conferred with endovascular repair was maintained throughout the study period such that the all-cause mortality risk for open repair relative to endovascular repair remained elevated (hazard ratio [HR] 1.24, 95% CI 1.05-1.47). The average age of the patients who underwent endovascular repair was not significantly different compared with those treated with open repair (75 versus 76). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38746?source=see_link&amp;anchor=H783678#H783678\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Open versus endovascular aneurysm repair'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/48/19202?source=see_link\">",
"       \"Patient information: Endovascular surgery (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/62/34787?source=see_link\">",
"       \"Patient information: Abdominal aortic aneurysm (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436647\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The abdominal aorta is defined as aneurysmal when a localized dilation is identified, and the diameter of that region is increased more than 50 percent relative to normal aortic diameter. For most individuals, an aortic diameter greater than 3.0 cm is generally considered aneurysmal. (See",
"      <a class=\"local\" href=\"#H2369875877\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endovascular repair of abdominal aortic aneurysm (EVAR) represents a widely available alternative to open surgical repair. However, the precise role of EVAR continues to be defined. Guidelines from major medical and surgical societies recommend an individualized approach to the patient when choosing between open and endovascular repair, taking into account the patient's age, risk factors for perioperative morbidity and mortality, anatomic factors, and the experience of the surgeon. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38746?source=see_link&amp;anchor=H783678#H783678\">",
"       \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Open versus endovascular aneurysm repair'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The preprocedural evaluation of patients undergoing endovascular repair requires medical risk assessment and a careful quantitative and qualitative evaluation of aortoiliac anatomy to determine suitability for endovascular repair. With early endograft designs, about 50 percent of patients were not candidates for EVAR because of the site, extent, or morphology of the aneurysm, or unsuitability of access vessels. The availability of devices that allow a shorter proximal seal zone and lower profile devices have expanded the use of EVAR to almost two-thirds of patients with an infrarenal AAA. (See",
"      <a class=\"local\" href=\"#H440175\">",
"       'Anatomic suitability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endograft imaging is mandatory for the remainder of the patient&rsquo;s life to evaluate endograft integrity and positioning. We use a combination of plain abdominal radiographs which can evaluate the metal stent structure, computed tomography and duplex ultrasonography to assess the graft at initial postoperative follow-up and then 1, 6, and 12 months postoperatively, and annually thereafter. (See",
"      <a class=\"local\" href=\"#H436613\">",
"       'Postoperative care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Currently available endovascular grafts for infrarenal aortic repair share a bifurcated, modular design. There are no clear advantages of one design over another. The endovascular graft is constructed by the sequential delivery and deployment of device components in vivo. (See",
"      <a class=\"local\" href=\"#H441000\">",
"       'Endografts'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2369876151\">",
"       'Endograft placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Short-term mortality rates for endovascular therapy compare favorably with open surgical repair in randomized trials and large observational studies. The benefit is greatest for patients at highest surgical risk in whom the short-term mortality for endovascular repair is significantly lower compared with open repair (4.7 versus 19.2 percent at 30 days, in one report). It has not been definitively established that endovascular repair is superior to open surgical repair in the long term, even among patients at highest risk for surgery. (See",
"      <a class=\"local\" href=\"#H433042\">",
"       'Perioperative morbidity and mortality'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38746?source=see_link&amp;anchor=H783678#H783678\">",
"       \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Open versus endovascular aneurysm repair'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The overall complication rate for endovascular aneurysm repair, including access-related issues, is approximately 10 percent. Technical failures may be due to complications or the inability to resolve a type I leak, but these can usually be managed using adjunctive endovascular procedures. Open conversion may be required, but is uncommon, occurring in fewer than 2 percent of patients at the time of repair. Device-related complications include vascular injury as a result of device deployment and endoleak. (See",
"      <a class=\"local\" href=\"#H433042\">",
"       'Perioperative morbidity and mortality'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=see_link\">",
"       \"Complications of endovascular abdominal aortic repair\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/1\">",
"      Dillavou ED, Muluk SC, Makaroun MS. Improving aneurysm-related outcomes: nationwide benefits of endovascular repair. J Vasc Surg 2006; 43:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/2\">",
"      Giles KA, Pomposelli F, Hamdan A, et al. Decrease in total aneurysm-related deaths in the era of endovascular aneurysm repair. J Vasc Surg 2009; 49:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/3\">",
"      Johnston KW, Rutherford RB, Tilson MD, et al. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg 1991; 13:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/4\">",
"      Sandhu RS, Pipinos II. Isolated iliac artery aneurysms. Semin Vasc Surg 2005; 18:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/5\">",
"      Schanzer A, Greenberg RK, Hevelone N, et al. Predictors of abdominal aortic aneurysm sac enlargement after endovascular repair. Circulation 2011; 123:2848.",
"     </a>",
"    </li>",
"    <li>",
"     Boijsen, E: Anomalies and malformations. In: Abrams Angiography. Baum, S (Ed), Little, Brown, Boston 1997. p.1217.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/7\">",
"      Higashiura W, Kichikawa K, Sakaguchi S, et al. Accuracy of centerline of flow measurement for sizing of the Zenith AAA endovascular graft and predictive factor for risk of inadequate sizing. Cardiovasc Intervent Radiol 2009; 32:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/8\">",
"      Howell M, Villareal R, Krajcer Z. Percutaneous access and closure of femoral artery access sites associated with endoluminal repair of abdominal aortic aneurysms. J Endovasc Ther 2001; 8:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/9\">",
"      Mohan IV, Laheij RJ, Harris PL, EUROSTAR COLLABORATORS. Risk factors for endoleak and the evidence for stent-graft oversizing in patients undergoing endovascular aneurysm repair. Eur J Vasc Endovasc Surg 2001; 21:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/10\">",
"      Abu-Ghaida AM, Clair DG, Greenberg RK, et al. Broadening the applicability of endovascular aneurysm repair: the use of iliac conduits. J Vasc Surg 2002; 36:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/11\">",
"      Ham SW, Chong T, Moos J, et al. Arch and visceral/renal debranching combined with endovascular repair for thoracic and thoracoabdominal aortic aneurysms. J Vasc Surg 2011; 54:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/12\">",
"      Prinssen M, Wixon CL, Buskens E, Blankensteijn JD. Surveillance after endovascular aneurysm repair: diagnostics, complications, and associated costs. Ann Vasc Surg 2004; 18:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/13\">",
"      Oderich, GS, Ricotta, et al. Surgeon-Modified Fenestrated and Branched Stent Grafts for High Risk Patients with Juxtarenal, Paravisceral and Thoracoabdominal Aortic Aneurysms: Comparison with Open Abdominal Debranching in a Single Center. J Vasc Surg 2009; 49:S48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/14\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     file://content.onlinejacc.org/cgi/reprint/47/6/e1.pdf (Accessed on March 23, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/16\">",
"      Chaikof EL, Brewster DC, Dalman RL, et al. The care of patients with an abdominal aortic aneurysm: the Society for Vascular Surgery practice guidelines. J Vasc Surg 2009; 50:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/17\">",
"      Volodos NL, Karpovich IP, Troyan VI, et al. Clinical experience of the use of self-fixing synthetic prostheses for remote endoprosthetics of the thoracic and the abdominal aorta and iliac arteries through the femoral artery and as intraoperative endoprosthesis for aorta reconstruction. Vasa Suppl 1991; 33:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/18\">",
"      Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. Ann Vasc Surg 1991; 5:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/19\">",
"      Schwarze ML, Shen Y, Hemmerich J, Dale W. Age-related trends in utilization and outcome of open and endovascular repair for abdominal aortic aneurysm in the United States, 2001-2006. J Vasc Surg 2009; 50:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/20\">",
"      Greenberg RK, Sternbergh WC 3rd, Makaroun M, et al. Intermediate results of a United States multicenter trial of fenestrated endograft repair for juxtarenal abdominal aortic aneurysms. J Vasc Surg 2009; 50:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/21\">",
"      Greenberg RK, Qureshi M. Fenestrated and branched devices in the pipeline. J Vasc Surg 2010; 52:15S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/22\">",
"      Ohrlander T, Sonesson B, Ivancev K, et al. The chimney graft: a technique for preserving or rescuing aortic branch vessels in stent-graft sealing zones. J Endovasc Ther 2008; 15:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/23\">",
"      Coscas R, Kobeiter H, Desgranges P, Becquemin JP. Technical aspects, current indications, and results of chimney grafts for juxtarenal aortic aneurysms. J Vasc Surg 2011; 53:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/24\">",
"      Patel HJ, Upchurch GR Jr, Eliason JL, et al. Hybrid debranching with endovascular repair for thoracoabdominal aneurysms: a comparison with open repair. Ann Thorac Surg 2010; 89:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/25\">",
"      Min SI, Min SK, Ahn S, et al. Comparison of costs of endovascular repair versus open surgical repair for abdominal aortic aneurysm in Korea. J Korean Med Sci 2012; 27:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/26\">",
"      Brown LC, Powell JT, Thompson SG, et al. The UK EndoVascular Aneurysm Repair (EVAR) trials: randomised trials of EVAR versus standard therapy. Health Technol Assess 2012; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/27\">",
"      Morimae H, Maekawa T, Tamai H, et al. Cost disparity between open repair and endovascular aneurysm repair for abdominal aortic aneurysm: a single-institute experience in Japan. Surg Today 2012; 42:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/28\">",
"      Hayes PD, Sadat U, Walsh SR, et al. Cost-effectiveness analysis of endovascular versus open surgical repair of acute abdominal aortic aneurysms based on worldwide experience. J Endovasc Ther 2010; 17:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/29\">",
"      Blackhouse G, Hopkins R, Bowen JM, et al. A cost-effectiveness model comparing endovascular repair to open surgical repair of abdominal aortic aneurysms in Canada. Value Health 2009; 12:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/30\">",
"      EVAR trial participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet 2005; 365:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/31\">",
"      Fotis T, Tsoumakidou G, Katostaras T, et al. Cost and effectiveness comparison of endovascular aneurysm repair versus open surgical repair of abdominal aortic aneurysm: a single-center experience. J Vasc Nurs 2008; 26:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/32\">",
"      Chaikof EL, Blankensteijn JD, Harris PL, et al. Reporting standards for endovascular aortic aneurysm repair. J Vasc Surg 2002; 35:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/33\">",
"      Moll FL, Powell JT, Fraedrich G, et al. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg 2011; 41 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/34\">",
"      de Maistre E, Terriat B, Lesne-Padieu AS, et al. High incidence of venous thrombosis after surgery for abdominal aortic aneurysm. J Vasc Surg 2009; 49:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/35\">",
"      Ruppert V, Leurs LJ, Steckmeier B, et al. Influence of anesthesia type on outcome after endovascular aortic aneurysm repair: an analysis based on EUROSTAR data. J Vasc Surg 2006; 44:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/36\">",
"      Parra JR, Crabtree T, McLafferty RB, et al. Anesthesia technique and outcomes of endovascular aneurysm repair. Ann Vasc Surg 2005; 19:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/37\">",
"      Verhoeven EL, Prins TR, van den Dungen JJ, et al. Endovascular repair of acute AAAs under local anesthesia with bifurcated endografts: a feasibility study. J Endovasc Ther 2002; 9:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/38\">",
"      Haas PC, Krajcer Z, Diethrich EB. Closure of large percutaneous access sites using the Prostar XL Percutaneous Vascular Surgery device. J Endovasc Surg 1999; 6:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/39\">",
"      Papazoglou K, Christu K, Iordanides T, et al. Endovascular abdominal aortic aneurysm repair with percutaneous transfemoral prostheses deployment under local anaesthesia. Initial experience with a new, simple-to-use tubular and bifurcated device in the first 27 cases. Eur J Vasc Endovasc Surg 1999; 17:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/40\">",
"      Torsello GB, Kasprzak B, Klenk E, et al. Endovascular suture versus cutdown for endovascular aneurysm repair: a prospective randomized pilot study. J Vasc Surg 2003; 38:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/41\">",
"      Jean-Baptiste E, Batt M, Azzaoui R, et al. A comparison of the mid-term results following the use of bifurcated and aorto-uni-iliac devices in the treatment of abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2009; 38:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/42\">",
"      Fernandez JD, Craig JM, Garrett HE Jr, et al. Endovascular management of iliac rupture during endovascular aneurysm repair. J Vasc Surg 2009; 50:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/43\">",
"      Peterson BG, Matsumura JS. Internal endoconduit: an innovative technique to address unfavorable iliac artery anatomy encountered during thoracic endovascular aortic repair. J Vasc Surg 2008; 47:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/44\">",
"      G&ouml;rich J, Rilinger N, Sokiranski R, et al. Treatment of leaks after endovascular repair of aortic aneurysms. Radiology 2000; 215:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/45\">",
"      White GH, May J, Waugh RC, et al. Type III and type IV endoleak: toward a complete definition of blood flow in the sac after endoluminal AAA repair. J Endovasc Surg 1998; 5:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/46\">",
"      Veith FJ, Baum RA, Ohki T, et al. Nature and significance of endoleaks and endotension: summary of opinions expressed at an international conference. J Vasc Surg 2002; 35:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/47\">",
"      Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/48\">",
"      Katzen, B. The Guidant/EVT Ancure device. J Vasc Interv Radiol 2000; 11:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/49\">",
"      Wolf YG, Johnson BL, Hill BB, et al. Duplex ultrasound scanning versus computed tomographic angiography for postoperative evaluation of endovascular abdominal aortic aneurysm repair. J Vasc Surg 2000; 32:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/50\">",
"      McWilliams RG, Martin J, White D, et al. Detection of endoleak with enhanced ultrasound imaging: comparison with biphasic computed tomography. J Endovasc Ther 2002; 9:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/51\">",
"      Powell JT, Greenhalgh RM. Clinical practice. Small abdominal aortic aneurysms. N Engl J Med 2003; 348:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/52\">",
"      Sato DT, Goff CD, Gregory RT, et al. Endoleak after aortic stent graft repair: diagnosis by color duplex ultrasound scan versus computed tomography scan. J Vasc Surg 1998; 28:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/53\">",
"      Walsh SR, Tang TY, Boyle JR. Renal consequences of endovascular abdominal aortic aneurysm repair. J Endovasc Ther 2008; 15:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/54\">",
"      Mills JL Sr, Duong ST, Leon LR Jr, et al. Comparison of the effects of open and endovascular aortic aneurysm repair on long-term renal function using chronic kidney disease staging based on glomerular filtration rate. J Vasc Surg 2008; 47:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/55\">",
"      Tomlinson J, McNamara J, Matloubieh J, et al. Intermediate follow-up after endovascular aneurysm repair: can we forgo CT scanning in certain patients? Ann Vasc Surg 2007; 21:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/56\">",
"      AbuRahma AF. Fate of endoleaks detected by CT angiography and missed by color duplex ultrasound in endovascular grafts for abdominal aortic aneurysms. J Endovasc Ther 2006; 13:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/57\">",
"      AbuRahma AF, Welch CA, Mullins BB, Dyer B. Computed tomography versus color duplex ultrasound for surveillance of abdominal aortic stent-grafts. J Endovasc Ther 2005; 12:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/58\">",
"      Sandford RM, Bown MJ, Fishwick G, et al. Duplex ultrasound scanning is reliable in the detection of endoleak following endovascular aneurysm repair. Eur J Vasc Endovasc Surg 2006; 32:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/59\">",
"      Elkouri S, Panneton JM, Andrews JC, et al. Computed tomography and ultrasound in follow-up of patients after endovascular repair of abdominal aortic aneurysm. Ann Vasc Surg 2004; 18:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/60\">",
"      Chaer RA, Gushchin A, Rhee R, et al. Duplex ultrasound as the sole long-term surveillance method post-endovascular aneurysm repair: a safe alternative for stable aneurysms. J Vasc Surg 2009; 49:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/61\">",
"      Dias NV, Ivancev K, Malina M, et al. Direct intra-aneurysm sac pressure measurement using tip-pressure sensors: in vivo and in vitro evaluation. J Vasc Surg 2004; 40:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/62\">",
"      Cantisani V, Ricci P, Grazhdani H, et al. Prospective comparative analysis of colour-Doppler ultrasound, contrast-enhanced ultrasound, computed tomography and magnetic resonance in detecting endoleak after endovascular abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 2011; 41:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/63\">",
"      Perini P, Sediri I, Midulla M, et al. Single-centre prospective comparison between contrast-enhanced ultrasound and computed tomography angiography after EVAR. Eur J Vasc Endovasc Surg 2011; 42:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/64\">",
"      Mirza TA, Karthikesalingam A, Jackson D, et al. Duplex ultrasound and contrast-enhanced ultrasound versus computed tomography for the detection of endoleak after EVAR: systematic review and bivariate meta-analysis. Eur J Vasc Endovasc Surg 2010; 39:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/65\">",
"      Karthikesalingam A, Al-Jundi W, Jackson D, et al. Systematic review and meta-analysis of duplex ultrasonography, contrast-enhanced ultrasonography or computed tomography for surveillance after endovascular aneurysm repair. Br J Surg 2012; 99:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/66\">",
"      Gilabert R, Bu&ntilde;esch L, Real MI, et al. Evaluation of abdominal aortic aneurysm after endovascular repair: prospective validation of contrast-enhanced US with a second-generation US contrast agent. Radiology 2012; 264:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/67\">",
"      Iezzi R, Basilico R, Giancristofaro D, et al. Contrast-enhanced ultrasound versus color duplex ultrasound imaging in the follow-up of patients after endovascular abdominal aortic aneurysm repair. J Vasc Surg 2009; 49:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/68\">",
"      Sheehan MK, Barbato J, Compton CN, et al. Effectiveness of coiling in the treatment of endoleaks after endovascular repair. J Vasc Surg 2004; 40:430.",
"     </a>",
"    </li>",
"    <li>",
"     Cynamon J. The role of arteriography in endovascular grafting techniques. In: Endovascular Grafting Techniques, Parodi JC, Veith F, Marin M (Eds), Lippincott Williams and Wilkins, Philadelphia 1999. p.7.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/70\">",
"      Greenhalgh RM, Brown LC, Kwong GP, et al. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. Lancet 2004; 364:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/71\">",
"      Prinssen M, Verhoeven EL, Buth J, et al. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med 2004; 351:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/72\">",
"      Schermerhorn ML, O'Malley AJ, Jhaveri A, et al. Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population. N Engl J Med 2008; 358:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/73\">",
"      Wilt TJ, Lederle FA, Macdonald R, et al. Comparison of endovascular and open surgical repairs for abdominal aortic aneurysm. Evid Rep Technol Assess (Full Rep) 2006; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/74\">",
"      Lederle FA, Kane RL, MacDonald R, Wilt TJ. Systematic review: repair of unruptured abdominal aortic aneurysm. Ann Intern Med 2007; 146:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/75\">",
"      Teufelsbauer H, Prusa AM, Wolff K, et al. Endovascular stent grafting versus open surgical operation in patients with infrarenal aortic aneurysms: a propensity score-adjusted analysis. Circulation 2002; 106:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/27/31162/abstract/76\">",
"      Jackson RS, Chang DC, Freischlag JA. Comparison of long-term survival after open vs endovascular repair of intact abdominal aortic aneurysm among Medicare beneficiaries. JAMA 2012; 307:1621.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15203 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31162=[""].join("\n");
var outline_f30_27_31162=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H436647\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2369875877\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H440564\">",
"      ANATOMIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H440571\">",
"      Aortoiliac anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H441378\">",
"      Aneurysm extent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H441448\">",
"      Measurement definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H441631\">",
"      Renal artery anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H440427\">",
"      AORTOILIAC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25899791\">",
"      INDICATIONS FOR REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H440175\">",
"      Anatomic suitability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H441797\">",
"      - Aortic neck diameter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H441855\">",
"      - Aortic neck length",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H441862\">",
"      - Aortic neck angulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H441871\">",
"      - Iliac artery and access vessel morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H441905\">",
"      - Other considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25900007\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H441000\">",
"      ENDOGRAFTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H441022\">",
"      Stent-graft design",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444449\">",
"      Advanced devices and techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H441029\">",
"      Choice of graft",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89888610\">",
"      - Cost",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2369876062\">",
"      PREOPERATIVE RISK ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H439885\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444809\">",
"      Antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444816\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2357599518\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444823\">",
"      Prophylactic renal artery stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444831\">",
"      Hypogastric embolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2369876151\">",
"      ENDOGRAFT PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H841452149\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H841452056\">",
"      Vascular access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H841452208\">",
"      Percutaneous access",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H841452215\">",
"      - Iliac conduits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H841452071\">",
"      Graft deployment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64453742\">",
"      Troubleshooting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H64453750\">",
"      - Gate cannulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H436569\">",
"      - Handling endoleak",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H436613\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2369876318\">",
"      Endograft surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H433042\">",
"      PERIOPERATIVE MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H436647\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15203\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15203|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/49/8976\" title=\"diagnostic image 1\">",
"      CT angiogram of infrarenal AAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/0/9221\" title=\"diagnostic image 2\">",
"      Centerline measurements or abdominal aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/18/43301\" title=\"diagnostic image 3\">",
"      Aortouniliac endovascular graft",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?19/32/19973\" title=\"diagnostic image 4\">",
"      Coil embolization type II aortic endoleak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/45/15057\" title=\"diagnostic image 5\">",
"      Type III endoleak after endovascular aortic repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/24/35204\" title=\"diagnostic image 6\">",
"      Computed tomography after endovascular repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15203|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/11/32949\" title=\"figure 1\">",
"      Abdominal aortic aneurysm repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/14/43234\" title=\"figure 2\">",
"      Normal abdominal aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/52/40777\" title=\"figure 3\">",
"      Pelvic circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/29/9683\" title=\"figure 4\">",
"      Anatomy abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/50/19234\" title=\"figure 5\">",
"      Anatomic criteria for endovascular AAA repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/13/37074\" title=\"figure 6\">",
"      Types of endoleak after endovascular repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15203|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/27/26040\" title=\"picture 1\">",
"      Iliac conduit for endograft placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/47/24307\" title=\"picture 2\">",
"      Type II endoleak after endovascular aortic repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15203|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/16/4365\" title=\"table 1\">",
"      Characteristics of abdominal endovascular devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/9/33950\" title=\"table 2\">",
"      Prophylaxis recommendations for vascular and IR procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33433?source=related_link\">",
"      Chronic kidney disease associated with atherosclerotic renovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=related_link\">",
"      Complications of endovascular abdominal aortic repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/29/9689?source=related_link\">",
"      Endovascular devices for abdominal aortic repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29304?source=related_link\">",
"      Iliac artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38746?source=related_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=related_link\">",
"      Management of cardiac risk for noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/62/34787?source=related_link\">",
"      Patient information: Abdominal aortic aneurysm (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/48/19202?source=related_link\">",
"      Patient information: Endovascular surgery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28487?source=related_link\">",
"      Renal ectopic and fusion anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8809?source=related_link\">",
"      Surgical and endovascular repair of iliac artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30904?source=related_link\">",
"      Surgical and endovascular repair of ruptured abdominal aortic aneurysm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_27_31163="Etiology AV block";
var content_f30_27_31163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of atrioventricular block",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physiologic and pathophysiologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased vagal tone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrosis and sclerosis of the conduction system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ischemic heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiomyopathy and myocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial AV block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyperkalemia, infiltrative malignancies, neonatal lupus syndrome, severe hypo- or hyperthyroidism, trauma, degenerative neuromuscular diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Iatrogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Digitalis, calcium channel blockers, beta blockers, amiodarone, adenosine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Catheter ablation of arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transcatheter closure of VSD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol septal ablation for HCM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transcatheter aortic valve implantation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31163=[""].join("\n");
var outline_f30_27_31163=null;
var title_f30_27_31164="Treatment summary I BCC";
var content_f30_27_31164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of treatment options for basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Treatment modality",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Five-year recurrence rate, percent",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Primary BCC",
"       </td>",
"       <td class=\"subtitle2\">",
"        Recurrent BCC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Surgical excision",
"       </td>",
"       <td rowspan=\"4\">",
"        5-10",
"       </td>",
"       <td rowspan=\"4\">",
"        12-17",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Margin-controlled. Usually performed under local anesthesia. Area of tissue removed (including important structures) can be more precisely controlled than with cryosurgery, radiation therapy, or electrosurgery - therefore limiting unnecessary damage to critical structures. Resultant scar can be optimized both cosmetically and functionally.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Invasive. Occasionally performed under conscious sedation or general anesthesia with their inherent risks. Random margin results in both a poorer cure rate compared to Mohs and the unnecessary sacrifice of normal tissues, which in critical, or cosmetically sensitive areas, results in potentially unnecessary disfigurement.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Mohs surgery",
"       </td>",
"       <td rowspan=\"4\">",
"        1",
"       </td>",
"       <td rowspan=\"4\">",
"        6",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        100 percent margin-control. Offers highest cure rate for both primary and recurrent BCCs while maximizing preservation of normal tissue. No sedation or general anesthesia required.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arguably more costly than simple excision, cryosurgery or electrosurgery (not radiation). Invasive. Longer procedure compared to simple excision, cryosurgery or electrosurgery (not radiation). Requires special training in the technique.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Cryosurgery",
"       </td>",
"       <td rowspan=\"4\">",
"        8",
"       </td>",
"       <td rowspan=\"4\">",
"        13",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cost effective, relatively quick, requires a single visit, potential excellent cosmesis and cure rate in appropriately selected tumors, no sedation or general anesthesia required.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not margin-controlled. Requires considerable experience on the part of the clinician, wound care, pigmentary changes, possible permanent damage to underlying nerves or other critical structures.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31164=[""].join("\n");
var outline_f30_27_31164=null;
var title_f30_27_31165="Blood pressure AR with dexfen";
var content_f30_27_31165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    The incidence of aortic regurgitation with dexfenfluramine is associated with diastolic blood pressure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 254px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The frequency of any degree of aortic regurgitation (AR) in dexfenfluramine patients increases progressively with higher diastolic blood pressures (p = 0.03); there is no effect of diastolic pressure on the incidence of AR in control subjects.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Shively, BK, Roldan, CA, Gill, EA, et al, Circulation 1999; 100:2161.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31165=[""].join("\n");
var outline_f30_27_31165=null;
var title_f30_27_31166="Thrombolytic therapy in elderly";
var content_f30_27_31166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thrombolytic therapy may increase mortality over age 75",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 398px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mortality data from a retrospective study of 7864 patients 65 to 86 years of age with an ST elevation myocardial infarction. Among those &gt;75 years of age who received thrombolytic therapy, there was an increased 30-day mortality compared to no thrombolytic therapy (hazard ratio 1.38, p=0.003). As seen in other studies, thrombolytic therapy was associated with a survival benefit in patients aged 65 to 75.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Thiemann, DR, Coresh, J, Schulman, SP, et al, Circulation 2000; 101:2239.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31166=[""].join("\n");
var outline_f30_27_31166=null;
var title_f30_27_31167="Schematic CVVHDF post-filter";
var content_f30_27_31167=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F64868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F64868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Schematic of CVVHDF with post-filter infusion of replacement fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 291px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_27_31167=[""].join("\n");
var outline_f30_27_31167=null;
